<PAGE>
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

================================================================================

                                                                    EXHIBIT 10.1

                               PURCHASE AGREEMENT

                                    between:

                                ORION CORPORATION
         a corporation organized and existing under the laws of Finland;

                                       and

                                   GTX, INC.,
                             a Delaware corporation

                                   ----------

                          Dated as of December 13, 2004

                                   ----------

================================================================================
<PAGE>
                               PURCHASE AGREEMENT

     This Purchase Agreement is entered into as of December 13, 2004 (the "Date
of Agreement"), by and between GTx, Inc., a Delaware corporation ("GTx"), and
Orion Corporation, a corporation organized and existing under the laws of
Finland ("Orion") (GTx and Orion shall hereinafter be referred to individually
as a "Party," and collectively as the "Parties").

                                    RECITALS

A. GTx and Orion are parties to an Amended and Restated Toremifene License and
Supply Agreement effective as of March 30, 2000, as amended, governing the
Parties' rights and obligations with respect to the research, development,
commercialization and manufacture of certain pharmaceutical products based on
the compound known as Toremifene (the "Current Agreement").

B. Orion and Shire US, Inc. ("Shire"), entered into a [ * ] dated as of
September 6, 1999 (the "Shire Agreement"), granting Shire [ * ] marketed under
the brand name Fareston(R) for the treatment of breast cancer in the USA.

C. Orion has negotiated with Shire an agreement whereunder the Shire Agreement
will be terminated and Orion will acquire [ * ] Shire's [ * ] for the treatment
of breast cancer in the USA (the "Fareston Repurchase Agreement"), which rights
and interests will be transferred to GTx pursuant to this Agreement and the
Amended Agreement (as defined below).

D. Concurrently with the closing of the Fareston Repurchase Agreement, GTx and
Orion will, as described below, enter into an agreement that will supercede and
replace the Current Agreement, as amended.

E. Orion wishes to sell to GTx, and GTx wishes to acquire from Orion, such
assets on the terms set forth in this Agreement.

F. Certain capitalized terms used in this Agreement are defined in Exhibit A.

                                    AGREEMENT

GTx and Orion, intending to be legally bound, agree as follows:

1.   PURCHASE AND SALE OF ASSETS; RELATED AGREEMENTS

     1.1 ASSETS TO BE TRANSFERRED. Upon the terms and subject to the conditions
of this Agreement, on the Closing Date (as defined below), Orion shall sell,
transfer, convey, assign, grant and deliver to GTx, and GTx shall purchase,
acquire and receive, the following properties, rights, claims and assets
relating to Products:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       1.
<PAGE>
          (A) PRODUCT FILINGS.

               (I) The rights of sponsor in and to NDA [ * ] and all related
INDs filed with the FDA for Products (but excluding any Drug Master Files filed
with the FDA) (such filings and approvals, the "Product Filings").

          (B) FARESTON TRADEMARK IN THE USA.

               (I) All right, title and interest in the trademark Fareston in
the USA (Registration #1460565).

          (C) ASSETS FROM SHIRE.

               (I) All right, title and interest in and to the Fareston Business
Assets.

               (II) The Fareston Product inventory [ * ] (the "Fareston Product
Inventory"), consisting of [ * ]. The Parties will agree on the [ * ] of the
Fareston Product Inventory to be purchased by GTx prior to Closing.

          (D) CONTRACTS. All of Seller's rights under the contracts listed in
Part 1.1(d) of the Disclosure Schedule (the "Assumed Contracts"), provided that
to the extent such contracts prohibit such sale, transfer, conveyance,
assignment, grant or delivery ("Restricted Contracts"), then for any such
Restricted Contract not transferred or assigned on the Closing Date, the Parties
shall [ * ] to effect such transfer or assignment to GTx promptly thereafter.

     All of the foregoing assets are hereinafter collectively referred to as the
"Purchased Assets."

     For the avoidance of doubt, all other assets of Orion including, without
limitation, other proprietary rights of Orion, equipment and other tangible and
intangible personal property, remain the property of Orion and are not subject
to this Agreement.

     1.2 INTELLECTUAL PROPERTY LICENSE TO PURCHASED ASSETS. Orion hereby grants
to GTx a perpetual, irrevocable, royalty-free, nonexclusive license, with the
right to grant sublicenses through multiple tiers of sublicensees, to use in or
practice under in the USA any and all Intellectual Property Rights of Orion that
may be embodied in or cover the Purchased Assets to use, sell, offer for sale
and import Fareston Product in accordance with the Amended Agreement, including
without limitation the Fareston Business Assets and the Fareston Product
Inventory, to the extent not otherwise provided pursuant to the Amended
Agreement.

     1.3 LIABILITIES TO BE ASSUMED. Upon the terms and subject to the conditions
of this Agreement, on the Closing Date, GTx shall assume and agree to perform
and discharge Orion's Liability arising on and after January 1, 2005, under and
pursuant to the Assumed Contracts; provided, however, that as to any Assumed
Contracts that are transferred to GTx after such date, as provided in this
Agreement, GTx shall assume, perform and discharge Orion's Liability thereunder
only to the extent arising on or after the date upon which such transfer is
effected.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       2.
<PAGE>
     1.4 LIABILITIES NOT TO BE ASSUMED. Except as specifically set forth in
Section 1.3, on the Closing Date, GTx is not assuming any other Liabilities or
Contracts of Orion ("Excluded Liabilities and Contracts"), and all such
Liabilities and Contracts shall be and remain the responsibility of Orion,
including Liabilities that arise under any Assumed Contract prior to January 1,
2005.

     1.5 DEPOSIT; PURCHASE PRICE.

          (A) On the Date of Agreement, GTx shall pay Orion a deposit of [ * ]
(the "Deposit"). The Deposit will be creditable against the Purchase Price
described in Section 1.5(b).

          (B) In consideration for the sale and transfer of the Purchased Assets
to GTx upon the Closing, the Fareston Product inventory described in Section
1.1(c)(ii), and for other rights granted to GTx pursuant to the Transactional
Agreements, including extending GTx's rights in Toremifene under the Amended
Agreement, GTx shall pay Orion upon execution of this Agreement an amount equal
to (i) [ * ], which is the amount paid [ * ] under [ * ] (such amount, the
[ * ]), [ * ] (ii) [ * ], which is [ * ]. The payments described in (i) and (ii)
together shall be $5,223,963 (the "Purchase Price"). GTx shall pay to Orion the
Purchase Price, less the Deposit, upon the Closing Date.

          (C) If Orion fails to execute any of the Transactional Agreements or
to otherwise close in accordance with the terms and conditions herein on or
before the Scheduled Closing Time (or at any later time as the Parties may
mutually agree), then the Deposit shall be immediately returned to GTx and no
Party shall have any further rights or obligations hereunder.

          (D) Any amounts payable by GTx shall be paid by wire transfer to:

               [ * ]

     1.6 OTHER AGREEMENTS. At the Closing, GTx and Orion shall enter into the
Amended Agreement, the Pharmacovigilance Agreement, and the Quality Agreement in
substantially the forms attached hereto as Exhibit B, C and D, respectively. The
Parties shall also provide to each other any other documents reasonably
necessary to evidence or effect the transactions contemplated by this Agreement,
including without limitation a bill of sale.

     1.7 ALLOCATION OF PURCHASE PRICE. Promptly following the Date of Agreement,
GTx and Orion shall in good faith determine the appropriate allocation of the
Purchase Price among the Purchased Assets. The Parties shall use commercially
reasonable efforts to [ * ] arising from the purchase of the Purchased Assets by
GTx. The allocation prescribed by such exhibit shall be conclusive and binding
upon Orion and GTx for all purposes, and Orion and GTx shall file Tax Returns or
other documents with any Governmental Body that are consistent with such
allocation; provided, however that if a Governmental Body disagrees with such
allocation, then GTx may alter such allocation to conform with such Governmental
Body's requirements.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       3.
<PAGE>
     1.8 FURTHER ACTION. If, at any time after the Closing, any further action
shall be necessary on the part of either Party hereto to effect the intentions
of the Parties as expressed in this Agreement, as and when requested by a Party
and at such Party's expense, each such Party shall take all such further action
as may reasonably be necessary to effect such intentions, including without
limitation providing to the other Party information relevant to determining the
amount of Taxes due with respect to the transactions contemplated in this
Agreement.

     1.9 CLOSING. The consummation of the transactions contemplated by this
Agreement (the "Closing") shall take place at Cooley Godward, 5 Palo Alto
Square, Palo Alto, CA 94306 on December 29, 2004 (the "Scheduled Closing Time")
(or at such other place as GTx and Orion shall designate), at 9:00 a.m. (Pacific
Daylight Time). For purposes of this Agreement, "Closing Date" shall mean the
time and date as of which the Closing actually takes place.

2.   REPRESENTATIONS AND WARRANTIES OF ORION

     Orion hereby represents and warrants as follows:

     2.1 DUE ORGANIZATION.

          (A) Orion is a corporation duly organized under the laws of Finland,
and has all necessary power and authority:

               (I) to conduct its business in the manner in which it is
currently being conducted; and

               (II) to own and use its assets in the manner in which its assets
are currently owned and used.

          (B) Orion has never approved, or commenced any proceeding or made any
election contemplating, the winding up or cessation of Orion's business or
affairs.

     2.2 RIGHT TO ASSIGN PURCHASED ASSETS; TITLE TO PURCHASED ASSETS.

          (A) The Purchased Assets have been assigned to Orion pursuant to the
Fareston Repurchase Agreement and, except for the Assumed Contracts, are owned
by Orion free and clear of any Encumbrances, and Orion has good, valid and
freely transferable title to all of the Purchased Assets, free and clear of any
Encumbrances.

          (B) To the Knowledge of Orion, neither the execution, delivery or
performance of any of the Transactional Agreements nor the consummation of any
of the Transactions will, with or without notice or the lapse of time, result in
or give any other Person the right or option to cause or declare: (i) a loss of,
or Encumbrance on, any Purchased Asset; (ii) a breach of any Contract; (iii) the
release, disclosure or delivery of any Purchased Asset by or to any escrow agent
or other Person; or (iv) the grant, assignment or transfer to any other Person
of any license or other right or interest under, to or in any of the Purchased
Asset.

     2.3 CONTRACTS.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       4.
<PAGE>
          (A) Part 1.1(d) of the Disclosure Schedule identifies each Assumed
Contract. To Orion's reasonable belief, it has delivered to GTx accurate and
complete copies of all Contracts identified in Part 1.1(d) of the Disclosure
Schedule, including all amendments thereto. To Orion's Knowledge, each Assumed
Contract is valid and in full force and effect.

          (B) There is no basis upon which any party to any Assumed Contract may
object to (i) the assignment to GTx of any right under such Assumed Contract, or
(ii) the delegation to or performance by GTx of any obligation under such
Assumed Contract, except for restrictions on assignment or delegation expressly
set forth in any such Assumed Contract.

     2.4 PROCEEDINGS; ORDERS.

          (A) To the Knowledge of Orion, there is no pending Proceeding and no
Person has threatened by written notice to commence any Proceeding, that
challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with, any of the Transactions.

          (B) To the Knowledge of Orion, no event has occurred, and no claim,
dispute or other condition or circumstance exists, that might give rise to or
serve as a basis for the commencement of any Proceeding described in Section
2.4(a).

          (C) To the Knowledge of Orion, there is no Order to which any of the
Purchased Assets are subject.

     2.5 AUTHORITY; BINDING NATURE OF AGREEMENTS.

          (A) Orion has the right, power and authority to enter into and to
perform its obligations under each of the Transactional Agreements to which it
is or becomes a party.

          (B) The execution, delivery and performance by Orion of the
Transactional Agreements to which it is or may become a party have been duly
authorized by all necessary action on the part of Orion.

          (C) This Agreement constitutes the legal, valid and binding obligation
of Orion, enforceable against Orion in accordance with its terms, subject to (i)
laws of general application relating to bankruptcy, insolvency and the relief of
debtors and (ii) rules of law governing specific performance, injunctive relief
and other equitable remedies.

          (D) Upon the execution of each of the other Transactional Agreements
at the Closing, each of such other Transactional Agreements to which Orion is a
party will constitute the legal, valid and binding obligation of Orion and will
be enforceable against Orion in accordance with its terms.

     2.6 CONSENTS. Except as set forth in Part 2.6 of the Disclosure Schedule,
Orion was not, is not and will not be required to make any filing with or give
any notice to, or to obtain any Consent from, any Person in connection with the
execution and delivery of any of the Transactional Agreements or the
consummation or performance of any of the Transactions.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       5.
<PAGE>
     2.7 NO DEBARMENT; COMPLIANCE WITH LAWS. Orion hereby certifies that, to the
Knowledge of Orion: (i) it has not been debarred or convicted of a crime which
could lead to debarment, and (ii) it has not utilized the services of any
individual who, or any entity that, in the performance of services in connection
with Products has been debarred or has been convicted of a crime which could
lead to debarment under the Generic Drug Enforcement Act of 1992, 21 United
States Code Section 306(a) and (b), as amended. Orion hereby represents and
warrants that, to the Knowledge of Orion and except as set forth in Part 2.7 of
the Disclosure Schedule, the marketing, promotion, sale, and/or distribution of
the Fareston Products by Shire and the operation of the Purchased Assets have
been conducted in material compliance with all applicable laws or regulations.

     2.8 FILINGS. All filings, submissions, data and representations made by
Shire with regulatory authorities in the USA in connection with Fareston
Products, whether in connection with the registration or approval of the
Fareston Product, have been true, complete and accurate in all material
respects.

3.   REPRESENTATIONS AND WARRANTIES OF GTX

     GTx represents and warrants as follows:

     3.1 DUE ORGANIZATION.

          (A) GTx is a corporation duly organized under the laws of the State of
Delaware, and has all necessary power and authority:

               (I) to conduct its business in the manner in which it is
currently being conducted; and

               (II) to own and use its assets in the manner in which its assets
are currently owned and used.

          (B) GTx has never approved, or commenced any proceeding or made any
election contemplating, the winding up or cessation of GTx's business or
affairs.

     3.2 AUTHORITY; BINDING NATURE OF AGREEMENT.

          (A) GTx has the corporate right, power and authority to enter into and
perform its obligations under each of the Transactional Agreements to which it
is or becomes a party.

          (B) The execution, delivery and performance by GTx of the
Transactional Agreements shall have been duly authorized by all necessary action
on the part of GTx.

          (C) This Agreement constitutes the legal, valid and binding obligation
of GTx, enforceable against GTx in accordance with its terms, subject to (i)
laws of general application relating to bankruptcy, insolvency and the relief of
debtors, and (ii) rules of law governing specific performance, injunctive relief
and other equitable remedies.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       6.
<PAGE>
          (D) Upon the execution of each of the other Transactional Agreements
at the Closing, each of such other Transactional Agreements to which GTx is a
party will constitute the legal, valid and binding obligation of GTx and will be
enforceable against GTx in accordance with its terms.

     3.3 CONSENTS. Except as set forth in Part 3.3 of the Disclosure Schedule,
GTx was not, is not and will not be required to make any filing with or give any
notice to, or to obtain any Consent from, any Person in connection with the
execution and delivery of any of the Transactional Agreements or the
consummation or performance of any of the Transactions.

     3.4 PROCEEDINGS; ORDERS.

          (A) To the Knowledge of GTx, there is no pending Proceeding and no
Person has threatened by written notice to commence any Proceeding, that
challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with any of the Transactions.

          (B) To the Knowledge of GTx, no event has occurred, and no claim,
dispute or other condition or circumstance exists, that might directly or
indirectly give rise to or serve as a basis for the commencement of any such
Proceeding described in Section 3.4(a).

          (C) To the Knowledge of GTx, there is no Order to which GTx, or any of
the assets owned or used by GTx, is subject.

     3.5 NO DEBARMENT. GTx hereby certifies that, to the Knowledge of GTx: (i)
it has not been debarred or convicted of a crime which could lead to debarment,
and (ii) it has not utilized the services of any individual who, or any entity
that, in the performance of services in connection with Products has been
debarred or has been convicted of a crime which could lead to debarment under
the Generic Drug Enforcement Act of 1992, 21 United States Code Section 306(a)
and (b), as amended.

4.   PRE-CLOSING COVENANTS OF ORION

     4.1 FARESTON REPURCHASE AGREEMENT. On or before the Closing Date, Orion
shall have executed the Fareston Repurchase Agreement with Shire.

     4.2 OPERATION OF BUSINESS. Orion shall ensure that, prior to the Closing
Date:

          (A) Shire shall conduct the Fareston Product operations in the
ordinary course of business;

          (B) Orion does not enter into or permit any of the Purchased Assets or
Products to become bound by any Contract that would adversely affect or limit
GTx's rights under this Agreement or the Transactional Agreements; and

          (C) Shire does not take any action outside the ordinary course of
business with respect to the Fareston Product or the Purchased Assets.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       7.
<PAGE>
     4.3 FILINGS AND CONSENTS. Orion shall ensure that: (a) all filings, notices
and Consents required to be made, given and obtained by Orion in order to
consummate the Transactions are made, given and obtained on a timely basis; and
(b) prior to the Closing Date, Orion cooperates with GTx and prepares and makes
available such documents and takes such other actions as GTx may request in good
faith, in connection with any filing, notice or Consent that GTx is required or
elects to make, give or obtain.

     4.4 BEST EFFORTS. During the Pre-Closing Period, Orion shall use its Best
Efforts to cause the conditions set forth in Section 6 to be satisfied on a
timely basis.

     4.5 CONFIDENTIALITY. Orion shall not, during the Pre-Closing Period,
without GTx's prior approval, issue or disseminate any press release or other
publicity or otherwise make any disclosure of any nature regarding any of the
Transactions or the existence or terms of this Agreement, except as permitted in
Section 11.4.

5.   PRE-CLOSING COVENANTS OF GTX

     5.1 FILINGS AND CONSENTS. GTx shall ensure that: (a) all filings, notices
and Consents required to be made, given and obtained by GTx in order to
consummate the Transactions are made, given and obtained on a timely basis; and
(b) prior to the Closing Date, GTx cooperates with Orion and prepares and makes
available such documents and take such other actions as Orion may request in
good faith, in connection with any filing, notice or Consent that Orion is
required or elects to make, give or obtain.

     5.2 BEST EFFORTS. During the Pre-Closing Period, GTx shall use its Best
Efforts to cause the conditions set forth in Section 7 to be satisfied.

     5.3 CONFIDENTIALITY. GTx shall not, during the Pre-Closing Period, without
Orion's prior approval, issue or disseminate any press release or other
publicity or otherwise make any disclosure of any nature regarding any of the
Transactions or the existence or terms of this Agreement, except as permitted in
Section 11.4.

6.   CONDITIONS PRECEDENT TO GTX'S OBLIGATION TO CLOSE

     GTx's obligation to purchase the Purchased Assets, and enter into the
Amended Agreement, the Pharmacovigilance Agreement, and the Quality Agreement in
substantially the forms attached hereto as Exhibit B, C and D, respectively, and
to take the other actions required to be taken by GTx at the Closing is subject
to the satisfaction, at or prior to the Closing, of each of the following
conditions (any of which may be waived by GTx, in whole or in part, in writing):

     6.1 ACCURACY OF REPRESENTATIONS. All of the representations and warranties
made by Orion in this Agreement (considered collectively), and each of said
representations and warranties (considered individually), shall have been
accurate in all material respects as of the date of this Agreement, and shall be
accurate in all material respects as of the Scheduled Closing Time as if made at
the Scheduled Closing Time, without giving effect to any update to the
Disclosure Schedule.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       8.
<PAGE>
     6.2 PERFORMANCE OF OBLIGATIONS.

          (A) The Fareston Repurchase Agreement shall have been executed by the
parties thereto and a copy shall have been delivered to GTx. Orion shall have
executed each of the Amended Agreement, the Pharmacovigilance Agreement and the
Quality Agreement as described in Section 1.6.

          (B) All of the covenants and obligations that Orion is required to
comply with or to perform at or prior to the Closing (considered collectively),
and each of said covenants and obligations (considered individually), shall have
been duly complied with and performed in all material respects.

     6.3 ADDITIONAL DOCUMENTS. GTx shall have received such documents as GTx may
request in good faith for the purpose of (i) evidencing the accuracy of any
representation or warranty made by Orion, (ii) evidencing the compliance by
Orion with, or the performance by Orion of, any covenant or obligation set forth
in this Agreement, (iii) evidencing the satisfaction of any condition set forth
in this Section 6, or (iv) otherwise facilitating the consummation or
performance of any of the Transactions.

     6.4 NO PROCEEDINGS. Since the Date of Agreement, there shall not have been
commenced or threatened against GTx, or against any Person affiliated with GTx,
any Proceeding (a) involving any material challenge to, or seeking material
damages or other material relief in connection with, any of the Transactions, or
(b) that may have the effect of preventing, delaying, making illegal or
otherwise interfering with any of the Transactions.

     6.5 NO OTHER CONDITIONS. Subject to the fulfillment (or waiver) of the
above conditions, GTx shall at Closing execute the Amended Agreement, the
Pharmacovigilance Agreement, and the Quality Agreement in substantially the
forms attached hereto as Exhibit B, C and D, respectively.

7.   CONDITIONS PRECEDENT TO ORION'S OBLIGATION TO CLOSE

     Orion's obligation to sell the Purchased Assets and enter into the Amended
Agreement, the Pharmacovigilance Agreement, and the Quality Agreement in
substantially the forms attached hereto as Exhibit B, C and D, respectively, and
to take the other actions required to be taken by Orion at the Closing is
subject to the satisfaction, at or prior to the Closing, of each of the
following conditions:

     7.1 ACCURACY OF REPRESENTATIONS. All of the representations and warranties
made by GTx in this Agreement (considered collectively), and each of said
representations and warranties (considered individually), shall have been
accurate in all material respects as of the date of this Agreement and shall be
accurate in all material respects as of the Scheduled Closing Time as if made at
the Scheduled Closing Time.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       9.
<PAGE>
     7.2 GTX'S PERFORMANCE.

          (A) GTx shall have made the payments contemplated by Sections 1.5(a)
and (b).

          (B) All of the other covenants and obligations that GTx is required to
comply with or to perform pursuant to this Agreement at or prior to the Closing
(considered collectively), and each of said covenants and obligations
(considered individually), shall have been complied with and performed in all
material respects.

     7.3 NO PROCEEDINGS. Since the date of this Agreement, there shall not have
been commenced or threatened against Orion or against any Person affiliated with
Orion, any Proceeding (i) involving any material challenge to, or seeking
material damages or other material relief in connection with, any of the
Transactions, or (ii) that may have the effect of preventing, delaying, making
illegal or otherwise interfering with any of the Transactions

     7.4 [ * ]

     7.5 NO OTHER CONDITIONS. Subject to the fulfillment (or waiver) of the
above conditions, Orion shall at Closing execute the Amended Agreement, the
Pharmacovigilance Agreement, and the Quality Agreement in substantially the
forms attached hereto as Exhibit B, C and D, respectively.

8.   INDEMNIFICATION, ETC.

     8.1 SURVIVAL OF REPRESENTATIONS.

          (A) The representations and warranties made by Orion in this Agreement
(including without limitation the representations and warranties set forth in
Section 2) shall survive the Closing and shall expire [ * ] after the Closing
Date (the "Expiration Date" for such representation and warranty) and any
Liability of Orion (for indemnification or otherwise) with respect to such
representations and warranties shall thereupon cease; provided, however, that
if, at any time prior to the Expiration Date, any Indemnitee (acting in good
faith) delivers to Orion a written notice alleging the existence of an
inaccuracy in or other Breach of any of such representations and warranties and
asserting a claim for recovery under Section 8.2 based on such alleged
inaccuracy or other Breach, then the claim asserted in such notice shall survive
the Expiration Date until such time as such claim is fully and finally resolved.

          (B) The representations and warranties made by GTx in this Agreement
(including without limitation the representations and warranties set forth in
Section 3) shall survive the Closing and shall expire [ * ] after the Closing
Date, and any Liability of GTx (for indemnification or otherwise) with respect
to such representations and warranties shall thereupon cease; provided, however,
that if, at any time prior to the Expiration Date, any Orion Indemnitee (acting
in good faith) delivers to GTx a written notice alleging the existence of an
inaccuracy in or other Breach of any of such representations and warranties and
asserting a claim for recovery under Section 8.4 based on such alleged
inaccuracy or other Breach, then the claim asserted in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      10.
<PAGE>
such notice shall survive the Expiration Date until such time as such claim is
fully and finally resolved.

          (C) For purposes of this Agreement, each statement or other item of
information set forth in the Disclosure Schedule or in any update to the
Disclosure Schedule shall be deemed to be a representation and warranty made by
Orion in this Agreement.

     8.2 INDEMNIFICATION BY ORION. Subject to Section 8.3 and 8.6, from and
after the Closing Date, Orion shall hold harmless and indemnify each of GTx
Indemnitees from and against, and shall reimburse each of GTx Indemnitees for,
[ * ] Damages which are suffered or incurred by any of GTx Indemnitees or to
which any of GTx Indemnitees may otherwise become subject at any time [ * ] and
which arise from or as a result of:

          (A) Any Breach of any representation or warranty made by Orion in
Section 2 of this Agreement;

          (B) Orion's [ * ] use of the Purchased Assets prior to the Closing
Date, including without limitation (i) Orion's [ * ] sale, distribution,
marketing or manufacture of [ * ], including any rebates, discounts, returns,
recalls or allowances attributable to sales [ * ] prior to the Closing Date, and
(ii) any Third Party Claim on account of claims arising prior to the Closing
Date, including any regulatory action, proceeding, inquiry or investigation of
or pertaining to the Product;

          (C) Any Breach of any covenant or obligation of Orion in [ * ] or
[ * ] pursuant to this Agreement;

          (D) Any Liabilities not assumed by GTx under Section 1.3.

     Orion's obligations to indemnify GTx for claims arising out of the
manufacture, use, sale, importation, distribution, and/or marketing of the
Product for use in the Breast Cancer Field in all countries or territories
worldwide, except the USA, by Orion, its Affiliates, or Unaffiliated
Sublicensees are set forth in the Current Agreement and the Amended Agreement.

     8.3 LIMITATIONS.

          (A) Except with respect to claims based on actual fraud or injunctive
or any similar equitable relief that may be available to GTx, the rights of GTx
Indemnitees under Section 8.2 shall be the sole and exclusive remedies of GTx
Indemnitees with respect to claims resulting from or relating to any
misrepresentation, breach of warranty or failure to perform Orion's obligations
under this Agreement. Without limiting the generality of the foregoing, in no
event shall GTx, its successors or permitted assigns be entitled to claim or
seek rescission of the transactions consummated under this Agreement.

          (B) Orion shall only be liable under Section 8.2(a) with respect to
any claims that are properly asserted in writing pursuant to Section 8.1(a)
[ * ] of the Closing Date, except for any claim surviving such date pursuant to
Section 8.1; provided that any recovery on account

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      11.
<PAGE>
of a claim under Section 8.2(a) shall be limited to an amount that does not
exceed the total Purchase Price.

          (C) In no event shall Orion be responsible or liable for any Damages
or other amounts under Section 8.2 that are in the nature of lost profits or
lost income, damage to good-will or reputation or the like, or special,
indirect, consequential or punitive damages. Each of the GTx Indemnitees shall
use commercially reasonable efforts to pursue all legal rights and remedies
available in order to minimize the Damages for which indemnification is claimed
under Section 8.2.

     8.4 INDEMNIFICATION BY GTX. Subject to Sections 8.5 and 8.6, GTx shall hold
harmless and indemnify each of Orion Indemnitees from and against, and shall
reimburse each of Orion Indemnitees for, [ * ] Damages which are suffered or
incurred by any of Orion Indemnitees or to which any of Orion Indemnitees may
otherwise become subject at any time [ * ] and which arise from or as a result
of:

          (A) Any Breach of any representation or warranty made by GTx in
Section 3 of this Agreement;

          (B) Any Breach of any covenant or obligation by GTx in [ * ] or [ * ]
pursuant to this Agreement;

          (C) Any Liabilities assumed by GTx under Section 1.3.

     GTx's obligations to indemnify Orion for claims arising out of the
manufacture, use, sale, importation, distribution and/or marketing of Products
or the Purchased Assets by GTx, its Affiliates or licensees after the Closing
Date are set forth in the Current Agreement and the Amended Agreement.

     8.5 LIMITATIONS.

          (A) Except with respect to claims based on actual fraud, or injunctive
or similar equitable relief that may be available to Orion, the rights of Orion
Indemnitees under Section 8.4 shall be the sole and exclusive remedies of Orion
Indemnities with respect to claims resulting from any misrepresentation, breach
of warranty or failure to perform GTx's obligations under this Agreement.
Without limiting the generality of the foregoing, in no event shall Orion, its
successors or permitted assigns be entitled claim or seek rescission of the
transactions consummated under this Agreement.

          (B) GTx shall only be liable under Section 8.4(a) with respect to any
claims that are properly asserted in writing pursuant to Section 8.1(a) [ * ] of
the Closing Date except for any claims that survive such date pursuant to
Section 8.1.

          (C) In no event shall GTx be responsible and liable for any Damages or
other amounts under Section 8.4 that are in the nature of lost profits or lost
income, damage to good-will or reputation or the like, or special, indirect,
consequential or punitive damages. Each of Orion Indemnitees shall use
commercially reasonable efforts to pursue all legal rights and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      12.
<PAGE>
remedies available in order to minimize the Damages for which indemnification is
claimed under Section 8.4.

     8.6 INDEMNIFICATION PROCEDURES; DEFENSE OF THIRD PARTY CLAIMS. Promptly
after receipt by an Indemnitee under Section 8.2 or 8.4 of notice of any Third
Party Claim or the commencement of any Proceeding against it, such Indemnitee
will, if such claim is to be made against an Indemnitee under such Section, give
a Claim Notice to the indemnifying Party of the commencement of such claim, but
the failure to notify the indemnifying Party will not relieve the indemnifying
Party of any liability that it may have to any Indemnitee (except to the extent
that such failure prejudices the defense of such claim or Proceeding). The
indemnifying Party shall have the right, at its election and by written notice
to the Indemnitee within thirty (30) days after it receives a Claim Notice to
conduct and control the defense of such claim or Proceeding. If the indemnifying
Party makes such election:

          (A) Indemnitee shall make available to the indemnifying Party any
non-privileged documents and materials in possession of Indemnitee that may be
necessary to the defense of such claim or Proceeding;

          (B) The indemnifying Party shall keep Indemnitee informed of all
material developments and events relating to such claim or Proceeding;

          (C) The indemnifying Party shall have the right to participate in the
defense of such claim or Proceeding; and

          (D) The indemnifying Party shall not settle, adjust or compromise such
claim or Proceeding without prior written consent of Indemnitee.

If the indemnifying Party does not so elect, then with respect to any such claim
brought against an Indemnitee:

          (E) The indemnifying Party shall make available to the Indemnitee any
non-privileged documents and materials in its possession that may be necessary
or useful to the defense of such claim or Proceeding;

          (F) The indemnifying Party shall have the right to participate in the
defense of such claim or Proceeding at its own expense;

          (G) The Indemnitee shall keep the indemnifying Party informed of all
material developments and events relating to such claim or Proceeding and, if
requested by the indemnifying Party, shall confer with the indemnifying Party
regarding defense strategy; and

          (H) The Indemnitee shall not settle, adjust or compromise such claim
or Proceeding in a manner that may reasonably give rise to any liability of the
indemnifying Party (including by reasons of claims that may be asserted under
this Section 8) without the prior written consent of the indemnifying Party.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      13.
<PAGE>
     8.7 OTHER CLAIMS. A claim for indemnification for any matter not involving
a Third Party Claim may be asserted by Claim Notice to the Party from whom
indemnification is sought.

9.   POST-CLOSING COVENANTS

     9.1 TRANSFER OF NDA; ACCE0

          (A) Orion shall promptly execute all documents necessary to register
GTx as the owner of the Product Filings and the trademark Fareston in the USA
(registration number # 1460565). The Parties shall thereafter be responsible for
all governmental filings and regulatory actions (including without limitation
drug safety database updates and maintenance) after the Closing Date in
accordance with the Pharmacovigilance Agreement attached hereto as Exhibit C.
Orion may (at its expense) make and retain two (2) electronic copies and
photocopies of NDA [ * ] (one (1) for Orion [ * ] and one (1) copy of other
Product Filings for internal archival purposes and for purposes of defending
itself in any litigation (which copies shall not be deemed to confer upon Orion
any implied licenses, and shall be GTx's Confidential Information).

          (B) Without prejudice to what has been agreed between the Parties in
the Amended Agreement, if Orion requires access to certain portions of NDA [ * ]
and the Product Filings for legal or regulatory purposes, or for researching,
developing or manufacturing Products for use in the Breast Cancer Field outside
the USA or products other than Products (collectively, the "Orion Purposes");
then upon Orion's written request, GTx shall make such portions available to
Orion solely for such Orion Purposes on a temporary basis at a reasonable time
and at GTx's facilities. Orion may (at its expense) make and retain copies (in
electronic and/or paper copy format) of such portions of NDA [ * ] and the
Product Filings and use such copies solely for Orion Purposes. Any such copies
of NDA [ * ] or the Product Filings shall be Confidential Information of GTx.

          (C) If (i) the FDA, or equivalent regulatory authority outside the USA
(each, a "Regulatory Authority"), requires access to certain portions of NDA
[ * ] and the Product Filings or their counterparts outside the USA for legal or
regulatory purposes of the Party that does not own such items, or (ii) either
Party requires access to certain portions of NDA [ * ] and the Product Filings
or their counterparts outside the USA for legal or regulatory purposes of the
Party that does not own such items, including without limitation for making
patent-related submissions, then, in either of (i) or (ii), Orion or GTx (as
applicable), shall cooperate with such Regulatory Authority or the other Party
and make such portions available to the Regulatory Authority or the other Party
solely for such purpose on a temporary basis at a reasonable time and at Orion's
or GTx's facilities.

          (D) The Parties shall cooperate and work together to ensure that the
attorney-client privilege is preserved with respect to any documents in NDA
[ * ] and the Product Filings, in each case that are subject to such privilege
(and any other documents, information, or materials that are subject to such
privilege and may be transferred from or disclosed by one Party to the other
under this Agreement). In addition, the Parties acknowledge and agree that any
discovery by or disclosure to GTx of documents, information, or materials that
are not related to the Purchased Assets is inadvertent.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      14.
<PAGE>
     9.2 MARKETING PLAN. After the Closing Date, GTx shall use commercially
reasonable efforts to market the Fareston Product in the Breast Cancer Field in
the USA in accordance with a Sales and Marketing Plan which shall be attached as
Exhibit E within [ * ] after the Date of Agreement.

     9.3 LETTERS REGARDING NDA. Promptly after Closing, Orion shall deliver to
GTx an executed letter of "Transfer of Ownership of NDA" substantially in the
form set forth in Exhibit G. Promptly after receipt of such executed letter from
Orion, GTx shall deliver to Orion an executed "GTx FDA Letter" substantially in
the form set forth in Exhibit H.

10.  CONFIDENTIALITY

     10.1 CONFIDENTIAL INFORMATION. All Confidential Information disclosed
pursuant to this Agreement shall be deemed Confidential Information disclosed
under the Amended Agreement, and protected pursuant to such Agreement.

11.  MISCELLANEOUS PROVISIONS

     11.1 FURTHER ASSURANCES. Each Party hereto shall execute and/or cause to be
delivered to each other such instruments and other documents, and shall take
such other actions, as such other Party may reasonably request (prior to, at or
after the Closing) for the purpose of carrying out or evidencing any of the
Transactions.

     11.2 FEES AND EXPENSES. Each Party to this Agreement shall bear and pay all
fees, costs and expenses (including legal fees and accounting fees) that have
been incurred or that are incurred in the future by such Party in connection
with the transactions contemplated by this Agreement, including all fees, costs
and expenses incurred by such Party in connection with or by virtue of:

          (A) the negotiation, preparation and review of this Agreement
(including the Disclosure Schedule), the other Transactional Agreements and all
certificates, opinions and other instruments and documents delivered or to be
delivered in connection with the Transactions; and

          (B) the consummation and performance of the Transactions.

     11.3 NOTICES. Any notice or other communication required or permitted to be
delivered to any Party under this Agreement shall be in writing and shall be
deemed properly delivered, given and received when delivered (by hand, by
registered mail, by courier or express delivery service or by fax) to the
address or fax number set forth beneath the name of such Party below (or to such
other address or fax number as such Party shall have specified in a written
notice given to the other Parties hereto):

          if to Orion:

          Orion Corporation
          Orion Pharma
          Attn: President of Orion Pharma
          Orionintie 1 (P.O. Box 65)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      15.
<PAGE>
          FIN-02200 Espoo
          Finland
          Facsimile: 358-9-429-3044

          With a copy to:

          Orion Corporation
          Orion Pharma
          Attn: Legal Counsel
          Orionintie 1 (P.O. Box 65)
          FIN-02200 Espoo
          Finland
          Facsimile: 358-9-429-4088

          Notices to GTx shall be sent to:

          GTx, Inc.
          Attn: President, with a copy to the General Counsel
          3 North Dunlap Avenue
          Van Vleet Building, Third Floor
          Memphis, Tennessee 38163
          U.S.A.
          Telephone: 1-901-523-9700 x107
          Facsimile: 1-901-523-9772

          With a copy to:

          Cooley Godward LLP
          Five Palo Alto Square
          3000 El Camino Real
          Palo Alto, CA 94306
          Attention: Judith Hasko, Esq.
          Telephone: (650) 843-5065
          Facsimile: (650) 849-7400

     11.4 PUBLICITY. With regard to the existence and content of commercial
terms and conditions of this Agreement, unless agreed upon by the Parties,
neither Party shall originate any publicity, news release or other public
announcement, written or oral, whether to the public press, stockholders or
otherwise, relating to this Agreement, without the approval of the other Party,
except as required by law, including, without limitation, provisions regarding
the disclosure requirement for publicly quoted companies, and then only to the
minimum extent so required, in which event such Party shall give the other Party
a reasonable opportunity to review the form and content of the announcement
before such legally required announcement is made. Notwithstanding the
foregoing, GTx may originate any publicity, news release or other public
announcement, written or oral, whether to the public press, stockholders or
otherwise, relating to the use of a Toremifene based Product (except for
Toremifene based Products for use in the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      16.
<PAGE>
Breast Cancer Field in any country except the USA), provided that GTx forwards
to Orion such publicity, news release or other public announcement [ * ] prior
to such publicity, news release or other public announcement, except as
otherwise required by law or regulation, including without limitation disclosure
requirements promulgated by the Securities and Exchange Commission. It is agreed
that such publicity, news release or other public announcement does not require
the approval of Orion, unless Orion considers such publicity, news release or
other public announcement to be misleading or incorrect, in which case Orion
shall, within [ * ] after receiving such publicity, news release or other public
announcement, so notify GTx and provide written comments specifying changes that
Orion reasonably believes will correct such inaccuracy, except as otherwise
required by law or regulation. Such publicity, news release or other public
announcement shall include wording to the effect that Toremifene is a
proprietary compound of Orion, and that Toremifene has been licensed by Orion to
GTx for certain uses. [ * ].

     11.5 HEADINGS. The headings contained in this Agreement are for convenience
of reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of this
Agreement.

     11.6 COUNTERPARTS. This Agreement may be executed in several counterparts,
each of which shall constitute an original and all of which, when taken
together, shall constitute one agreement.

     11.7 GOVERNING LAW; DISPUTE RESOLUTION.

          (A) GOVERNING LAW. This Agreement, including the validity,
construction, interpretation and performance thereof, shall be governed entirely
by the laws of Sweden. It is the specific intent and agreement of the Parties
that the United Nations Convention on the International Sale of Goods shall not
apply to this Agreement.

          (B) DISPUTE RESOLUTION. All disputes arising out of or in connection
with this Agreement (except those involving actions commenced by or involving
Third Parties and affecting or involving only one of the Parties) shall be
resolved with the following mechanism:

               (I) ATTEMPTED AMICABLE RESOLUTION. The Parties shall promptly
give each other written notice of any disputes requiring resolution hereunder,
which written notice shall specify the Section(s) of this Agreement the other
Party is alleged to have breached and shall briefly state the initiating Party's
claims, and the Parties shall use reasonable efforts to resolve any such
disputes in an amicable manner.

     Any disputes arising in connection with this Agreement which cannot be
resolved in an amicable manner by representatives of the Parties shall be
referred, not later than thirty (30) days after initiation of dispute resolution
proceedings under this Section 11.7, to the following corporate officers of the
Parties for resolution:

     For GTx: President and Chief Executive Officer (or his or her designee)

     For Orion: President of Orion-Pharma (or his or her designee)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      17.
<PAGE>
     Such officers (or their designees) shall attempt to resolve the dispute and
shall communicate with each other by facsimile or telephone or in personal
meetings in an effort to resolve the dispute.

               (II) ARBITRATION. Any disputes (excluding any dispute,
controversy or claim arising out of or relating to the validity, enforceability,
scope or infringement of patent or trademark rights) arising in connection with
this Agreement which cannot be resolved by the Parties within forty-five (45)
days after initiation of dispute resolution proceedings under this Section 11.7
shall be finally settled by binding arbitration under the Rules of the
Arbitration Institute of the Stockholm Chamber of Commerce, Stockholm, Sweden in
accordance with said Rules then in effect with proceedings to be held in
Stockholm, Sweden in the English language. Reasonable submission of evidence
shall be permitted in any such proceeding to the extent permitted under and
consistent with such Rules. Judgment upon any award rendered by the
arbitrator(s) in such proceedings may be issued and enforced by any court having
competent jurisdiction. Any disputes arising out of or relating to the validity,
enforceability, scope or infringement of patent or trademark rights shall be
submitted for resolution by a court of competent jurisdiction.

     11.8 EFFECT OF COMMENCING DISPUTE RESOLUTION. If either Party in good faith
commences dispute resolution proceedings under Section 11.7: (a) any applicable
notice periods or cure periods hereunder shall be temporarily suspended pending
the outcome of such dispute resolution proceedings, and (b) the non-breaching
Party may, at its option, pay any amounts payable to the other Party that are in
dispute into an interest-bearing escrow account pending the outcome of such
dispute resolution proceedings.

     11.9 SUCCESSORS AND ASSIGNS; ASSIGNMENT. Neither Party may assign this
Agreement or any of its rights hereunder, nor delegate any of its duties or
obligations hereunder, to any Third Party without the prior written consent of
the other Party, except (i) to an Affiliate in accordance with the terms of this
Agreement, in which case notification thereof shall be provided to the other
Party prior to such assignment to an Affiliate, or (ii) in connection with a
merger, consolidation or similar reorganization. For clarity, this Agreement
shall survive any such merger, consolidation or reorganization of either Party
with or into, another party and no consent for such merger, consolidation or
reorganization shall be needed. Neither Party shall unreasonably withhold its
consent (which shall be provided promptly after a request is made) to any
contemplated assignment if such contemplated assignment is in connection with
the sale by either Party of all or substantially all of its assets to a Third
Party. Any assignment of this Agreement to an Affiliate of the assigning Party
shall not relieve the assigning Party of its responsibilities and obligations
hereunder. Any purported assignment or transfer in violation of this Section
11.9 shall be void.

     11.10 WAIVER. The failure by either Party at any time to enforce any of the
terms or provisions or conditions of this Agreement or exercise any right
hereunder shall not constitute a waiver of the same or affect that Party's
rights thereafter to enforce or exercise the same. No waiver of any of the
provisions of this Agreement shall be deemed binding unless executed in writing
by the Party to be bound by it.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      18.
<PAGE>
     11.11 AMENDMENTS. This Agreement may not be amended, modified, altered or
supplemented other than by means of a written instrument duly executed and
delivered on behalf of GTx and Orion.

     11.12 SEVERABILITY. In case one or more of the provisions contained in this
Agreement shall, for any reason, be held invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability shall not affect
any other provisions of this Agreement, but this Agreement shall be construed by
limiting such invalid, illegal or unenforceable provision, if such is not
possible, by deleting such provision from this Agreement.

     11.13 PARTIES IN INTEREST. Except for the provisions of Section 8 hereof,
none of the provisions of this Agreement is intended to provide any rights or
remedies to any Person other than the Parties hereto and their respective
successors and assigns (if any).

     11.14 INDEPENDENT CONTRACTORS. The Parties hereto are independent
contractors and nothing contained in this Agreement shall be construed to place
them in the relationship of partners, principal and agent, employer/employee or
joint venturer. Both Parties agree that they shall neither have the power or
right to bind or obligate the other, nor shall either hold itself out as having
such authority.

     11.15 ENTIRE AGREEMENT. This Agreement and the Transactional Agreements
(including all schedules and exhibits attached thereto) represents the entire
Agreement between the Parties relating to the subject matter hereof and
supersedes all prior arrangements, understandings, correspondence, notes,
minutes and agreements between the Parties (or their predecessors in interest)
whether written or oral. No supplement, modification or amendment of this
Agreement shall be binding unless executed by the Parties in writing and signed
by the duly authorized representatives of both Parties.

     11.16 DISCLOSURE SCHEDULE.

          (A) The information in the Disclosure Schedule constitutes (i)
exceptions to particular representations, warranties, covenants and obligations
of Orion as set forth in this Agreement or (ii) descriptions or lists of assets
and liabilities and other items referred to in this Agreement. If there is any
inconsistency between the statements in this Agreement and those in the
Disclosure Schedule (other than an exception expressly set forth as such in the
Disclosure Schedule with respect to a specifically identified representation or
warranty), the statements in this Agreement will control.

          (B) The Disclosure Schedule shall be arranged in sections
corresponding to the corresponding provision of this Agreement, and the
disclosures in any section of the Disclosure Schedule shall qualify (i) the
corresponding subsection of this Agreement and (ii) other subsections of the
Agreement to the extent it is clear (notwithstanding the absence of a specific
cross reference) from a reading of the disclosure that such disclosure logically
relates to such other sections.

                   REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      19.
<PAGE>
     The Parties hereto have caused this Agreement to be executed and delivered
as of the Date of Agreement.

ORION CORPORATION                       GTX, INC.


By:    /s/ Pekka Kaivola                By:    /s/ Mitchell Steiner, M.D.
       ------------------------------          ---------------------------------
       Pekka Kaivola                           Mitchell Steiner, M.D.

Title: Director                         Title: Vice-Chairman and CEO
       Orion Corporation Orion Pharma          GTx, Inc.


By:    /s/ Timo Lappalainen             By:    /s/ Marc Hanover
       ------------------------------          ---------------------------------
       Timo Lappalainen                        Marc Hanover

Title: Senior Vice President            Title: President and COO
       Orion Corporation Orion Pharma          GTx, Inc.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      20.
<PAGE>
                                    EXHIBITS

<TABLE>
<S>          <C>
Exhibit A:   Certain Definitions

Exhibit B:   Amended and Restated License and Supply Agreement

Exhibit C:   Pharmacovigilance Agreement

Exhibit D:   Quality Agreement

Exhibit E:   Sales and Marketing Plan

Exhibit F:   [ * ] Specifications

Exhibit G:   Letter of Transfer of Ownership of NDA

Exhibit H:   GTx FDA Letter
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      21.
<PAGE>
                                    EXHIBIT A

                               CERTAIN DEFINITIONS

     For purposes of the Agreement (including this Exhibit A):

     AFFILIATE. "Affiliate" shall mean and include any officer or director of
GTx or Orion or any Person which controls, is controlled by, or is under common
control with GTx or Orion.

     AGREEMENT. "Agreement" shall mean the Purchase Agreement to which this
Exhibit A is attached (including without limitation the Disclosure Schedule and
any other exhibits, schedules or attachments thereto), as it may be amended from
time to time.

     AMENDED AGREEMENT. "Amended Agreement" shall mean the Amended and Restated
License and Supply Agreement between the Parties dated as of January 1, 2005.

     BEST EFFORTS. "Best Efforts" shall mean efforts that a prudent Person
desiring to achieve a particular result would use in order to ensure that such
result is achieved as expeditiously as possible and that are commercially
reasonable given the nature of the particular result.

     BREACH. There shall be deemed to be a "Breach" of a representation,
warranty, covenant, obligation or other provision if there is or has been any
material inaccuracy in or breach of, or any material failure to comply with or
perform, such representation, warranty, covenant, obligation or other provision,
and the term "Breach" shall be deemed to refer to any such inaccuracy, breach,
failure, claim or circumstance.

     BREAST CANCER FIELD. "Breast Cancer Field" shall mean the prevention and
treatment of breast cancer.

     CLAIM NOTICE. "Claim Notice" shall mean a written notice that contains (i)
a description and the amount of any Damages incurred or that may be incurred by
GTx Indemnitees or Orion Indemnitees, (ii) a statement that GTx Indemnitees or
Orion Indemnitees are entitled to indemnification under Section 8.2 or 8.4 and a
reasonable explanation of the basis therefor, and (iii) a demand for payment in
the amount of such Damages.

     CLOSING. "Closing" shall have the meaning specified in Section 1.9 of the
Agreement.

     CLOSING DATE. "Closing Date" shall have the meaning specified in Section
1.9 of the Agreement.

     CONFIDENTIAL INFORMATION. "Confidential Information" shall mean, with
respect to a Party, all information of any kind whatsoever, and all tangible and
intangible embodiments thereof of any kind whatsoever, which is disclosed by
such Party to the other Party and is marked, identified as or otherwise
acknowledged to be confidential at the time of disclosure to the other Party.
For purposes of this Agreement, the Purchased Assets shall constitute
Confidential Information of GTx.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       A-1
<PAGE>
     CONSENT. "Consent" shall mean any approval, consent, ratification,
permission, waiver or authorization (including any Governmental Authorization).

     CONTRACT. "Contract" shall mean any written, oral, implied or other
agreement, contract, understanding, arrangement, instrument, note, guaranty,
indemnity, representation, supply agreement, sourcing agreement, warranty, deed,
assignment, power of attorney, certificate, purchase order, sales order, work
order, insurance policy, benefit plan, commitment, covenant, assurance or
undertaking of any nature.

     DAMAGES. "Damages" shall include any loss, damage, injury, Liability,
claim, demand, settlement, judgment, award, fine, penalty, Tax, fee (including
any reasonable legal fee, expert fee, accounting fee or advisory fee), cost
(including any reasonable cost of investigation), or reasonably related Third
Party expenses.

     DISCLOSURE SCHEDULE. "Disclosure Schedule" shall mean the schedule (dated
as of the date of the Agreement) delivered to GTx on behalf of Orion, a copy of
which is attached to the Agreement and incorporated in the Agreement by
reference.

     ENCUMBRANCE. "Encumbrance" shall mean any lien, pledge, hypothecation,
mortgage, security interest, encumbrance, equitable interest, preference, right
of possession, lease, tenancy, license, proxy, covenant, Order, option, right of
first refusal or preemptive right, whether arising out of an obligation to pay
any Taxes or otherwise.

     ENTITY. "Entity" shall mean any corporation (including any non-profit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited
liability company or joint stock company), firm or other enterprise,
association, organization or entity.

     EXPIRATION DATE. "Expiration Date" shall have the meaning set forth in
Section 8.1 of the Agreement.

     FARESTON BUSINESS ASSETS. "Fareston Business Assets" shall mean any and all
of: (a) [ * ]; and (b) [ * ]. For clarity, any information or data described
under this paragraph shall include any information or data in written or
electronic format.

     FARESTON PRODUCT. "Fareston Product" shall mean Orion Product in 60 mg
tablet form containing Toremifene that was promoted in the USA under the brand
name "Fareston" by Shire prior to the Date of Agreement for use in the Breast
Cancer Field.

     FDA. "FDA" shall mean the United States Food and Drug Administration and
any successor regulatory agency.

     FIELD. "Field" shall mean all uses of a Product in humans.

     GAAP. "GAAP" shall mean generally accepted accounting principles.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      A-2
<PAGE>
     GOVERNMENTAL AUTHORIZATION. "Governmental Authorization" shall mean any:

     (A) permit, license, certificate, franchise, concession, approval, consent,
ratification, permission, clearance, confirmation, endorsement, waiver,
certification, designation, rating, registration, qualification or authorization
that is, has been or may in the future be issued, granted, given or otherwise
made available by or under the authority of any Governmental Body or pursuant to
any Legal Requirement; or

     (B) right under any Contract with any Governmental Body.

     GOVERNMENTAL BODY. "Governmental Body" shall mean any:

     (A) nation, principality, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature;

     (B) federal, state, local, municipal, foreign or other government;

     (C) governmental or quasi-governmental authority of any nature (including
any governmental division, subdivision, department, agency, bureau, branch,
office, commission, council, board, instrumentality, officer, official,
representative, organization, unit, body or Entity and any court or other
tribunal);

     (D) multi-national organization or body; or

     (E) individual, Entity or body exercising, or entitled to exercise, any
executive, legislative, judicial, administrative, regulatory, police, military
or taxing authority or power of any nature.

     GTX. "GTx" shall have the meaning set forth in the introductory paragraph
to the Agreement.

     GTX INDEMNITEES. "GTx Indemnitees" shall mean the following Persons:

     (A) GTx;

     (B) GTx's current and future Affiliates;

     (C) The respective Representatives of the Persons referred to in clauses
"(a)" and "(b)" above; and

     (D) The respective successors and assigns of the Persons referred to in
clauses "(a)", "(b)" and "(c)" above.

     IND. "IND" shall mean an Investigational New Drug Application as defined in
the United States Food Drug and Cosmetic Act and applicable regulations
promulgated thereunder, or any equivalent Application to the equivalent agency
in any other country or group of countries, the filing of which is necessary to
commence clinical testing of a pharmaceutical product in humans in a particular
jurisdiction.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      A-3
<PAGE>
     INDEMNITEE. "Indemnitee" shall mean GTx Indemnitee and/or Orion Indemnitee.

     INTELLECTUAL PROPERTY. "Intellectual Property" shall mean rights in
database, data collections, diagrams, formulae, inventions (whether or not
patentable), know-how, logos, marks (including brand names, product names,
logos, and slogans), methods, processes, proprietary information, protocols,
schematics, specifications, techniques, URLs, web sites, works of authorship and
other forms of technology (whether or not embodied in any tangible form and
including all tangible embodiments of the foregoing, such as instruction
manuals, laboratory notebooks, prototypes, samples, studies and summaries).

     INTELLECTUAL PROPERTY RIGHTS. "Intellectual Property Rights" shall mean all
past, present, and future rights of the following types, which may exist or be
created under the laws of any jurisdiction in the world: (A) rights associated
with works of authorship, including exclusive exploitation rights, copyrights
and moral rights; (B) trademark and trade name rights and similar rights; (C)
trade secret rights; (D) patent and industrial property rights; (E) other
proprietary rights in Intellectual Property; and (F) rights in or relating to
registrations, renewals, extensions, combinations, divisions, and reissues of,
and applications for, any of the rights referred to in clauses "(A)" through
"(E)" above.

     KNOWLEDGE. "Knowledge" shall mean, as to Person, that such Person is
actually aware of a given factor or matter, or that such Person could be
expected to discover or otherwise become aware of such fact or matter in the
course of conducting a reasonably diligent and comprehensive investigation
concerning the truth or existence of such factor or other matter. An Entity
shall be deemed to have Knowledge of a particular fact or matter if any officer
or managerial level employee of such Entity has Knowledge of such fact or
matter.

     LEGAL REQUIREMENT. "Legal Requirement" shall mean any federal, state,
local, municipal, foreign or other law, statute, legislation, constitution,
principle of common law, resolution, ordinance, code, edict, decree,
proclamation, treaty, convention, rule, regulation, ruling, directive,
pronouncement, requirement, specification, determination, decision, opinion or
interpretation that is or has been issued, enacted, adopted, passed, approved,
promulgated, made, implemented or otherwise put into effect by or under the
authority of any Governmental Body.

     LIABILITY. "Liability" shall mean any debt, obligation, duty or liability
of any nature regardless of whether such debt, obligation, duty or liability
would be required to be disclosed on a balance sheet prepared in accordance with
GAAP and regardless of whether such debt, obligation, duty or liability is
immediately due and payable.

     [ * ].

     NDA. "NDA" shall mean a New Drug Application filed pursuant to the
requirements of the FDA, as more fully defined in 21 C.F.R. Section 314.5 et
seq., a Biologics License Application filed pursuant to the requirements of the
FDA, as more fully defined in 21 C.F.R. Section 601, and any equivalent
application filed with any equivalent regulatory authority.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      A-4
<PAGE>
     ORDER. "Order" shall mean any:

     (A) order, judgment, injunction, edict, decree, ruling, pronouncement,
determination, decision, opinion, verdict, sentence, subpoena, writ or award
that is, has been or may in the future be issued, made, entered, rendered or
otherwise put into effect by or under the authority of any court, administrative
agency or other Governmental Body or any arbitrator or arbitration panel; or

     (B) Contract with any Governmental Body that is, has been or may in the
future be entered into in connection with any Proceeding.

     ORION. "Orion" shall have the meaning specified in the introductory
paragraph of the Agreement.

     ORION INDEMNITEES. "Orion Indemnitees" shall mean the following Persons:

     (A) Orion;

     (B) Orion's current and future Affiliates;

     (C) The respective Representatives of the Persons referred to in clauses
"(a)" and "(b)" above; and

     (D) The respective successors and assigns of the Persons referred to in
clauses "(a)," "(b)" and "(c)" above.

     ORION PRODUCT. "Orion Product" shall mean tablets containing [ * ] of
Toremifene respectively, that are manufactured by Orion and are commercially
available as of the Date of Agreement, and such other dosage strength or
formulation of Toremifene as a therapeutically active ingredient as Orion may
manufacture.

     PERSON. "Person" shall mean any individual, Entity or Governmental Body.

     PRE-CLOSING PERIOD. "Pre-Closing Period" shall mean the period from the
date of the Agreement through the Closing Date.

     PROCEEDING. "Proceeding" shall mean any action, suit, litigation,
arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding and any informal proceeding), prosecution,
contest, hearing, inquiry, inquest, audit, examination or investigation that is
or has been or may be commenced, brought, conducted or heard by or before, or
that otherwise has involved or may involve, any Governmental Body or any
arbitrator or arbitration panel.

     PRODUCT. "Product" shall mean any pharmaceutical product for human use
within the Field containing Toremifene as a therapeutically active ingredient.

     PURCHASE PRICE. "Purchase Price" shall have the meaning specified in
Section 1.5 of the Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      A-5
<PAGE>
     PURCHASED ASSETS. "Purchased Assets" shall have the meaning set forth in
Section 1.1 to the Agreement.

     REGULATORY AUTHORITY. "Regulatory Authority" shall have the meaning
specified in Section 9.1.

     REPRESENTATIVES. "Representatives" shall mean officers, directors,
managerial level employees, agents, attorneys, accountants, advisors and other
representatives.

     TAX. "Tax" shall mean any tax (including any income tax, franchise tax,
capital gains tax, estimated tax, gross receipts tax, value added tax, surtax,
excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax,
property tax, business tax, occupation tax, inventory tax, occupancy tax,
withholding tax or payroll tax), levy, assessment, tariff, impost, imposition,
toll, duty (including any customs duty), deficiency or fee, and any related
charge or amount (including any fine, penalty or interest), that is, has been,
or may in the future be (a) imposed, assessed or collected by or under the
authority of any Governmental Body, or (b) payable pursuant to any tax sharing
agreement or similar Contract.

     TAX RETURN. "Tax Return" shall mean any return (including any information
return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document or information that
is, has been or may in the future be filed with or submitted to, or required to
be filed with or submitted to, any Governmental Body in connection with the
determination, assessment, collection or payment of any Tax or in connection
with the administration, implementation or enforcement of or compliance with any
Legal Requirement relating to any Tax.

     THIRD PARTY. "Third Party" shall mean any person or entity other than GTx,
Orion or an Affiliate of either of them.

     THIRD PARTY CLAIM. "Third Party Claim" shall mean any claim against any GTx
Indemnitee or Orion Indemnitee by a Third Party, whether or not involving a
Proceeding.

     TOREMIFENE. "Toremifene" shall mean [ * ].

     TRANSACTIONAL AGREEMENTS. "Transactional Agreements" shall mean the
Agreement and all other documents or agreements contemplated by Section 1.

     TRANSACTIONS. "Transactions" shall mean (a) the execution and delivery of
the respective Transactional Agreements, and (b) all of the transactions
contemplated by the respective Transactional Agreements, and the exercise by
Orion and GTx of their respective rights under the Transactional Agreements.

     USA. "USA" shall mean the United States of America including its fifty
states, the District of Columbia, Puerto Rico, and all its territories and
possessions.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      A-6
<PAGE>
                                    EXHIBIT B

                AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT

     THIS AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT (this "Agreement")
is entered into and made effective as of this 1st day of January, 2005 (the
"Restatement Date") by and between ORION CORPORATION, a corporation organized
and existing under the laws of Finland and having its principal office at
Orionintie 1 FIN-02200 Espoo, Finland ("Orion"), and GTX, INC., (fka
Genotherapeutics, Inc.) a corporation organized and existing under the laws of
the State of Delaware, U.S.A. and having its principal office at 3 North Dunlap
Avenue, Van Vleet Building, Third Floor, Memphis, Tennessee 38163, USA ("GTX").

     WHEREAS, Orion and GTX entered into a Toremifene License and Supply
Agreement effective as of March 30, 2000 (the "Effective Date"), to govern the
Parties' rights and obligations with respect to the research, development,
commercialization and manufacture of Product (as defined in said agreement) (the
"Original Agreement");

     WHEREAS, Orion and GTX amended and restated the Original Agreement on
October 22, 2001 (the "Amendment Date"), and then amended the Original Agreement
on March 5, 2003 (the "First Amendment"), and on December 29, 2003 (the "Second
Amendment");

     WHEREAS, Shire and Orion have entered into an agreement wherein Orion will
acquire all of Shire's rights and interests to Toremifene for the breast cancer
indication in the United States;

     WHEREAS, GTX desires to expand its license to include all of Orion's other
rights and interests in Toremifene for human use, except for the use of
Toremifene for the prevention and treatment of breast cancer in countries
outside of the United States and use of Toremifene in the animal health field
worldwide, and Orion desires to grant to GTX such licenses;

     WHEREAS, the Parties desire with this Agreement to supercede and replace
the Original Agreement, First Amendment and Second Amendment effective as of the
Restatement Date to provide that GTX shall have the sole responsibility for
researching, developing, registering and commercializing the Product (as defined
below) within the Field (as defined below) worldwide, except for the use of
Toremifene either for the prevention and treatment of breast cancer in countries
outside of the United States or for animal health; and

     WHEREAS, Orion shall have no monetary or other responsibilities for
researching, developing, registering or commercializing Product, but shall
remain responsible for manufacturing Orion Product (as defined below), as agreed
herein;

     NOW THEREFORE for and in consideration of the mutual covenants contained
herein, the receipt and sufficiency of which are hereby acknowledged, Orion and
GTX (hereinafter individually a "Party"; and collectively the "Parties") hereto
agree as follows:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-1
<PAGE>
1.   DEFINITIONS

     For purposes of this Agreement, the following terms shall be defined as set
forth below. Additional terms used in specific Sections of this Agreement shall
be defined in such Sections.

     1.1 "ADDITIONAL PRODUCT" shall have the meaning set forth in Section 2.1.5.

     1.2 "AFFILIATE" shall mean any business entity controlled by a Party, or
which controls a Party, or which is under common control with a Party. "Control"
herein means the direct or indirect ownership of more than fifty percent (50%)
of the authorized issued voting shares in such entity, or such other
relationship as in fact legally results in effective control over the
management, business and affairs of such entity or Party, as the case may be.

     1.3 "ANNUAL NET SALES" shall mean Net Sales (as defined below) in any
calendar year.

     1.4 "BREAST CANCER FIELD" shall mean the prevention and treatment of breast
cancer.

     1.5 "CALENDAR QUARTER" shall mean each of the three (3) month periods
beginning on January 1, April 1, July 1 and October 1 of each year during the
Term (as defined below).

     1.6 "COMPETING PRODUCT" shall mean any pharmaceutical product containing a
SERM as a therapeutically active ingredient as well as any salt thereof, which
product is licensed, sold and/or marketed for use in the Field, including, but
not limited to, other dosage forms licensed, sold and/or marketed for use in the
Field. Competing Product does not include Orion Product, but includes any
generic form of the Product.

     1.7 "CORRECTION FACTOR" shall have the meaning set forth in Section
3.1.3(b).

     1.8 "DMF" shall have the meaning provided in Section 7.5.

     1.9 "EUROPEAN UNION" shall include Austria, Belgium, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal,
Spain, Sweden, United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Malta, Poland, Slovakia, Slovenia, and any such other country or
territory that may become part of the European Union after the Restatement Date.

     1.10 "FARESTON PRODUCT" shall mean the Orion Product in 60 mg tablet form
containing Toremifene that was promoted in the USA under the brand name
"Fareston" by Shire prior to the Restatement Date for use in the Breast Cancer
Field.

     1.11 "FARESTON REPURCHASE AGREEMENT" shall mean the Repurchase Agreement
entered by and between Shire and Orion dated ________, 2004.

     1.12 "FARESTON U.S. WEB PAGES" shall have the meaning set forth in Article
9.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-2
<PAGE>
     1.13 "FIELD" shall mean all uses of a Product in humans. The Parties
expressly acknowledge that the use of Product in the field of animal health is
excluded from the scope of this Agreement.

     1.14 "FIRST COMMERCIAL SALE" means in each country, the date the Product is
first sold, marketed, or publicly made available for sale for use in a given
portion of the Field by GTX, its Affiliate or a GTX Unaffiliated Sublicensee.
Product for use in a given portion of the Field, distributed or used for
clinical trial purposes shall not be considered sold, marketed or made publicly
available for sale and shall not constitute First Commercial Sale.

     1.15 "GENERIC PRODUCT" shall mean a generic pharmaceutical product for
human use containing Toremifene as an active ingredient sold by an entity other
than GTX, its Affiliate or its Unaffiliated Sublicensee and which can be
substituted by the prescriber or dispenser for a Product for use in the Field
(excluding Products sold by or on behalf of Orion, in the Orion Territory in the
Orion Field or outside the Field).

     1.16 "GTX FINAL DEVELOPMENT AND REGISTRATION PLAN" shall mean the final
product development and registration plan for each Product in the Prostate
Cancer Field prepared by GTX, its Affiliate or a GTX Unaffiliated Sublicensee,
as the same may be modified from time to time pursuant to Section 7.4.

     1.17 "GTX KNOW-HOW" shall mean such non-patented and unpublished
non-clinical, pre-clinical and clinical documentation, information, and data
including information and data in U.S. IND [ * ], U.S. IND [ * ], and all
resulting marketing applications worldwide relating to the use of Toremifene or
any SERM in the Field, that is owned or controlled by, and disclosable by and
available to, GTX and its Affiliates as of the Effective Date or at any time
during the Term, including but not limited to all registration materials for the
Product developed, acquired or compiled by GTX and/or its Affiliates as of the
Effective Date or at any time during the Term, and all non-patented and
unpublished documentation, information and data relating to the formulation,
manufacture and/or quality control of the Product that is owned or controlled by
GTX and/or its Affiliates as of the Effective Date or at any time during the
Term.

     1.18 "GTX PATENTS" shall mean the patents issued from GTX Patent
Applications as of the Effective Date and other patents owned or controlled by
GTX and its Affiliates that are issued at any time during the Term, and that
claim technology used for the manufacture, sale or use of any SERM for use in
the Prostate Cancer Field (including any divisions, continuations,
continuations-in-part, re-examinations, reissues, additions, renewals and
extensions thereof). GTX Patents in existence as of the Restatement Date are set
forth in Part I of Schedule A. For purposes of this Agreement, the Parties
acknowledge that GTX Patents shall include United States Patents as set forth on
Schedule A, which claims the use of Product in the Prostate Cancer Field, which
patents are in the name of and owned by The University of Tennessee Research
Foundation. GTX represents and warrants that it has acquired sufficient rights
and licenses from The University of Tennessee Research Foundation to said
patents for the purpose of performing its obligations under this Agreement.

     1.19 "GTX PATENT APPLICATIONS" shall mean patent applications of the
University of Tennessee Research Foundation or GTX, as applicable, and/or
Affiliates of GTX pending as of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-3
<PAGE>
the Effective Date, and patent applications owned or controlled by the
University of Tennessee Research Foundation and/or GTX, as applicable, and/or
Affiliates of GTX, that are filed at any time during the Term, in each case that
claim technology used for the manufacture, sale or use of any SERM for use in
the Prostate Cancer Field (including any divisions, continuations,
continuations-in-part, re-examinations, reissues, additions, renewals and
extensions thereof). GTX Patent Applications in existence as of the Restatement
Date are set forth in Part II of Schedule A.

     1.20 "GTX PATENT RIGHTS" shall mean GTX Patents and GTX Patent
Applications.

     1.21 "GTX PRELIMINARY DEVELOPMENT AND REGISTRATION PLAN" shall mean the
preliminary product development plan for the development of the Product in the
Prostate Cancer Field prepared by GTX which has been provided to Orion prior to
Effective Date, and which was attached to the Original Agreement.

     1.22 "GTX TERRITORY" shall mean all countries or territories worldwide.

     1.23 "GTX UNAFFILIATED SUBLICENSEE" shall mean any sublicensee of GTX other
than a GTX Affiliate. For avoidance of doubt, Orion shall not be a GTX
Unaffiliated Sublicensee.

     1.24 "MAJOR COUNTRY" shall mean the United States of America including its
fifty states, the District of Columbia, Puerto Rico, and all other USA
territories and possessions ("USA"), Canada, Japan, Great Britain, France,
Germany, Spain and Italy.

     1.25 "MANUFACTURING COSTS" shall have the meaning set forth in Section 7.3.

     1.26 "MANUFACTURING PATENTS" shall have the meaning provided in Section
7.7.

     1.27 "MAT NET SALES OF FARESTON PRODUCT" shall mean the certain moving
annual total sales of the Fareston Product as defined in Section 3.1.3(b).

     1.28 "NET SALES" shall mean the invoiced gross sales of the Product to a
Third Party which is not a GTX Unaffiliated Sublicensee, less: (A) credits and
allowances or adjustments (consistent with generally accepted accounting
principles), granted to such customers on account of rejections, recalls or
returns of the Product previously sold; (B) any customary and reasonable trade
and cash discounts, rebates, including government rebates, granted in connection
with sale of Product to such customers; (C) sales, tariff duties and/or use
taxes directly imposed and with reference to particular sales; and (D) outbound
transportation prepaid or allowed, amounts allowed or credited on returns,
export licenses, import duties, value added tax, and prepaid freight.

     1.29 "ORION FIELD" shall mean the use of Toremifene in the Breast Cancer
Field.

     1.30 "ORION KNOW-HOW" shall mean such non-patented and unpublished
non-clinical, pre-clinical and clinical documentation, information, and data
relating to the Orion Product that is owned or controlled by, and disclosable by
and available to, Orion and its Affiliates as of the Effective Date or at any
time during the Term which is necessary for the development by GTX of Product
for use in the Field (including without limitation filing an application for
Regulatory

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-4
<PAGE>
Approval for the Product for use in the Field), including information and data
in the Orion Product NDA relating to Fareston Product, registration materials
for the Orion Product, documentation, information and data relating to the
formulation and/or quality control of the Orion Product. Except as otherwise
provided in Sections 7.7, 14.9, 16.1, 17.3.2, 17.4 and 21.2, Orion Know-How
shall exclude information relating to Orion's manufacture of Toremifene (as
defined below) and Orion Product (as defined below).

     1.31 "ORION PATENTS" shall mean the patents owned or controlled by Orion
that are directed to the compound Toremifene per se, and relate to the use or
sale of Toremifene and all other patents issued from Orion Patent Applications
during the Term (including any divisions, continuations, continuations-in-part,
re-examinations, reissues, additions, renewals and extensions thereof). Orion
Patents in existence as of the Restatement Date are set forth in Part I of
Schedule B. Schedule B shall be amended by Orion from time to time during the
Term to include future Orion Patents.

     1.32 "ORION PATENT APPLICATIONS" shall mean patent applications owned or
controlled by Orion and its Affiliates that are pending as of the Effective
Date, and patent applications owned or controlled by Orion and its Affiliates
that are filed at any time during the Term, in each case that are directed to
the compound Toremifene per se and relate to the use or sale of Toremifene
(including any divisions, continuations, continuations-in-part, re-examinations,
reissues, additions, renewals and extensions thereof). Orion Patent Applications
in existence as of the Restatement Date are set forth in Part II of Schedule B.
Schedule B shall be amended by Orion from time to time during the Term to
include future Orion Patent Applications.

     1.33 "ORION PATENT RIGHTS" shall mean Orion Patents and Orion Patent
Applications.

     1.34 "ORION PRODUCT" shall mean tablets containing [ * ] of Toremifene
respectively, that are manufactured by Orion and are commercially available as
of the Restatement Date, and such other dosage strength or formulation of
Toremifene as a therapeutically active ingredient as Orion may agree to
manufacture pursuant to Section 17.4.

     1.35 "ORION PRODUCT NDA" shall mean U.S. NDA [ * ].

     1.36 "ORION TERRITORY" shall mean all countries and territories worldwide,
except for the USA.

     1.37 "ORION UNAFFILIATED SUBLICENSEE" shall mean any licensee or
sublicensee under the Orion Patent Rights, other than an Orion Affiliate, GTX, a
GTX Affiliate or a GTX Unaffiliated Sublicensee.

     1.38 "OTHER PRODUCT" shall have the meaning set forth in Section 17.4.

     1.39 "PREMIUM" shall mean, with respect to an equity investment by a Third
Party in GTX, an amount equal to the difference between the total consideration
paid for the purchase of shares of GTX stock and the fair market value of such
stock, as defined herein. Such fair market value shall be equal to the trading
price of a share of GTX common stock on the date such Third Party investment is
made (or, if such date is not a trading day, the price of a share of GTX

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-5
<PAGE>
common stock on the most recent trading day prior to the date of such
investment, and if such Third Party investment occurs concurrent with the
initial public offering, then the price per share at which stock is offered to
the public), multiplied by the number of shares issued to such Third Party
investor.

     1.40 "PRODUCT" shall mean any pharmaceutical product for human use within
the Field containing Toremifene as a therapeutically active ingredient.

     1.41 "PRODUCT ROYALTY ADJUSTMENT DATE" shall have the meaning set forth in
Section 3.1.3(a).

     1.42 "PROSTATE CANCER FIELD" shall mean the prevention and treatment of
prostate cancer, which shall mean for the purposes of hereof: preventing
prostate carcinogenesis; suppressing or inhibiting prostate cancer; reducing the
risk of developing prostate cancer; increasing the survival rate of a subject
with prostate cancer; and treating prostate cancer. Furthermore, the Prostate
Cancer Field shall include the prevention and/or treatment of osteoporosis,
gynecomastia, hot flashes, and other side effects induced by chemical or
surgical androgen deprivation therapy in the treatment of prostate cancer.

     1.43 "PURCHASE AGREEMENT" shall mean the agreement between Orion and GTX
dated December 13, 2004.

     1.44 "REGULATORY APPROVAL" shall mean all governmental approvals required
to import, market, promote and sell the Product for use in the Field in any
given country or territory in the GTX Territory, including but not limited to,
product registrations, medical approvals and price and marketing approvals.

     1.45 "ROYALTY INCOME" shall have the meaning set forth in Section 3.1.5.

     1.46 "SALES OF GENERIC PRODUCT" shall mean the documented sale and use of a
Generic Product.

     1.47 "[ * ]" shall have the meaning set forth in Section 3.1.6.

     1.48 "SERM" shall mean Toremifene (as described in the Orion Patent
Rights), including its isomers, metabolites, derivatives or analogs having
either antiestrogenic or estrogenic pharmacological properties.

     1.49 "SHIRE" shall mean Shire US, Inc., a corporation duly organized and
existing under the laws of New Jersey, USA, and having its principal offices in
Wayne, Pennsylvania, which had rights to Product in the USA in the Breast Cancer
Field prior to the Restatement Date.

     1.50 "SPECIFICATIONS" shall mean the current specifications (as of the
Restatement Date) for the Orion Product, as such specifications are, with regard
to [ * ] containing Toremifene, set forth in the Orion Product NDA, and with
regard to [ * ] and [ * ] tablet of Orion Product set forth in Schedule C
(Copies of such current specifications are set forth in Schedule C attached
hereto and made a part hereof.) The Specifications shall also include any other
modified or additional specifications applicable to Orion Product which may be

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-6
<PAGE>
manufactured by Orion, pursuant to Section 17.3 or 17.4. Schedule C may be
amended from time to time as necessary to reflect modifications to the
Specifications that may be implemented pursuant to Section 17.3 or to include
Specifications for any Other Product that Orion may agree to manufacture
pursuant to Section 17.4.

     1.51 "TERM" shall mean the period commencing on the effective date of the
Original Agreement and continuing, on a country by country basis until the later
of (a) the date of expiration or invalidation of the last to expire or be
invalidated of the GTX Patent Rights, or (b) the expiration or termination of
the last to expire of the marketing or regulatory exclusivity granted by the
FDA, the European Medicines Agency or other equivalent regulatory authority for
Product, each of (a) and (b) herein as subject to earlier termination under
Article 21.

     1.52 "THIRD PARTY" or "THIRD PARTIES" shall mean any party or parties other
than GTX, Orion, an Affiliate of GTX, or an Affiliate of Orion.

     1.53 "TOREMIFENE" shall mean [ * ].

     1.54 "TRADEMARKS" shall mean the trademarks GTX selects and registers for
the Product in the GTX Territory in accordance with Article 10 of this
Agreement, and the trademark Fareston(R) in the USA used by Shire prior to the
Restatement Date for the Fareston Product.

     1.55 "USA" shall mean the United States of America including its fifty
states, the District of Columbia, Puerto Rico, and all its territories and
possessions.

     1.56 "U.S. FDA" shall mean the United States Food and Drug Administration
and any successor regulatory agency.

     1.57 "U.S. IND" shall mean an Investigational New Drug Application filed
with the U.S. FDA.

     1.58 "U.S. NDA" shall mean a New Drug Application filed with the U.S. FDA.

     1.59 "UPFRONT AND MILESTONE INCOME" shall have the meaning provided in
Section 3.1.1(c).

     1.60 "VALID CLAIM" shall mean a claim of an issued patent which has not
expired and which has not been held revoked, invalid or unenforceable by
decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed with the time allowed for appeal having expired, and
which has not been admitted to be invalid through reissue or disclaimer or
otherwise.

2.   GRANT AND SCOPE OF RIGHTS GRANTED

     2.1 ORION GRANTS TO GTX.

          2.1.1 LICENSE GRANTS. Orion hereby grants to GTX for the Term:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-7
<PAGE>
                    (I) an exclusive right and license, with the right to grant
sublicenses as provided in Section 2.1.4, under Orion Patent Rights and Orion
Know-How, to develop, use, have used, sell, have sold, import, market and
distribute the Product in the Field in the GTX Territory, except in the Orion
Field in the Orion Territory; and

                    (II) a non-exclusive right and license, with the right to
grant sublicenses as provided in Section 2.1.4, under the Orion Patents and
Orion Know-How, to perform research and preclinical development activities in
accordance with Section 2.5 using the Powder (as defined in Section 14.6.2) to
be provided to GTX pursuant to Section 14.6.2, except in the Orion Field in the
Orion Territory.

     For the avoidance of doubt, nothing herein shall limit or restrict or be
construed to limit or restrict Orion from using, and GTX acknowledges that Orion
may use, Toremifene and Product (i) as a reference compound and reference
product in its research and development activities for the Field and for uses
outside the Field, and (ii) in conducting business activities in the Orion Field
in and for the Orion Territory, as well as in the field of animal health.

     Licenses under Section 2.1.1(i) may be expanded to include the right to
make and have made Products as provided in Sections 7.7, 14.9, 16.1, 17.3.2,
17.4 and 21.2.2 on such terms as are set forth in such Sections.

          2.1.2 MANUFACTURING RIGHTS RESERVED. Except as otherwise provided in
Sections 7.7, 14.9, 16.1, 17.3.2, 17.4 and 21.2.2, Orion retains the exclusive
right to manufacture or have manufactured Toremifene, Orion Product and Product
including, without limitation, any Toremifene and Orion Product to be supplied
to GTX under this Agreement and subject to Sections 7.7, 14.9, 16.1, 17.3.2,
17.4 and 21.2.2 herein, during the Term GTX undertakes to purchase all its
requirement of Product exclusively from Orion.

          2.1.3 USE OF ORION KNOW-HOW. Under the license granted pursuant to
Section 2.1.1(i), GTX shall, subject to the terms and conditions of this
Agreement, including without limitation Article 8, have the right to use and
reference Orion Know-How in support of GTX's clinical trials and applications
for Regulatory Approval within the Field for the Product in the GTX Territory.
Subject to the license rights granted hereunder, Orion retains full ownership
rights to all Orion Know-How.

          2.1.4 SUBLICENSING. GTX shall have the right to sublicense its rights
received under this Agreement in the GTX Territory to any Third Party, except
that GTX shall not have the right to grant sublicenses to any Third Party to
market, sell or offer for sale the Fareston Product for use in the Breast Cancer
Field in the USA. For any permitted sublicense granted by GTX, GTX shall notify
Orion within fifteen (15) days after execution of an agreement between GTX and a
GTX Unaffiliated Sublicensee. GTX shall endeavor to include in its agreement
with each GTX Unaffiliated Sublicensee a provision stating that, upon
termination of this Agreement, such Unaffiliated Sublicensee and Orion shall
discuss, and as appropriate, negotiate the terms and conditions under which
Orion and such sublicensee would be willing to collaborate with regard to the
further development and/or commercialization of the Product for use in the field
in which GTX and such sublicensee were previously developing and/or
commercializing Products, provided that any such further development and/ or
commercialization of the Product by Orion

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-8
<PAGE>
and such sublicensee shall be subject to and conditioned by a definite written
agreement, if any, accepted and signed by duly authorized representatives of
Orion. GTX shall forward to Orion a complete copy of each sublicense agreement.
No sublicense shall relieve GTX of any of its obligations or commitments under
this Agreement and GTX shall cause its Affiliates and GTX Unaffiliated
Sublicensees to comply with all of GTX obligations and commitments under this
Agreement.

     GTX shall remain jointly and severally liable to Orion with its
Affiliate(s) and GTX Unaffiliated Sublicensee(s) that obtain a sublicense under
the licenses granted to GTX pursuant to Section 2.1.1 for performance of GTX's
obligations under this Agreement. GTX shall be responsible for complying and
ensuring that such of its Affiliates and GTX Unaffiliated Sublicensees, as
applicable, comply with all relevant laws, regulations and requirements relating
to the importation, packaging, distribution, marketing, promotion, sale and use
of Product in the GTX Territory.

     Orion shall have the right to propose to GTX one or more potential
sub-licensees under GTX's rights to the Product for use in the Field (other than
in the Orion Field) in South Korea and China (including, for the purpose of this
Agreement, the People's Republic of China and Taiwan). GTX shall consider such
proposal(s) in good faith when appointing such a sub-licensee for the Product
for use in the Field (other than in the Orion Field) for South Korea and China.

          2.1.5 GTX RIGHTS OF FIRST NEGOTIATION. Orion grants GTX, on a country
by country basis, the right of first negotiation to negotiate further agreements
under commercially reasonable terms and conditions regarding the further
development, registration, promotion, marketing, sales and distribution of a
pharmaceutical product for human use within the Prostate Cancer Field containing
SERMs as the active ingredient (a) which is covered by a Valid Claim within the
GTX Patent Rights in such country; and (b) for which Orion has both a license or
other right to develop and commercialize such products and has commenced, within
five (5) years after the Amendment Date, a Phase I clinical trial for such
product anywhere in the world for a primary indication falling within the
Prostate Cancer Field (a product fulfilling (a) and (b), hereinafter referred to
as "Additional Product"). If Orion decides to offer to any Third Party the
opportunity to participate in the development or commercialization of such
Additional Product, or if Orion commences Phase I clinical trials for such
Additional Product, it shall so notify GTX in writing. [ * ] after GTX's receipt
of such notice from Orion regarding commercially reasonable terms and conditions
for obtaining rights in and to such Additional Product, GTX shall notify Orion
in writing if it wishes to enter into negotiations with respect to such
Additional Product. Should GTX elect to exercise such right, the Parties agree
to negotiate in good faith the commercially reasonable terms and conditions for
a letter of intent to be completed [ * ] of receipt by Orion of such
notification from GTX. Any deadlines may be extended by mutual written
agreement. Should GTX fail to provide written notification to Orion by the end
of [ * ], or GTX notifies Orion that it does not wish to enter into
negotiations; or the Parties, despite conducting good faith negotiations, are
unable to finalize the commercial terms of the letter of intent [ * ], GTX shall
have no further rights in the SERM, and Orion shall be free to contract with a
Third Party concerning same or itself further pursue the development,
registration, promotion, marketing, sales and distribution of such Additional
Product.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-9
<PAGE>
          2.1.6 GTX RIGHTS TO NEGOTIATE FOR RIGHTS IN THE ORION FIELD IN THE
ORION TERRITORY. With respect to the development and commercialization of
Products in the Orion Field in the Orion Territory, GTX shall have the following
rights:

               (A) As of the Restatement Date, Orion has Third Party licensees
that have rights to develop and/or commercialize the Product in the Orion Field
and in the Orion Territory. If any such sublicense terminates at any time during
the Term after the Restatement Date, and if Orion desires to seek another Third
Party sublicensee under such rights, then Orion shall so notify GTX and GTX
shall have a right to negotiate with Orion the terms under which GTX may obtain
such rights to such Product in the Orion Field and in the Orion Territory, on
the following basis:

               (B) If GTX is interested in negotiating with Orion for such
rights to Product in the Orion Field and in the Orion Territory, it shall notify
Orion thereof in writing within thirty (30) days of receiving Orion's notice.
The Parties shall negotiate in good faith for a period of ninety (90) days after
Orion receives GTX's notice of interest on the terms of an agreement governing
such rights and during said period Orion shall not grant such rights to any
Third Party. If the Parties fail within such ninety (90) day period to execute
such an agreement, then Orion shall thereafter be free to contract with any
Third Party with respect to the rights in question.

     2.2 NO IMPLIED LICENSES. Any rights not expressly granted by either Party
to the other Party in this Agreement are expressly reserved by the Party owning
or controlling such rights and, accordingly, no licenses other than those
specified herein shall be deemed granted by this Agreement by implication,
estoppel or otherwise.

     2.3 UNITED STATES GOVERNMENT RIGHTS. In the event it is determined that any
GTX Patent Rights were developed with the support of the United States
Government or any agency thereof (the "Government"), the Government will retain
rights in the GTX Patent Rights as set forth in Title 35 U.S.C. Section 200 et
seq. All rights herein granted to GTX are subject to any such rights held by the
Government and further subject to any restrictions or obligations that may be
imposed by the Government pursuant to such rights, at such time that it is
determined.

     2.4 ORION'S RIGHT OF FIRST NEGOTIATION.

          2.4.1 Whereas Orion has considerable knowledge and experience in the
marketing, sales and distribution of pharmaceutical products in, inter alia,
Scandinavia (which term shall for purpose of this Section 2.4 comprise the
countries of Denmark, Finland, Norway and Sweden), GTX undertakes to regard
Orion as its preferential partner for the marketing, sales and distribution of
the Product in Scandinavia for use in the Field (other than in the Orion Field
in the Orion Territory), subject to this Section 2.4.1. Consequently, GTX
grants, and shall cause its Affiliates and Unaffiliated Sublicensees who receive
a sublicense under the license granted to GTX pursuant to Section 2.1.1 in
Scandinavia to grant, to Orion a right of first negotiation to negotiate in good
faith an agreement(s) under commercially reasonable terms and conditions
regarding the marketing, sales and/or distribution by Orion of the Product in
Scandinavia for use in the Field (other than in the Orion Field in the Orion
Territory), with the express understanding

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-10
<PAGE>
that such commercially reasonable terms and conditions shall not comprise an
obligation to develop and register the Product for use in the Field in any
country of Scandinavia.

          2.4.2 Within thirty (30) days after Orion's receipt of a first written
offer from GTX regarding commercially reasonable terms and conditions governing
such rights, Orion shall notify GTX in writing if it wishes to negotiate the
terms and conditions under which Orion could obtain the rights contemplated in
this Section 2.4. Should Orion so exercise such right, the Parties shall
negotiate exclusively with each other and in good faith the commercially
reasonable terms and conditions for a license and distribution agreement for the
marketing, sales and distribution by Orion of the Product in Scandinavia for use
in the Field (excluding the Orion Field in the Orion Territory), such
negotiations to be completed within one hundred and eighty (180) days from the
date of Orion's notification to GTX. Any deadlines may be extended by mutual
agreement upon reasonable request. If Orion fails to provide written
notification to GTX by the end of the thirty (30) day period; Orion notifies GTX
that it does not wish to enter into negotiations; or the Parties, despite
conducting good faith negotiations, are unable to finalize the material
commercial terms of agreement within such one hundred and eighty (180) day
period (any such event, a "Termination of the Orion Right"), Orion shall have no
further right under this Agreement to market, sell and distribute the Product in
Scandinavia and GTX shall be free to offer to or enter into an agreement with
any Third Party or any GTX Affiliate with respect to such activities after the
Termination of the Orion Right occurs.

          2.4.3 In the event that GTX's Unaffiliated Sublicensee for Product for
use in the Field in the USA does not obtain the right and license to sell, have
sold, import, market and distribute the Product in the Field in Europe at the
time of execution of the sublicense agreement for the Product for use in the
Field in the USA, then Orion shall, on the terms and conditions of Sections
2.4.1 and 2.4.2, have a right of first negotiation to negotiate in good faith an
agreement(s) under commercially reasonable terms and conditions regarding the
marketing, sales, and/or distribution of the Product for use in the Field in
Europe.

     2.5 USE OF TOREMIFENE BY GTX FOR RESEARCH. Subject to Sections 2.1.1(ii)
and 14.6.2, GTX may use the Powder provided to it pursuant to Section 14.6.2 to
perform stability studies and other activities with respect to Products for use
in the Field that are necessary for supporting Regulatory Approval of Products
or expanding the indications for Products within the Field. GTX shall, upon
Orion's request therefor, provide Orion with written updates of any and all
activities undertaken by or on behalf of it pursuant to this Section 2.5, and
with the results thereof in reasonable detail.

     2.6 PROHIBITED ACTIONS. During the Term of this Agreement, Orion shall not
grant any rights to any Third Party that are inconsistent with the licenses
granted to GTX pursuant to Section 2.1.1.

3.   PAYMENTS

     3.1 TYPES OF PAYMENTS. For the rights, privileges and licenses granted
hereunder, GTX shall pay Orion in the manner provided as follows:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-11
<PAGE>
          3.1.1 In the event GTX or its Affiliate receives Upfront and Milestone
Income (as defined in Section 3.1.1(c)), GTX shall pay Orion as follows:

               (A) Any Upfront and Milestone Income for the sublicensing of
Product rights in the Prostate Cancer Field shall first be applied to [ * ] both
prior to and after the Effective Date with respect to the [ * ], and also for
the [ * ].

               (B) Upon full reimbursement of such [ * ] pursuant to Section
3.1.1(a), any remaining Upfront and Milestone Income (the "Net Upfront and
Milestone Income") shall then be paid by GTX to Orion as follows:

                    (I) GTX shall pay Orion [ * ] of the portion of Net Upfront
and Milestone Income that is [ * ]; and

                    (II) [ * ] of the portion of the Net Upfront and Milestone
Income that is [ * ].

               (C) For the purposes of this Agreement, "Upfront and Milestone
Income" shall mean any bona fide consideration (either in cash or non-cash form)
received by GTX or its Affiliate from a GTX Unaffiliated Sublicensee for
sublicensing GTX's rights in and to the Product for use in the Prostate Cancer
Field in the GTX Territory excluding: (i) Royalty Income (as defined in Section
3.1.5); (ii) cost of goods payments for supply of Product manufactured by Orion
and supplied at the prices set forth in Article 14 herein below, or payments to
reimburse GTX's fully burdened costs of manufacturing or having manufactured
Product by or on behalf of GTX as permitted under this Agreement; (iii) in the
form of a loan; or (iv) for the purchase of an equity interest in GTX (except to
the extent such purchase price is a Premium over the fair market value of such
stock, in which case the Premium, but not the portion of such price that is at
the fair market value of such stock, shall be included in Upfront and Milestone
Income). Notwithstanding the foregoing, if GTX receives Upfront and Milestone
Income received in the form described in (ii) or (iii) [ * ]. For example and
without limitation, [ * ].

          3.1.2 If GTX is Acquired prior to the first Regulatory Approval of
Product for use in the Prostate Cancer Field, then GTX shall pay to Orion an
amount equal to the lesser of one million dollars ($1,000,000) or one percent
(1%) of the fair market value of GTX at the time of such acquisition. "Acquired"
means that GTX either (i) sells all or substantially all of its assets to a
Third Party, or (ii) is merged with or consolidated or reorganized into a Third
Party, or becomes a subsidiary of a Third Party, and, as a result of such
transaction, the stockholders of GTX immediately prior to such transaction own
less than fifty percent (50%) of the surviving parent entity.

          3.1.3 ROYALTIES PAYABLE ON COMMERCIAL SALES OF FARESTON PRODUCT UNTIL
PRODUCT ROYALTY ADJUSTMENT DATE.

               (A) For commercial sales of the Fareston Product by GTX or its
Affiliates after the Restatement Date, until the earlier to occur of (y) [ * ],
or (z) the [ * ] of a Product for use in the Prostate Cancer Field (any such
Product in the Prostate Cancer Field,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-12
<PAGE>
hereinafter referred to as a "New Product", and the date that is the earlier to
occur of (y) or (z), hereinafter referred to as the "Product Royalty Adjustment
Date"), GTX shall pay to Orion a running royalty on Net Sales of Fareston
Product by GTX, its Affiliate or its Unaffiliated Sublicensee, as follows:

                    (I) Up until the end of the calendar month immediately
preceding the month in which the [ * ] occurs, the royalty due to Orion with
respect to Net Sales of the Fareston Product by GTX, its Affiliates and/or
Unaffiliated Sublicensees in the USA shall be [ * ] of Net Sales of Fareston
Product.

                    (II) Commencing upon the first day of the calendar month in
which the [ * ] occurs, and for the [ * ], the royalty due to Orion with respect
to Net Sales of the Fareston Product shall be [ * ] of Net Sales of Fareston
Product by GTX, its Affiliates and/or Unaffiliated Sublicensees during such
period of time, or (B) [ * ] of the MAT Net Sales of Fareston Product (as
calculated and defined in Section 3.1.3(b)).

                    (III) Upon the first day of the [ * ] occurs, and for the
[ * ], the royalty due to Orion with respect to Net Sales of Fareston Product by
GTX, its Affiliates and Unaffiliated Sublicensees shall be [ * ] of Net Sales of
Fareston Product by GTX, its Affiliates and Unaffiliated Sublicensees during
such period of time, or (B) [ * ] of [ * ] MAT Net Sales of Fareston Product.

               (B) The Parties have agreed to use a moving annual total ("MAT")
of sales of Fareston Product in the USA in calculating royalties due on Net
Sales of Fareston Product in the USA during [ * ] of the first New Product,
which MAT takes into account and reflects [ * ] during such period of time. Such
MAT shall be based upon (i) the [ * ] of such New Product and (ii) the actual
Net Sales of the Fareston Product in the USA during the [ * ], as follows:
First, the "Correction Factor" shall be calculated, which shall be equal to the
Net Sales of Fareston Product by GTX, its Affiliates and/or Unaffiliated
Sublicensees in the USA during the [ * ] occurs, divided by the Net Sales of
Fareston Product during the [ * ] occurs in the USA, provided that in no event
will the Correction Factor be [ * ]. Then, the "MAT Net Sales of Fareston
Product" shall be calculated, which shall be equal to the Correction Factor
multiplied by actual Net Sales of the Fareston Product during [ * ] occurs.

               (C) For example and without limitation, if the Net Sales of the
Fareston Product have been [ * ] for [ * ] prior to the [ * ] occurs, and [ * ]
for [ * ] preceding the beginning of the [ * ] occurs, then the Correction
Factor would be [ * ]. Accordingly, the MAT Net Sales of Fareston Product would
be [ * ] of the actual Net Sales of the Fareston Product during the [ * ].

               (D) Commencing upon the Product Royalty Adjustment Date, the
royalty for Fareston Product shall be paid pursuant to Section 3.1.4 and shall
no longer be due pursuant to Sections 3.1.3(a) and (b).

               (E) For clarity, sales of any New Product shall not be included
in the calculation of Net Sales of Fareston Product under this Section 3.1.3,
but shall instead be subject to the royalty due pursuant to Section 3.1.4, no
matter when such sales occur.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-13
<PAGE>
          3.1.4 ROYALTIES PAYABLE ON OTHER COMMERCIAL SALES OF PRODUCT. Except
as provided for the Fareston Product prior to the Product Royalty Adjustment
Date in Section 3.1.3, GTX shall pay to Orion a royalty on Net Sales of Product
by GTX or its Affiliates, equal to [ * ] of Net Sales of such Products, on a
country by country basis, subject to the provisions of Sections 3.1.8 and
21.2.2.

          3.1.5 Subject to the provisions of Sections 3.1.8 and 21.2.2, and
except as provided for the Fareston Product prior to the Product Royalty
Adjustment Date in Section 3.1.3, in the event GTX receives running royalty
income from GTX Unaffiliated Sublicensees for sublicensing GTX's rights in and
to any Product and/or based upon sales by GTX Unaffiliated Sublicensees of any
Product in the GTX Territory ("Royalty Income"), GTX shall pay Orion the lesser
of, on a country by country basis, either (a) [ * ] of such Royalty Income; or
(b) [ * ] of such Product by such GTX Unaffiliated Sublicensees provided,
however, that in no event shall the amounts due to Orion pursuant to this
Section 3.1.5 be [ * ] of Net Sales of such Product by such GTX Unaffiliated
Sublicensees

          3.1.6 Notwithstanding Sections 3.1.3 through 3.1.5, if GTX enters into
an agreement with a Third Party to [ * ] and GTX is [ * ] (a [ * ]), then in
lieu of the payments to Orion under Sections 3.1.3 through 3.1.5, GTX shall pay
to Orion [ * ] of [ * ]. Additionally, GTX shall not be obligated to pay Orion
any amounts under Sections 14.4 or 14.6 for Product supplied to GTX for the
purpose of [ * ], as the Parties have agreed that the amounts due to Orion
pursuant to this Section 3.1.6 shall be in lieu of any payments that would
otherwise be due to Orion for the supply of such Product if this Section 3.1.6
were not applicable.

          3.1.7 As of December 31, 2000, an upfront license fee of four hundred
thousand dollars ($400,000) (the "Upfront License Fee"), was paid in full by GTX
to Orion. This payment shall be creditable by GTX against fees or payments due
to Orion with respect to Upfront and Milestone Income pursuant to Section 3.1.1.

          3.1.8 If a Generic Product is sold in any Major Country of the GTX
Territory, and, for two (2) succeeding Calendar Quarters the Sales of Generic
Product in that country [ * ] of the sales of Product (calculated on a unit
basis) in that country by GTX, its Affiliates and Unaffiliated Sublicensees,
then the royalty on Net Sales owed by GTX to Orion under Section 3.1.4 and the
payments due to Orion on Royalty Income pursuant to Section 3.1.5, respectively,
shall be reduced to [ * ] of the amount otherwise due to Orion pursuant to
either Section 3.1.4 or 3.1.5, as applicable, with regard to such country with
such reduction to be applicable to the immediately succeeding Calendar Quarter
only.

          3.1.9 For clarity, in no event shall a royalty be due with respect to
the sale of a given unit of Fareston Product pursuant to more than one of
Sections 3.1.3, 3.1.4 or 3.1.5.

     3.2 NON-REFUNDABILITY. All milestone payments GTX makes to Orion pursuant
to Section 3.1.1 shall be non-refundable once paid. However, if this Agreement
is terminated for any reason prior to a given milestone payment becoming due or
if the events specified for a given milestone payment do not occur, then GTX
shall have no obligation to make such milestone payment.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-14
<PAGE>
     3.3 ROYALTY REPORTS AND PAYMENTS. Commencing with the first Calendar
Quarter in which GTX, its Affiliates or a GTX Unaffiliated Sublicensees make the
First Commercial Sale of a Product, GTX shall provide Orion with a written
report of Net Sales and Royalty Income on a country-by-country basis within
forty-five (45) days after the last day of March, June, September and December
for Royalty Income accruing on Net Sales during the three (3) preceding calendar
months. Concurrently with the submission of each such written report, GTX shall
pay or cause to be paid to Orion the total amount of royalties shown to be due
thereon.

     3.4 CURRENCY. GTX shall make all Upfront and Milestone Income and royalty
payments to Orion pursuant to Section 3.1 in U.S. Dollars except that GTX shall
make all cost of goods payments to Orion pursuant to Article 14 in euros. Where
royalty payments are made, payments earned shall be first determined by GTX in
the currency of the country where the Net Sales on the sales giving rise to
payments were made and then converted directly to its equivalent in U.S.
dollars. The rates of exchange for converting the currencies involved to U.S.
dollars shall be the Foreign Exchange Rates quoted in the Wall Street Journal
rate on the last business day of the quarterly period in which the royalty
payments were earned.

     3.5 NO ROYALTIES PAYABLE BETWEEN AFFILIATES. No royalties shall be payable
to a Party on sales between the other Party, its Affiliates or between the
Party's Affiliates.

     3.6 NO MULTIPLE ROYALTIES. No multiple royalties shall be payable because
the Product, its manufacture, use or sale is or shall be covered by multiple
patents.

4.   LIAISON

     Representatives of the Parties shall meet bi-annually or as otherwise
agreed to review the development, sales and marketing activities for Product
conducted by GTX, its Affiliates or its Unaffiliated Sublicensees for use in the
Field in the GTX Territory, with the exact dates and locations of such meetings
to be mutually agreed upon. Such meetings shall alternate between GTX's and
Orion's offices or be at other mutually agreed upon locations, with each Party
to be responsible for the travel and living costs and expenses of its own
representatives attending such meetings.

5.   PAYMENT, RECORD KEEPING AND AUDIT RIGHTS

     5.1 METHOD OF PAYMENT. In the event of any required tax withholding, the
paying Party will provide the receiving Party with any relevant certificates or
documents required for national, state or local tax credit and reporting
purposes. Payments hereunder shall not be creditable against any other amounts
payable by a Party under this Agreement, except as otherwise expressly stated
herein. All payments shall be made by bank wire transfer (e.g., "SWIFT" or other
comparable electronic transfer method) to such account(s) as the receiving Party
shall designate beforehand in writing to the paying Party. Payments shall be
deemed paid once funds are freely available to the receiving Party at such
account(s).

     5.2 LATE PAYMENTS. The Party entitled to payment hereunder reserves the
right to charge the paying Party interest on any amounts owing from the paying
Party which are overdue

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-15
<PAGE>
by more than fourteen (14) business days at a rate of [ * ] per annum, or the
maximum rate allowed by law, whichever is lower, calculated from the date any
payment was due and payable.

     5.3 RECORD KEEPING AND AUDIT RIGHTS. Each Party shall keep or cause to be
kept accurate records relating to Net Sales, royalties, development and any
other costs and expenses subject to payment, deduction or reimbursement by
either Party to the other Party in sufficient detail to enable the amounts
payable hereunder to be determined. Upon the written request of either Party
(but not more frequently than once in any calendar year), the requesting Party
may retain an independent certified public accountant, subject to approval by
the other Party (which approval shall not be unreasonably withheld), to review
such records to verify the accuracy of the payments made or payable hereunder.
Such accountant shall be required to execute a confidentiality agreement in a
form reasonably acceptable to the audited Party and shall report to the auditing
Party only the amount of any underpayment or overcharge. Within ten (10)
business days after completion of such review, the Parties shall reconcile any
underpayment or overcharge. The auditing Party shall pay the cost of any review
of records conducted at its request under this Section. However, if the review
establishes underpayment or overcharge by the audited Party of over three
percent (3%) during the period of the review, the audited Party shall promptly
reimburse the auditing Party for the fees and expenses of the accountant. Such
audit rights may be exercised by the Parties only with respect to records for
the current calendar year and the preceding two (2) calendar years.

6.   GTX PRODUCT MARKETING AND SALES ACTIVITIES

     6.1 MINIMUM SALES REQUIREMENTS FOR USA.

          6.1.1 LEVELS OF MSRS. GTX shall have annual minimum sales requirements
for Product for use in the Prostate Cancer Field ("MSRs") in the second year and
fourth year after Product Launch in the USA for the Prostate Cancer Field equal
to [ * ] of GTX's annual Product Sales Projections (as defined below) in the USA
for the Prostate Cancer Field. To establish such projections for the purpose of
the foregoing sentence, GTX shall provide to Orion quarterly Product Sales
Projections in the USA for the Prostate Cancer Field, within ninety (90) days
after GTX, its Affiliate or Unaffiliated Sublicensee completes the last pivotal
clinical trial as provided in the GTX Final Development and Registration Plan
for Product in the Prostate Cancer Field in the USA. The Parties shall set forth
in Schedule D GTX's MSR obligations within sixty (60) days after GTX provides
such projections, and such MSRs shall be made a part hereof. Beginning with the
[ * ] year after Product Launch in USA for use in the Prostate Cancer Field
until the end of the Term, GTX shall have an annual MSR equal to [ * ] of the
average of GTX's Actual Product Sales (as defined below) in the USA for Product
in the Prostate Cancer Field for the [ * ]. "Product Sales Projections" means
GTX's good faith estimates of the target patient population in a given year for
Products in the Prostate Cancer Field in the USA, multiplied by the price per
tablet of Product for use in the Prostate Cancer Field in the USA that GTX plans
to be able to charge during the [ * ] after Product Launch. "Actual Product
Sales" means GTX's, its Affiliate's or a GTX Unaffiliated Sublicensee's actual
Net Sales of Product in the Prostate Cancer Field during a given year in the
USA.

     For example, in year [ * ] if the target patient population in the USA is
[ * ] subjects in the Prostate Cancer Field and the Product would be consumed by
such patients [ * ] for the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-16
<PAGE>
Prostate Cancer Field at a hypothetical price of [ * ], GTX's Product Sales
Projections for the USA would [ * ]. The hypothetical price for a tablet set
forth above is hypothetical and was only used for the sole purpose of explaining
the mechanism for calculating the Product Sales Projections and MSRs. Nothing
contained in such example shall be so construed to deny the right of GTX to
freely set its resale price of the Product.

          6.1.2 PRODUCT LAUNCH DATE. "Product Launch in USA" shall be determined
by the date on which the Product has received Regulatory Approval and is
commercially available in the USA as follows: (i) if such date occurs during the
first six (6) months of any calendar year (i.e., January 1-June 30), Product
Launch in USA shall be deemed to have occurred on January 1 of such calendar
year, and (ii) if such date occurs during the last six (6) months of any
calendar year (i.e., July 1-December 31), Product Launch in USA shall be deemed
to have occurred on January 1 of the following calendar year.

          6.1.3 ADJUSTMENT. GTX's annual Product Sales Projections for the
Prostate Cancer Field in the USA shall be subject to adjustment by written
agreement of the Parties, with a corresponding adjustment in the MSRs, in the
event of government intervention in given markets (including, but not limited
to, government mandated health care reforms, rebates or regulatory changes),
failure to obtain (or delay in obtaining) approval for a Product indication in
the Prostate Cancer Field, or other events or causes affecting the market for
the Product for use in the Prostate Cancer Field beyond the control of GTX,
including but not limited to lower than anticipated pricing approvals measured
on an aggregate basis throughout USA; GTX Patent Rights and/or Orion Patent
Rights invalidation, infringement or expiration; Product safety and/or efficacy
issues and/or major therapeutic advances materially affecting the market
potential for the Product for use in the Prostate Cancer Field (including but
not limited to new surgical procedures or introduction of new competitive
products with superior safety and/or efficacy profiles); or a Force Majeure
event (as described in Article 27).

          6.1.4 FAILURE TO ACHIEVE MSRS. If GTX's annual Product Sales in USA
for the Prostate Cancer Field are less than the MSRs in any applicable calendar
year, GTX shall, without prejudice to its payment obligations under Section 3.1,
pay Orion royalties corresponding to the "shortfall" between the actual
royalties paid by GTX for such year and the royalties which would have been
payable pursuant to Section 3.1 had GTX achieved the MSRs during such year,
subject to Section 6.1.3. GTX's payment of such "shortfall" hereunder shall be
Orion's sole and exclusive remedy for GTX's failure to achieve MSRs in USA for
such year. However, if GTX fails to pay such "shortfall," then Orion may,
without prejudice to its right to such shortfall, also terminate this Agreement
pursuant to Section 21.2.2.

     6.2 NO MINIMUM SALES REQUIREMENTS OUTSIDE OF USA; NO MINIMUM SALES
REQUIREMENTS FOR SALES OF FARESTON PRODUCT. GTX shall not have any minimum sales
requirements with respect to sale of Product in any countries in the GTX
Territory outside of the USA. GTX shall not have any MSRs with respect to any
sales of Fareston Product or for any Product for use outside the Prostate Cancer
Field. GTx agrees that it will continue to sell Fareston Product in the Breast
Cancer Field in the USA until at least the Royalty Adjustment Date. If GTX
desires, after such date, to cease commercialization of the Fareston Product in
the Breast Cancer Field in the USA, then it may so notify Orion in writing. In
such case, the Parties shall discuss the reasons why GTX desires to cease such
commercialization activities. If Orion

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-17
<PAGE>
approves such proposal by GTX to cease commercializing the Fareston Product in
the Breast Cancer Field in the USA (such approval not to be unreasonably
withheld), then GTX may cease such activities. Without limiting the foregoing,
Orion may not withhold its approval of a proposal by GTX under this Section 6.2
if GTX would be incurring, or based on GTX's reasonable projections would be
likely to incur, a loss if it continues to commercialize Fareston Product in the
Breast Cancer Field in the USA.

     6.3 MARKETING AND SALES EFFORTS IN THE MAJOR COUNTRIES.

          6.3.1 COMMERCIALLY REASONABLE OBLIGATION. On a country by country
basis, subject to Sections 6.3 and 6.4, during the period commencing with
Regulatory Approval in a Major Country, and for the remainder of the Term, GTX,
its Affiliate and/or a GTX Unaffiliated Sublicensee shall use commercially
reasonable efforts to promote, market, distribute and sell the Product for use
in the Prostate Cancer Field in such Major Country. For purposes of this Section
6.3, "commercially reasonable" shall mean using, in the relevant Major
Countries, an equivalent degree of effort as GTX, its Affiliate or a GTX
Unaffiliated Sublicensee would use to promote, market, distribute and sell a
product of its own that is of comparable market potential in such Major Country
during the same time period (as determined by consideration of, without
limitation, potential market, patent protection, and availability of competitive
products), including but not limited to, engaging in the following activities
(subject to any applicable U.S. FDA restrictions or other applicable legal
restrictions):

               (A) Using reasonable diligence to establish and maintain good
business relationships with hospitals, health systems, doctors and other medical
professionals in accordance with standard and customary practices in such Major
Country;

               (B) Using commercially reasonable efforts to establish and
maintain an adequate capacity of sales personnel consisting of reasonably
qualified personnel who have been certified, as trained by GTX, its Affiliate or
a GTX Unaffiliated Sublicensee, to promote and market the Product for use in the
Prostate Cancer Field in such Major Country, and to provide such sales force
with adequate sales and promotional materials for the Product;

               (C) Promoting and detailing the Product for use in the Prostate
Cancer Field throughout such Major Country, provided that GTX, its Affiliate or
a GTX Unaffiliated Sublicensee may, in its discretion use relatively greater
promotional and detailing efforts (i) in some Major Countries than it uses in
other of such countries, and (ii) in some parts of each Major Country than in
other parts thereof, consistent with its overall marketing plan; and further
provided, however, that the foregoing shall in no event be deemed to limit GTX's
its Affiliate or a GTX Unaffiliated Sublicensee overall obligations under the
first paragraph of this Section 6.3.1.

               (D) Advertising the Product for use in the Prostate Cancer Field
in professional journals and publications and sponsoring or attending
appropriate symposia, trade exhibitions and medical education programs in a
manner equivalent to that used for GTX's, its Affiliate's or a GTX Unaffiliated
Sublicensee's, as applicable, own products of comparable market potential in
such Major Country; and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-18
<PAGE>
               (E) Formulating and using reasonable efforts to implement annual
sales and marketing plans for the Product for use in the Prostate Cancer Field
in such Major Country and providing copies of such plans to Orion for review and
comment, provided that Orion shall not have approval rights with respect to such
plans.

          6.3.2 SALES OBJECTIVES AND OTHER FACTORS FOR THE USA. GTX and Orion
shall agree in writing upon annual target sales objectives for the Product for
use in the Prostate Cancer Field in the USA, commencing with the fourth calendar
year after First Commercial Sale of the Product for use in the Prostate Cancer
Field in the USA, provided that such annual target sales objectives shall not be
considered MSRs for any purposes, but instead shall be used by the Parties for
informational and planning purposes and shall be one (1) factor, among others,
to be considered in assessing whether GTX has complied with its commercially
reasonable obligations hereunder. GTX's level of sales and marketing expenses
for the Product for use in the Prostate Cancer Field in the USA and events or
causes affecting the market for the Product for use in the Prostate Cancer Field
beyond the control of GTX shall also be among the factors to be considered in
assessing whether GTX has complied with its commercially reasonable obligations
hereunder.

     6.4 PRODUCT LAUNCH.

          6.4.1 TIMING OF LAUNCH. GTX shall use commercially reasonable efforts
to launch the Product for use in a given indication in the Prostate Cancer Field
as soon as practical in every Major Country of the GTX Territory where GTX, its
Affiliates and/or GTX Unaffiliated Sublicensees have obtained Regulatory
Approval for such indication. Notwithstanding the foregoing, GTX, its Affiliate
or a GTX Unaffiliated Sublicensee may, acting in good faith in the exercise of
its reasonable business judgment, determine either to delay the launch of the
Product for use in a given indication in the Prostate Cancer Field or not to
launch the Product for use in a given indication in the Field in any given
country in the GTX Territory other than a Major Country, which decision to delay
or not to launch shall not be deemed a failure to use commercially reasonable
efforts. Further, GTX's, its Affiliates' or a GTX Unaffiliated Sublicensee's
decision to delay the launch of the Product for use in the Prostate Cancer Field
in any Major Country for up to six (6) months after GTX or its Affiliates have
obtained Regulatory Approval in such country, shall not be deemed a failure to
use commercially reasonable efforts pursuant to Section 6.3 to the extent that
GTX can demonstrate that such delay was attributable to bona fide business
reasons affecting the Product.

          6.4.2 DECISIONS NOT TO LAUNCH. GTX shall promptly notify Orion in
writing if GTX, its Affiliate or a GTX Unaffiliated Sublicensee, as applicable,
determines to delay the launch of the Product for use in a given indication in
the Prostate Cancer Field in any Major Country after obtaining Regulatory
Approval of Product therefor. If such decision is due to any reasons other than
the potential for, or the existence of, adverse business effects in such Major
Country, then such decision shall be deemed a material breach of this Agreement
pursuant to Section 21.2.2 and GTX shall be subject to the provisions of such
Section within thirty days (30) after GTX's decision not to launch in such Major
Country.

     6.5 MARKETING COSTS AND EXPENSES. Except as otherwise provided herein or as
otherwise mutually agreed by the Parties, GTX, its Affiliate or a GTX
Unaffiliated Sublicensee

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-19
<PAGE>
shall bear all costs and expenses connected with its marketing and sales
activities for the Product for use in the Field and its performance under this
Agreement.

     6.6 MARKETING PLANS AND REPORTS.

          6.6.1 MARKETING PLANS. GTX shall develop and provide to Orion by
October 31 of each year during the Term marketing and sales plans for the
Product for each Major Country for the following calendar year, commencing with
the calendar year in which Regulatory Approval is obtained in each respective
country. Such plans shall include the projected Annual Net Sales and the
projected advertising and promotion budgets for such year, and shall not be
applicable to the calculation of MSRs in connection with the sale of Products in
the Prostate Cancer Field in the USA pursuant to Section 6.1, for which GTX
shall separately provide information.

          6.6.2 MARKETING AND SALES REPORTS FOR PRODUCT. GTX shall provide to
Orion, within forty-five (45) days after the end of each calendar year, a
written marketing activities and sales report for each of the Major Countries in
which Product is launched. The report shall include at least a description of
sales, marketing and promotion activities and a list of scientific conferences
or other events involving the particular Product or its therapeutic area,
accompanied by a general description of the nature and extent of GTX's
participation in such conferences or events.

7.   GTX PRODUCT DEVELOPMENT AND REGISTRATIONS

     7.1 GTX DEVELOPMENT AND REGISTRATION ACTIVITIES.

          7.1.1 GTX ACTIVITIES. In accordance with the GTX Preliminary
Development and Registration Plan and the GTX Final Development and Registration
Plan, GTX shall undertake development and registration activities for the
Product for use in the Prostate Cancer Field in the GTX Territory, including but
not limited to, conducting or sponsoring, and completing or having completed in
accordance with U.S. FDA regulations and Good Clinical Practice regulations
under the European Union legislation and directives requirements, all clinical
studies and other activities required for Regulatory Approval under the GTX
Final Development and Registration Plan. Without limiting the provisions of
Section 7.7, GTX shall use its commercially reasonable efforts to pursue such
development and registration activities under the GTX Final Development and
Registration Plan with the objective of filing applications for Regulatory
Approval in all Major Countries throughout the GTX Territory in the Prostate
Cancer Field according to the anticipated filing dates set forth in the GTX
Final Development and Registration Plan timetable [ * ]. GTX's Regulatory
Approvals in the GTX Territory shall be owned solely by GTX.

          7.1.2 ORION ACTIVITIES.

               (A) Orion shall use its commercially reasonable efforts to assist
GTX in obtaining and maintaining the U.S. FDA Regulatory Approval of Products in
the Prostate Cancer Field and of the Fareston Product in the Breast Cancer Field
in the USA (including obtaining and/or maintaining the Orion Product NDA and all
related U.S. INDs filed with the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-20
<PAGE>
U.S. FDA for such Products, and any other required Regulatory Approvals in the
Major Countries of the GTX Territory relating to the manufacture, use, marketing
or sale of Product for use in the Prostate Cancer Field or of Fareston Product
in the Breast Cancer Field in the USA (by providing to GTX relevant information,
documents and data in its possession in relation to regulatory inquiries during
the Regulatory Approval process for Products, necessary additional letters of
cross-reference or authorization equivalent to those described in Section 7.5 to
its registrations for Product in the Orion Field in the Orion Territory, and
other similar assistance). Orion shall maintain the DMF filed with the U.S. FDA
and all equivalent regulatory authorities outside of the USA for Product as well
as its registrations for Product in the Orion Field in the Orion Territory
during the Term, provided that Orion may notify GTX that Orion intends to cease
maintenance of any such DMF and/or registration, in which case GTX shall have
the right to maintain such filing, at GTX's expense, by notifying Orion in
writing within thirty (30) days after it receives Orion's notice hereunder that
it desires to maintain such filing. If GTX elects to maintain such filing, Orion
shall cooperate reasonably with GTX to effect the transfer of such DMF and/or
registration to GTX.

               (B) Orion shall perform any stability testing for the bulk Orion
Product to be manufactured and supplied by Orion to GTX that is required by
regulatory authorities in any Major Country. Such testing shall be provided at
no cost to GTX, except that GTX will reimburse Orion's direct costs of
performing any such stability testing that must be conducted solely for the
[ * ] tablet of the Orion Product. Orion employees shall, at Orion's cost and
expense, have the right to participate in all FDA and other regulatory agency
meetings regarding the use of the Product in the Field.

               (C) Orion shall have no obligation to research, develop,
register, commercialize any Product or carry out any studies or testing in
relation to Products, including without limitation with respect to any new or
additional strength, dosage form, formulation or route of administration of the
Orion Product or the Product, or provide any documentation, information or data
relating to the foregoing, except as expressly provided in Section 7.1.2(a) or
otherwise set forth in this Agreement, unless the Parties expressly mutually
agree otherwise in writing after the Restatement Date. Other than as expressly
agreed in this Agreement, Orion shall have no obligation to fund or pay for any
of the costs and expenses of such activities. All studies, trials, tests,
activities, documentation, data and information required by any regulatory or
other governmental agency or which is necessary or useful for the research,
development, registration or commercialization of the Product shall, unless
otherwise expressly agreed to herein as between the Parties, be for the sole
cost and responsibility of GTX.

          7.1.3 AUTHORIZATION LETTERS. Any regulatory filings (including without
limitation any DMFs that GTX may develop if it obtains the right to manufacture
Product) compiled and filed by or on behalf of GTX shall remain the property of
GTX, but GTX shall, upon request therefor by Orion, negotiate with Orion the
terms under which GTX would provide appropriate authorization letters to
relevant regulatory bodies to enable Orion to reference such regulatory filings
for purposes of applying for and supporting Orion's applications for Regulatory
Approval of products containing Toremifene outside the Field.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-21
<PAGE>
     7.2 FDA FILE. As of the Restatement Date, Orion shall have transferred the
Orion Product NDA and all Investigational New Drug Applications (as defined in
21 C.F.R. Section 212) for Products filed with the FDA to the name of GTX, as
set forth in the Purchase Agreement.

     7.3 DEVELOPMENT AND REGISTRATION COSTS. Except as otherwise expressly
provided in this Agreement or otherwise mutually agreed in writing by the
Parties after the Restatement Date, GTX shall bear all costs and expenses
related to Product registration and regulatory activities (other than for
Product for the Orion Field in the Orion Territory), including without
limitation costs of filing, obtaining and maintaining all such Regulatory
Approvals throughout the GTX Territory, as well as all costs and expenses for
the research and development of the Product for use in the Field (other than for
Product for the Orion Field in the Orion Territory), provided that GTX shall not
be responsible for any costs related to the manufacture of the Orion Product
(except for payments that GTX must make to Orion pursuant to Section 7.1.2(b) or
Article 14 (such costs collectively referred to herein as "Manufacturing
Costs"). Except for the Manufacturing Costs or as otherwise expressly provided
in this Article 7, Orion shall bear no responsibility for any costs or expenses
related to Product registration, regulatory, research or development activities
in relation to the Product.

          7.3.1 DEVELOPMENT AND REGISTRATION COSTS PRIOR TO RESTATEMENT DATE.
The Parties agree that GTX shall, notwithstanding anything to the contrary in
the Original Agreement or otherwise, also bear all costs and expenses related to
Product research, development, registration, regulatory compliance and other
activities relating to the development of Product that were incurred prior to
the Amendment Date by GTX (excluding any Manufacturing Costs) (hereinafter
referred to as "Incurred Costs"). Consequently, except as set forth in Section
3.1.1, GTX shall forever release and discharge Orion of any and all claims that
it purports to have at the Amendment Date or may have thereafter against Orion
with respect to Incurred Costs.

     7.4  GTX DEVELOPMENT AND REGISTRATION PLAN.

          7.4.1 COMPLETION OF GTX FINAL DEVELOPMENT AND REGISTRATION PLAN. The
GTX Preliminary Development and Registration Plan for development and
registration of Product in the Prostate Cancer Field was attached to the
Original Agreement as Schedule B. GTX will prepare a GTX Final Development and
Registration Plan for such activities for each Major Country in a timely fashion
upon receiving approval from the appropriate regulatory authority in each Major
Country of a plan for regulatory approval in that country. Immediately upon
completion of the GTX Final Development and Registration Plan for each Major
Country, [ * ]. GTX shall provide a copy of such plan to Orion.

          7.4.2 ORION'S RIGHT TO COMMENT ON AND OBJECT TO PLAN. Orion shall have
the right to comment on each GTX Final Development and Registration Plan for
Product for the Prostate Cancer Field for each Major Country. Additionally,
Orion shall have the right to object to each GTX Final Development and
Registration Plan for each Major Country to the extent such plan could
reasonably be deemed to affect adversely Orion's development, commercialization,
sales or registration of Toremifene in the Orion Field in the Orion Territory or
outside the Field. GTX undertakes to change and/or amend the GTX Final
Development and Registration Plan for Product for the Prostate Cancer Field for
each Major Country to the extent Orion has so objected thereto as necessary to
alleviate or obviate such adverse effect. Orion shall provide GTX with

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-22
<PAGE>
such comments and/or objections within thirty (30) days from Orion's receipt of
the GTX Final Development and Registration Plan.

          7.4.3 CHANGES TO SUCH PLAN. GTX may modify the GTX Final Development
and Registration Plan, as GTX deems necessary and consistent with Section 7.4.1,
but shall notify Orion of such changes. Any changes to the GTX Final Development
and Registration Plan for each Major Country shall also be subject to Section
7.4.2.

     7.5  ORION DOCUMENTATION AND DATA.

          7.5.1 GTX ACCESS TO ORION KNOW-HOW. Orion has provided and shall
continue to provide GTX with copies of the Orion Know-How, documentation,
information and data listed or referenced in the GTX Preliminary Development and
Registration Plan, and GTX shall be authorized to use and reference the same in
its applications for Regulatory Approval and regulatory compliance activities in
relation to such Regulatory Approvals. Any Product Drug Master Files ("DMFs")
compiled or owned by Orion shall remain the property of Orion, but Orion shall,
upon reasonable request therefor by GTX, provide appropriate authorization
letters to relevant regulatory bodies in the GTX Territory within forty-five
(45) days from such request to enable GTX to reference such DMFs for purposes of
GTX's applications for Regulatory Approval and regulatory compliance activities
in the GTX Territory as provided for in Section 7.1. For the avoidance of doubt,
neither Party is obligated to disclose the contents of its DMFs to the other
Party.

          7.5.2 GTX ACCESS TO DATA. During the Term, Orion shall provide GTX,
within forty-five (45) days of receipt of a written request from GTX specifying
in detail the documentation, information and/or data requested, access to Orion
Know-How in Orion's control and possession (and freely disclosable) that GTX
reasonably requires for regulatory filings for the use of Product in the Field
in the GTX Territory, including any Orion Know-How concerning the use of the
Product in the Orion Field in the Orion Territory to the extent such information
may be reasonably required by GTX for such regulatory filings. . In instances
where documentation, information and/or data requested are required by the U.S.
FDA or other regulatory agency to be submitted in a time frame shorter than
forty-five (45) days, GTX shall notify Orion, and GTX and Orion shall agree on a
shorter time frame for provision of such materials within the time required by
the FDA. In the event any of such Orion Know-How is not in the control or
possession of Orion but is controlled by a Third Party, Orion and GTX shall
discuss in good faith commercially reasonable efforts that Orion may, at its
discretion, decide to take to assist GTX in accessing such Orion Know-How,
provided that nothing herein shall obligate Orion to take steps to arrange, or
incur costs, to access such Orion Know-How from such Third Party, and provided
further that if requested by GTX, Orion will grant GTX the necessary
authorizations to approach any such Third Party for such access. Upon GTX's
request, Orion shall provide GTX with copies of such Orion Know-How referenced
in the preceding sentences only in such form and content as is available to
Orion, provided that, upon Orion's request, GTX shall reimburse Orion for
Orion's direct out-of-pocket cost of making such copies and providing GTX with
such Orion Know-How.

     GTX shall also provide to Orion quarterly reports summarizing GTX's
development activities for Products in the Field (excluding the Orion Field in
the Orion Territory).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-23
<PAGE>
          7.5.3 LETTER OF CROSS REFERENCE. Orion agrees that the Cross Reference
letter dated December 10, 1999 from Orion to GTX shall remain in effect to the
extent it enables GTX or its Affiliates to reference regulatory filings for the
Orion Product in all countries outside of the USA. Such Cross Reference letter
may not be revoked by Orion unless this Agreement is terminated. During the
Term, Orion shall permit GTX, its Affiliates and the GTX Unaffiliated
Sublicensees to reference, and shall provide GTX with an appropriate
authorization letter to enable GTX, its Affiliates and the GTX Unaffiliated
Sublicensees to reference, all applications or filings for Regulatory Approval
for Orion Products for use in the Orion Field and related DMFs that are
identified in Schedule E hereof (hereinafter "Orion Product Approvals") for the
purpose of applying for and supporting Regulatory Approval of Products for use
in the Field within the GTX Territory. Orion shall update Schedule E from time
to time during the Term to set forth all Orion Product Approvals and DMFs that
are owned and controlled by Orion. GTX recognizes that Orion has obtained the
Orion Product Approvals solely for the purpose of its proprietary product
Fareston(R), and that nothing herein shall be construed so as to obligate Orion
to maintain or cause to be maintained any Orion Product Approvals solely for
allowing GTX, its Affiliates and/or GTX Unaffiliated Sublicensees to refer
thereto, provided that during the Term, Orion shall not withdraw such Orion
Product Approvals in the absence of commercially justifiable reasons in relation
to Fareston(R). Orion shall, prior to withdrawing such Orion Product Approvals,
offer to GTX the right to maintain such approvals, at GTX's expense. If GTX
elects to maintain such approvals, Orion shall reasonably cooperate with GTX to
enable GTX to assume such responsibility.

          7.5.4 ADDRESS. All requests by GTX to Orion for documentation,
information or data, as agreed herein, shall be addressed only to the attention
of such person(s) as is/are designated in writing or in electronic form by Orion
from time to time.

     7.6 GTX REGISTRATION AND MARKETING APPROVAL APPLICATIONS. GTX, its
Affiliates and/or GTX Unaffiliated Sublicensees shall have the responsibility
and the right to submit registration applications for Regulatory Approval and
marketing and price approval of the Product for use in the Field within the GTX
Territory; provided, however, that GTX shall not have the responsibility to
submit such applications for approval of the Product for use in the Orion Field
in the Orion Territory.

     7.7 FAILURE TO FILE OR EXTEND. Orion shall have the right to terminate its
obligations under Section 7.1.2(a) and its obligations to manufacture and supply
to GTX Orion Product upon one hundred and eighty (180) days prior written notice
to GTX, if Regulatory Approval has not been granted for the Product for use in
the Prostate Cancer Field in the USA by December 31, 2009. Any such notice
hereunder shall be given no later than sixty (60) days after December 31, 2009,
provided that GTX shall inform Orion in writing by December 31, 2009, whether or
not Regulatory Approval has been granted for the Product for use in the Prostate
Cancer Field in the USA by such date. The time for Orion to provide notice to
GTX of its decision to exercise its right with regard to the event described
above shall be deemed to commence upon the receipt by Orion of such notice from
GTX, provided that nothing shall be construed so as to prevent Orion from
exercising its right hereunder if Orion discovers, either by itself or through a
Third Party, that Regulatory Approval has not been granted for the Product for
use in the Field in the USA by December 31, 2009. Effective upon the date that
GTX receives any notice from Orion pursuant to this Section 7.7 and during the
Term, Orion hereby grants GTX a contingent license under the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-24
<PAGE>
Orion Patent Rights and Orion Know-How and all other patents and patent
applications owned or controlled by Orion during the Term that relate to the
manufacture, use or sale of Toremifene or Orion Product ("Manufacturing
Patents") to make and have made Product for use in the Field in the GTX
Territory (except in the Orion Field in the Orion Territory). Such license shall
be exclusive and sublicensable (but only for the purposes of having manufactured
the Products for GTX, its Affiliates or Unaffiliated Sublicensees). Orion shall
as soon as practically possible after providing any notice to GTX pursuant to
this Section 7.7 provide GTX with such then-existing manufacturing, process and
quality control procedures, documentation and other relevant know-how and
information to the extent reasonably necessary to enable GTX to exercise its
manufacturing right pursuant to this Section 7.7 (hereinafter "Product
Manufacturing Know-How"), including without limitation providing up to ten (10)
person-days of technology transfer assistance at GTX's site of manufacture of
Product using Orion personnel skilled in such manufacturing operations, at no
charge to GTX.

     7.8 REIMBURSEMENT OF ORION COSTS. Except as provided for otherwise in this
Article 7, GTX shall reimburse Orion for all costs and expenses incurred by
Orion in fulfilling its obligations under this Article 7 with respect to
Products in the Field, subject to the following: (a) such reimbursable amounts
shall include costs of assistance provided by Orion for activities relating to
the Prostate Cancer Field only to the extent such costs (i) are incurred by
Orion after [ * ], or (ii) have been invoiced to GTX prior to [ * ]; (b) such
reimbursable amounts shall include costs of assistance provided by Orion for
activities outside of the Prostate Cancer Field and the Breast Cancer Field,
with the amounts described in this subsection (b) including Orion's [ * ]; (c)
such reimbursable amounts shall not include [ * ]; and (d) such reimbursable
amounts shall not include [ * ]. Orion shall issue an invoice for all such
reasonable costs and expenses so incurred that are reimbursable hereunder during
each Calendar Quarter, and GTX shall effect payment of such invoice within
thirty (30) days from the date of the invoice.

8.   CONFIDENTIALITY AND PUBLICITY

     8.1 CONFIDENTIALITY OBLIGATION. Each Party shall hold the other Party's
Confidential Information (as defined below) of which it becomes informed in
connection with this Agreement or the Original Agreement in strictest confidence
and shall not disclose such Confidential Information to Third Parties or
otherwise use it, except to the extent such use or disclosure is expressly
permitted by the terms of this Agreement or is reasonably necessary for the
performance of this Agreement.

     8.2 PERMITTED DISCLOSURES. Permitted disclosures of Confidential
Information hereunder include, but are not limited to: (A) disclosures to
regulatory agencies to the extent required for Regulatory Approval, including
but not limited to, GTX Product registrations and applications in the GTX
Territory (to the extent expressly permitted hereunder), and (B) disclosures to
the Parties' Affiliates, employees, agents and independent contractors
(including clinical investigators, consultants and contract research
organizations) who have a bona fide "need to know", and GTX Unaffiliated
Sublicensees, and prospective sublicensees, provided that for such permitted
disclosures under subsection (B) the disclosing Party shall obligate the
recipients to maintain the confidentiality of Confidential Information under
terms substantially similar to those contained in this Article 8.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-25
<PAGE>
     8.3 CONFIDENTIAL INFORMATION. "Confidential Information" includes, but is
not limited to, any information relating to the terms of this Agreement, the
Original Agreement, the Product, the Orion Product, GTX Know-How, GTX Patent
Rights, Orion Patent Rights, Orion Know-How, GTX Preliminary Development and
Registration Plan, GTX Final Development and Registration Plan, clinical and
non-clinical studies involving the Product, and all sales and marketing plans
for the Product, as well as information concerning all other products and the
business affairs, manufacturing processes and other activities of the disclosing
Party that are designated as confidential in writing or orally disclosed,
provided such oral disclosure is confirmed as confidential in writing within
thirty (30) days thereafter. However, such obligations shall not apply to
Confidential Information to the extent such information is:

               (A) PUBLICLY AVAILABLE INFORMATION. Which at the time of
disclosure is or later comes into public domain by publication or otherwise
through no fault of the receiving Party;

               (B) PREVIOUSLY KNOWN INFORMATION. Which can be demonstrated by
documentation or other competent proof to have been in the receiving Party's
possession prior to disclosure;

               (C) SUBSEQUENTLY RECEIVED INFORMATION. Which is subsequently
received by the receiving Party from a Third Party who is not bound by any
confidentiality undertaking to the disclosing Party or to any of its Affiliates
with respect to said information;

               (D) INDEPENDENTLY DEVELOPED INFORMATION. Which is independently
developed by or for the receiving Party without reference to the disclosing
Party's Confidential Information; or

               (E) LEGALLY REQUIRED DISCLOSURES OF INFORMATION. Which is legally
required to be disclosed pursuant to any statute or regulation or any judicial
or administrative order, including any material or information requested by the
Securities and Exchange Commission (or any equivalent securities exchange) or
Finnish equivalent thereof to the extent that such information cannot be treated
confidential.

     8.4 DURATION OF CONFIDENTIALITY OBLIGATION. The confidentiality obligations
of the Parties hereunder shall remain in effect during the Term and shall
survive the termination or expiration of this Agreement for any reason and be
effective until the later of five (5) years after such termination or
expiration, or ten (10) years after the Restatement Date.

     8.5 PUBLICITY AND ANNOUNCEMENTS.

          8.5.1 With regard to the existence and content of commercial terms and
conditions of this Agreement, unless agreed upon by the Parties, neither Party
shall originate any publicity, news release or other public announcement,
written or oral, whether to the public press, stockholders or otherwise,
relating to this Agreement or any amendment hereto, without the approval of the
other Party, except as required by law, including, without limitation,
provisions regarding the disclosure requirement for publicly quoted companies,
and then only to the minimum extent so required, in which event such Party shall
give the other Party a

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-26
<PAGE>
reasonable opportunity to review the form and content of the announcement before
such legally required announcement is made.

          8.5.2 GTX may originate any publicity, news release or other public
announcement, written or oral, whether to the public press, stockholders or
otherwise, relating to the use of the Product in the Field provided that GTX
forwards to Orion such publicity, news release or other public announcement
fourteen (14) days prior to such publicity, news release or other public
announcement, except as otherwise required by law or regulation, including
without limitation disclosure requirements promulgated by the Securities and
Exchange Commission. It is agreed that such publicity, news release or other
public announcement does not require the approval of Orion, unless Orion
considers such publicity, news release or other public announcement to (a) fall
within the scope of Section 8.5.1; or (b) be misleading or incorrect, in which
case Orion shall, within five (5) business days after receiving such publicity,
news release or other public announcement, so notify GTX and provide written
comments specifying changes that Orion reasonably believes will correct such
inaccuracy, except as otherwise required by law or regulation. If requested by
Orion, such publicity, news release or other public announcement shall include
wording to the effect that Toremifene is a proprietary compound of Orion, and
that Toremifene has been licensed by Orion to GTX for use in the Field.

9.   FARESTON PRODUCT WEBSITE FOR USA

     9.1 FARESTON WEBSITE. During the Term of this Agreement or as long as the
Fareston Product is sold in USA (whichever period is shorter), Orion shall
maintain, (including, without limitation, by renewing the applicable domain
name(s)), and operate, either itself or via Third Party subcontractor(s), the
internet site with the domain name www.fareston.com (or any successor site or
domain name thereof). Promptly following the execution of this Agreement, Orion
and GTX shall mutually agree upon a process or means whereby Orion shall provide
GTX with a means to access said website in order to update and maintain web
pages for the Fareston Product that are directed towards residents of the USA
(the "FARESTON U.S. WEB PAGES"). The Parties acknowledge and agree that GTX
shall have sole control over, and responsibility for, the content of the
Fareston U.S. Web Pages, including, without limitation, the "look and feel"
thereof. Orion hereby grants GTX a non-exclusive, sublicenseable license in the
GTX Territory under such intellectual property rights owned or controlled by
Orion during the Term that are strictly necessary for GTx, its Affiliates and
Unaffiliated Sublicensees to exercise the rights granted to GTX pursuant to this
Section 9.1 with respect to the Fareston U.S. Web Pages. It is understood and
agreed that nothing herein shall obligate Orion to perform the foregoing tasks
[ * ]. GTX shall be responsible for ensuring that the Fareston U.S. Web Pages
conform with all applicable laws and regulations. To the extent allowed by
applicable laws and regulations, Orion shall have a right to build on and join
and/or establish a link to the foregoing site for the Fareston Product in
connection with its retained rights for Fareston Product, and to grant to its
Affiliates and Unaffiliated Sublicensees such rights, at any time, at its sole
discretion, with the reasonable costs thereof payable by the supplier of such
link or contents. GTX shall reasonably cooperate with Orion in regard to any
additions to such site. Such additions, if any, will be placed in an easily
visible location on such site as agreed between the Parties.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-27
<PAGE>
10.  TRADEMARKS

     10.1 TRADEMARKS.

          10.1.1 GTX shall market and sell the Product for use in the Field in
the GTX Territory under the Trademarks. GTX shall own and control all Trademarks
(including, as provided in the Purchase Agreement, the trademark Fareston(R) in
the USA). For avoidance of doubt, GTX shall not have any rights to use the
trademark Fareston(R) outside of the USA. GTX shall notify Orion if GTX decides
to change, alter, modify or replace the Trademark initially selected by it for a
given Product.

          10.1.2 If GTX exercises its right of first negotiation to obtain
rights to sell Orion Product in the Orion Field under Section 2.1.6, then the
Parties agree that any letter of intent and final agreement governing the terms
under which GTX would obtain such rights shall provide for Orion to grant to GTX
an exclusive, sublicensable license under the trademark Fareston(R) in the
relevant country outside the USA (or any counterpart to such trademark that
Orion is then using to market, promote, and commercialize Orion Products in the
relevant country or countries) to advertise, promote, market or sell such Orion
Product.

     10.2 TRADEMARK FILING AND MAINTENANCE. GTX shall be responsible for filing,
maintaining, prosecuting and defending the Trademarks in the GTX Territory
(including, for the avoidance of doubt, the trademark Fareston(R) in the USA).

     10.3 TRADEMARK DOCUMENTATION. If requested by Orion, GTX shall provide
Orion with copies of all documents relating to the maintenance of the Trademark
in the GTX Territory, at Orion's expense.

11.  PATENT OWNERSHIP AND WARRANTIES

     11.1 PATENT OWNERSHIP.

          11.1.1 Subject to the license rights granted to GTX hereunder, Orion
retains full ownership of all Orion Patent Rights and shall be responsible for
filing, prosecuting, and maintaining Orion Patent Rights as provided for in
Article 12.

          11.1.2 Subject to the license rights granted to Orion hereunder, GTX
retains full ownership of all GTX Patent Rights and shall be responsible for
filing, prosecuting, and maintaining GTX Patent Rights as provided for in
Article 12.

     11.2 ORION PATENT WARRANTIES. Orion warrants and represents that, to the
best of its management's knowledge as of the Effective Date: (A) Schedule B sets
forth all of the Orion Patent Rights as of the Effective Date and as of the
Restatement Date which are directed to the composition of matter, use or sale of
the compound Toremifene per se; (B) except for the Orion Field in the Orion
Territory, Orion has not and will not grant, license, convey, assign, and/or
transfer to any Third Party any rights to Orion Patent Rights for use in the
Field, or any rights to manufacture the Product or Toremifene for use in the
Field, or other rights to any Third Party, in each case inconsistent with the
licenses and other rights granted to GTX hereunder, (C) based

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-28
<PAGE>
upon Orion's reasonably diligent investigation, the Orion Patent Rights are (i)
valid, in full force, and enforceable, and (ii) there are no existing valid
Third Party patents in the GTX Territory that might be infringed by the
manufacture or sale of the Orion Product by Orion to GTX under this Agreement
for the Prostate Cancer Field, or in the USA for the Breast Cancer Field, and
(D) the use and/or sale of Products in the Field and in the GTX Territory by
GTX, its Affiliates or Unaffiliated Sublicensees pursuant to this Agreement will
not, in the absence of a license from Orion, infringe any patents owned or
controlled by Orion other than the Orion Patent Rights. Additionally, Orion
represents and warrants to GTX that to the best of its management's knowledge as
of the Restatement Date, Orion has not received any written claims or assertions
from any Third Party alleging that the use of Toremifene in the Field (other
than as may be for use and/or sale of Products in the Orion Field in the Orion
Territory) infringes such Third Party's patent rights.

     11.3 GTX PATENT WARRANTIES. GTX warrants and represents that [ * ] as of
the Effective Date: (A) Schedule A sets forth all of the GTX Patent Rights as of
the Effective Date which cover the Product for use in the Prostate Cancer Field
and that it had full right and authority to grant to Orion and Orion Affiliate
the rights granted to it under Section 2.4; (B) subject to Section 2.1.4, GTX
has not and will not grant to any Third Party any rights under the Orion Patent
Rights or Orion Know-How inconsistent with GTX's licenses under this Agreement,
and (C) there are no circumstances existing that render it likely that the
United States Government or any agency thereof to exercise such rights as set
forth and/or referenced to in Section 2.3, if GTX's development, registration
and commercialization of the Product for use in the Prostate Cancer Field will
be carried out as agreed herein; and (D) (i) the GTX Patent Rights are valid, in
full force, and enforceable and (ii) upon GTX's reasonably diligent
investigation, there are no existing valid and enforceable Third Party patents
in the GTX Territory (other than any that may be owned or controlled by Shire)
that might be infringed by the marketing, promotion, distribution, importation,
offer for sale or sale of the Product in the Prostate Cancer Field by GTX, its
Affiliates and GTX Unaffiliated Sublicensees.

12.  PATENT PROSECUTION AND INFRINGEMENT; TRADEMARKS

     12.1 ORION PATENT FILING AND PROSECUTION. Orion shall, at its sole expense,
prosecute, maintain and defend Orion Patent Rights in the GTX Territory and
Orion shall control all Orion Patent Rights filings and actions. Orion shall use
its commercially reasonable efforts to obtain extensions in the Major Countries
in the GTX Territory in which such extensions are available.

     12.2 GTX PATENT FILING AND PROSECUTION. GTX shall, as its sole expense,
file, prosecute, maintain and defend GTX Patent Rights in the GTX Territory and
GTX shall control all GTX Patent Rights filings and actions. GTX shall use its
commercially reasonable efforts to obtain GTX Patent Rights protection and
commercially reasonable efforts to obtain GTX Patent Rights extensions in any
countries in the GTX Territory in which such extensions are available.

     12.3 NOTIFICATION OF INFRINGEMENT. The Parties shall promptly inform each
other of any information that comes to their attention involving actual or
apparent infringements or misappropriations of Orion Patent Rights, Orion
Know-How, GTX Patent Rights, GTX Know-How, or Trademarks by any Third Party, or
claims of alleged infringement made by any

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-29
<PAGE>
Third Party in the GTX Territory against Orion, its Affiliates, or Orion
Unaffiliated Sublicensees, GTX, its Affiliates, or GTX Unaffiliated
Sublicensees, resulting from the manufacture, importation, marketing, sale or
use of the Product in the Field.

     12.4 INFRINGEMENT OF THIRD PARTIES RIGHTS BY ORION. Orion shall, at its
sole discretion, direct or defend in its own name and at its own expense any
legal or other action or proceeding, including any settlement or negotiation,
with respect to any alleged infringement of a Third Party patent or other
proprietary right as a result of Orion's, its Affiliates', or Orion Unaffiliated
Sublicensees' manufacture of Toremifene or Orion Product for use in the Field,
or the use or sale of Product in the Orion Field in the Orion Territory
excluding actions and proceedings covered by Section 12.5. During the time any
such proceeding or any appeal thereof is pending, Royalty Income payable by GTX
under Section 3.1 in the country in which such proceeding is pending shall be
paid by GTX into an interest-bearing escrow account pending the outcome of such
proceeding. Upon a favorable final resolution of such proceeding or any appeal
thereof, GTX shall resume paying Orion the full royalties in such country, and
all funds in such escrow account shall be paid to Orion. Upon an unfavorable
final resolution of such proceeding or any appeal thereof, the funds in such
escrow account shall be applied toward the damage award in such action, if any,
and the balance, if any, shall be paid to Orion. If Orion fails to defend such
proceeding or discontinues the defense, all funds in such escrow account shall
be returned to GTX and GTX shall have no further obligation to pay Royalty
Income in such country.

     12.5 INFRINGEMENT OF THIRD PARTIES RIGHTS BY GTX. GTX shall, at its sole
discretion, direct or defend in its own name and at GTX's own expense in the GTX
Territory any legal or other action or proceeding, including any settlement or
negotiation, with respect to any alleged infringement of a Third Party patent,
trademark or other proprietary right as a result of GTX's, its Affiliates', or
GTX Unaffiliated Sublicensees' making, having made, importing, marketing,
distributing, using or selling the Product in GTX Territory for use in the
Field, excluding actions and proceedings covered by Section 12.4.

     12.6 INFRINGEMENT INDEMNIFICATION.

          12.6.1 ORION INFRINGEMENT INDEMNIFICATION. Orion shall indemnify,
defend and hold GTX (including for purposes of this Section 12.6.1, GTX
Affiliates and GTX Unaffiliated Sublicensees), its and their officers,
directors, and employees, and permitted successors and assigns, harmless from
and against any and all liabilities, damages, claims, demands, costs and/or
expenses (including reasonable attorneys' fees) (collectively, "Losses") claimed
by any Third Party in any patent or proprietary right infringement suit or
action which may be brought as a result of Orion's, its Affiliates', or Orion
Unaffiliated Sublicensees' manufacture of Toremifene or Orion Product, except to
the extent such Losses arise out of claims for which GTX shall defend, indemnify
and hold Orion harmless pursuant to Section 12.6.2, and further subject to the
conditions of indemnification set forth in Section 15.7.

          12.6.2 GTX INFRINGEMENT INDEMNIFICATION. GTX shall indemnify, defend
and hold Orion (including for purposes of this Section, Orion's Affiliates and
Unaffiliated Sublicensees) its and their officers, directors, and employees, and
permitted successors and assigns, harmless from and against any and all Losses
claimed by any Third Party in any suits or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-30
<PAGE>
actions relating to patent, trademark or other proprietary right infringements
as a result of GTX's, its Affiliates', or GTX Unaffiliated Sublicensees' making
or having made, importing, marketing, using or selling the Product or Other
Product under a Trademark in GTX Territory for use in the Field, except to the
extent such Losses arise out of claims for which Orion shall indemnify, defend
and hold GTX harmless pursuant to Section 12.6.1, and further subject to the
conditions of indemnification set forth in Section 15.7.

     12.7 TERMINATION FOR INFRINGEMENT OF THIRD PARTY RIGHTS. Should either
Party be prevented by reason of an adverse, non-appealable court or
administrative proceeding, order or judgment or arbitral award against it from
manufacturing, making, using or selling the Orion Product and/ or Product in any
country within the GTX Territory as required or permitted under this Agreement,
then, as to such country so affected, the other Party may, upon sixty (60) days
prior written notice thereof to the other Party, terminate this Agreement upon
written notice to the other Party with respect to such country, and the Parties
shall make a final transition accounting and settlement for outstanding bona
fide costs, payments and expenses to which each Party is entitled hereunder with
respect to such country.

     12.8 THIRD PARTY INFRINGEMENT OF ORION PATENT RIGHTS.

          12.8.1 ORION ENFORCEMENT. Orion shall have the first right but not the
obligation, to commence, at its own expense, appropriate measures to enforce
Orion Patent Rights [ * ] against infringement by Third Parties relating to the
manufacture, use, sale, offer for sale, or import of products containing
Toremifene for use in the Field within a reasonable period of time after Orion
becomes aware of such infringement (including, but not limited to, by notifying
the infringing Third Party of such infringement and demanding that such Third
Party cease and desist from such infringement). If such infringement does not
cease, Orion shall have the right to commence a legal proceeding to enforce
Orion Patent Rights, if any, against such Third Party infringements within a
reasonable period of time of the date Orion becomes aware of such infringement.
Orion shall notify GTX promptly after Orion becomes aware of such infringement,
and, upon request therefor by GTX, keep GTX reasonably informed regarding
Orion's intended strategy in such situation. Additionally, if within a
reasonable period of time from the date GTX becomes aware of any alleged Third
Party infringement of such Orion Patent Rights, either by notice from Orion or
otherwise, Orion has not commenced a legal proceeding against such infringement,
or if at any time Orion discontinues the pursuit of such proceeding, GTX may, at
its option, commence, continue or intervene, as the case may be, in such
proceeding, provided, however, that with respect to any such proceedings in any
country, GTX shall first request Orion to notify GTX whether any Third Party has
a right to enforce the relevant Orion Patent Rights in the relevant countries,
in which event Orion shall promptly respond to such request, and further
provided that GTX' rights hereunder are subject and secondary to any rights that
Orion has granted to any Third Party prior to the Restatement Date in such
country with respect to enforcement of the relevant Orion Patent Rights. During
the time any such proceeding or any appeal thereof is pending, no Royalty Income
shall be payable under Section 3.1 in the country in which such proceeding is
pending. Upon a favorable final resolution of such proceeding or any appeal
thereof, GTX shall resume paying Orion the full royalties in such country, and
GTX shall also be liable for payment of any back royalties payable for such
period for which such a proceeding has been pending. Orion's commencement of
such proceeding shall be at Orion's own expense, provided that Orion shall be
entitled to retain all

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-31
<PAGE>
recoveries in such proceeding or any appeal thereof. Such commencement by Orion
shall not relieve either Party of its obligations under Section 12.6.

          12.8.2 GTX ENFORCEMENT.

               (A) GTX shall have the first right but not the obligation, to
commence, at its own expense appropriate measures to enforce United States
Patent Nos. [ * ] against infringement by Third Parties, within a reasonable
period of time after GTX becomes aware of such infringement (including, but not
limited to, by notifying the infringing Third Party of such infringement and
demanding that such Third Party cease and desist from such infringement). If
such infringement does not cease, GTX shall have the right to commence a legal
proceeding to enforce said Orion Patent Rights, if any, against Third Party
infringements within a reasonable period of time of the date GTX becomes aware
of such infringement. GTX shall notify Orion promptly after GTX becomes aware of
such infringement, and, upon request therefor by Orion, keep Orion reasonably
informed regarding GTX's intended strategy in such situation. Additionally, if
within a reasonable period of time from the date GTX becomes aware of any
alleged Third Party infringement of said Orion Patent Rights, either by notice
from Orion or otherwise, GTX has not commenced a legal proceeding against such
infringement, or if at any time GTX discontinues the pursuit of such proceeding,
Orion may, at its option, commence, continue or intervene, as the case may be,
in such proceeding, provided, however, that with respect to any such proceedings
in the USA, Orion's right to commence, continue, or intervene in such proceeding
are subject to and secondary to any rights that GTX has granted to any Third
Party prior to the Restatement Date in such country with respect to enforcement
of the relevant patent rights. During the time any such proceeding or any appeal
thereof is pending, no Royalty Income shall be payable under Section 3.1 in the
country in which such proceeding is pending. Upon a favorable final resolution
of such proceeding or any appeal thereof, GTX shall resume paying Orion the full
royalties in such country, and GTX shall also be liable for payment of any back
royalties payable for such period for which such a proceeding has been pending.
GTX's commencement, continuation or intervention in such proceeding shall be at
GTX's own expense, provided that GTX shall be entitled to retain all recoveries
in such proceeding or any appeal thereof. Such commencement, continuation or
intervention by GTX shall not relieve either Party of its obligations under
Section 3.1 or 12.6.

     12.9 THIRD PARTY INFRINGEMENT OF GTX PATENT RIGHTS; THIRD PARTY
INFRINGEMENT OF TRADEMARKS AND THE TRADEMARK FARESTON(R).

          12.9.1 GTX shall have the sole right, but not the obligation, at its
own expense, to commence appropriate measures to enforce GTX Patent Rights and
rights to Trademarks against Third Party infringements (including, but not
limited to, notifying the infringing Third Party of such infringement and
demanding that such Third Party cease and desist from such infringement) and, if
such infringement does not cease, commence a legal proceeding to enforce such
GTX Patent Rights or rights to Trademarks, if any, against Third Party
infringements. GTX's commencement of such proceeding shall be at GTX's own
expense, provided that GTX shall be entitled to retain all recoveries in such
proceeding or any appeal thereof. Such commencement by GTX shall not relieve
either Party of its obligations under Section 12.6.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-32
<PAGE>
     12.10 MUTUAL COOPERATION. In the event of any infringement litigation in
the GTX Territory involving the Product or Orion Product or any Orion Patent
Rights or GTX Patent Rights or a Trademark, the non-prosecuting or non-defending
Party shall render such reasonable assistance as may be requested by the
prosecuting or defending Party in connection with such infringement actions. If
Orion requests GTX's assistance in connection with such infringement claims or
actions, Orion shall reimburse GTX for such direct, documented out-of-pocket
expenses as are reasonably incurred by GTX during the course of it providing
such requested assistance. If GTX requests Orion's assistance in connection with
such infringement claims or actions, GTX shall reimburse Orion for such direct,
documented out-of-pocket expenses as are reasonably incurred by Orion during the
course of it providing such requested assistance. Before incurring such
expenses, the Parties shall in good faith agree in writing on the nature and
extent of assistance to be rendered, and an estimate of the total expenses,
which expenses shall be monitored periodically.

     12.11 PATENT CHALLENGES.

          12.11.1 If GTX, its Affiliate, or GTX Unaffiliated Sublicensee, either
directly or through a contractor or agent, challenges the validity of any Orion
Patent Rights in any Major Country within the GTX Territory (other than in a
Major Country that is a member of the European Union) and does not cease such
challenge within thirty (30) days of receipt of written notice from Orion, then
such challenge shall be deemed a material breach of this Agreement and Orion
shall have the right to terminate this Agreement by written notice with
immediate effect, at Orion's sole discretion, in its entirety or with respect to
such country.

          12.11.2 If Orion challenges the validity of any GTX Patent Rights in
any Major Country in the GTX Territory (other than in a Major Country that is a
member of the European Union) and does not cease such challenge within thirty
(30) days of receipt of written notice from GTX, then such challenge shall be
deemed a material breach of this Agreement and GTX shall be entitled to
terminate this Agreement by written notice with immediate effect, at GTX's sole
discretion, in its entirety or with respect to such country.

     12.12 ACTIVITIES DURING INFRINGEMENT LITIGATION.

          12.12.1 In the event of any patent or trademark or other proprietary
right infringement litigation involving the Product in GTX Territory in which
GTX defends or prosecutes such litigation pursuant to Section 12.8 or 12.9, GTX
may, at any time following one hundred eighty (180) days after the commencement
of such litigation, request in writing that Orion suspend the manufacture of the
Orion Product for use in the Field in the part of the GTX Territory so affected
pending resolution of such litigation if GTX reasonably deems such action
necessary or advisable to mitigate possible damages that may be incurred during
the pendency of such litigation. If Orion elects not to comply with such request
within thirty (30) days after receipt thereof, then all damages resulting from
Orion's continued manufacturing of the Product for use in the Field in the part
of the GTX Territory so affected (other than for the Orion Field in the Orion
Territory) after Orion's receipt of such request shall be borne by Orion and be
subject to Orion's indemnification obligation to GTX pursuant to Section 15.6.1.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-33
<PAGE>
          12.12.2 In the event of any patent or trademark or other proprietary
right infringement litigation involving the Product in the GTX Territory in
which Orion defends or prosecutes such litigation pursuant to Section 12.8 or
12.9, Orion may, at any time following one hundred eighty (180) days after the
commencement of such litigation, request in writing that GTX suspend the import,
distribution, marketing, sale and use of the Product, and suspend Orion's
manufacture and supply of Orion Product for GTX hereunder, in the part of the
GTX Territory so affected pending resolution of such litigation if Orion
reasonably deems such action necessary or advisable to mitigate possible damages
that may be incurred during the pendency of such litigation. If GTX elects not
to comply with such request within thirty (30) days after receipt thereof, then
all damages resulting from GTX's continued importing, distribution, marketing,
sale and use of the Product in the part of the GTX Territory so affected after
GTX's receipt of such request shall be borne by GTX and be subject to GTX's
indemnification obligation to Orion pursuant to Section 15.6.2. If GTX elects to
comply with such request, such compliance shall be considered a suspension of
GTX's marketing and sales obligations, notwithstanding Article 6.

          12.12.3 In the event either Party receives a written claim of any
alleged or actual infringement of a Third Party patent or trademark or other
proprietary right as a result of Orion's, its Affiliate(s) or Unaffiliated
Sublicensee(s') manufacturing of or selling Orion Product to GTX, or GTX, its
Affiliates, or GTX Unaffiliated Sublicensees making, having made, marketing,
using or selling the Product in GTX Territory for use in the Field, each Party
shall so notify the other Party and the Parties shall confer regarding the basis
for such claim, and discuss how the Parties may resolve the situation. Orion
shall have the right to suspend its manufacture and supply of the Orion Product
in and/or to the part of the GTX Territory so affected upon twenty (20) days
prior written notice to GTX pending resolution of such claim or any related
infringement litigation, if necessary to mitigate damages that may be incurred.
If Orion exercises its rights hereunder, the Parties shall thereafter discuss
from time to time whether the situation has been resolved and, accordingly,
whether Orion is in a position to resume the supply of Orion Product pursuant to
this Agreement.

13.  COMPETING PRODUCTS

     13.1 OBLIGATIONS WITH RESPECT TO COMPETING PRODUCTS.

          13.1.1 Beginning on the Effective Date and until the expiration of the
last of the Orion Patent Rights on a country by country basis in the Major
Countries, GTX and GTX Affiliates undertake not to market or sell a Competing
Product in such country, excluding those countries of the Major Countries within
the European Union, in which countries GTX and GTX Affiliates undertake not to
market or sell any Competing Product for a period of five (5) years from the
Amendment Date.

          13.1.2 However, nothing contained in this Section 13.1 shall be
construed as preventing either Party from conducting research and development
activities relating to a Competing Product during such period or thereafter.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-34
<PAGE>
14.  PRODUCT ORDERS, SUPPLY AND PAYMENTS

     14.1 ORION SUPPLY OBLIGATIONS.

          14.1.1 PRODUCT SUPPLY. During the Term, Orion shall, subject to the
terms of this Article 14 and Section 7.7, supply GTX and GTX Affiliates with
their requirements of Orion Product. Orion shall supply the Product in bulk
tablet form.

          14.1.2 PRODUCT DELIVERY. Orion shall supply Orion Product to GTX only
against receipt of GTX's written purchase orders. Except as otherwise provided
herein or as otherwise expressly agreed in writing by the Parties, delivery
shall be within ninety (90) days from receipt and confirmation by Orion of GTX's
purchase order. Orion shall confirm the delivery dates within ten (10) business
days after receipt of GTX's purchase orders and, subject to the provisions of
Section 14.2, Orion shall use its best reasonable efforts to fill such orders on
the requested delivery dates, but shall in any event fill such orders within
ninety (90) days from receipt and confirmation of GTX's purchase order. Orion
shall deliver Orion Product [ * ] to a carrier designated by GTX (with the
foregoing being interpreted to effect [ * ]. GTX shall pay shipping costs and
shall assume title to and risk of loss for Orion Product purchased hereunder
after such delivery to GTX's designated carrier.

          14.1.3 PRODUCT SHIPPING INSTRUCTIONS. GTX shall provide Orion with
appropriate instructions for each shipment of Orion Product hereunder
designating the desired carrier, destination and method of transport. If Orion
becomes aware that the designated carrier is unable to accept the desired
shipment within the requested delivery period, Orion shall promptly notify GTX
and GTX shall promptly designate another carrier or carriers.

     14.2 ORION AFFILIATES AND SUBCONTRACTORS. Orion may satisfy its supply
obligations under this Agreement either directly or through any Orion Affiliate
(provided that such Orion Affiliate has a manufacturing site which has received
all required regulatory approvals and that Orion guarantees the performance of
such Affiliate), and such supply by Orion Affiliates shall not be deemed an
infringement of GTX's rights hereunder.

     14.3 GTX FORECASTS.

          14.3.1 ROLLING FORECASTS. Within ninety (90) days after the
Restatement Date, GTX shall inform Orion in writing of GTX's bona fide, good
faith estimated requirements of Fareston Product in the GTX Territory during the
year 2005. Thereafter, for the remainder of the Term, GTX shall provide to Orion
by September 30 of each year a purchase forecast of GTX's estimated requirements
of Orion Product for the twenty four (24) month period beginning with October 1
of the then current year, allocated for each calendar month of such period,
provided that if during any calendar year GTX expects to order Product from
Orion to support the launch of Product for use in the Field but outside of the
Breast Cancer Field, then not later than ninety (90) days prior to GTX's
anticipated first order of Orion Product from Orion to support the launch of
Product for such use, GTX shall update the most recently provided purchase
forecast to include GTX's good faith estimated requirements of Orion Product to
support such launch (if not already included in the then-applicable forecast).
GTX shall update its purchase estimates to Orion on a monthly basis by
indicating by the end of each month revised estimates or confirming

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-35
<PAGE>
that no revisions are necessary, which shall provide Orion with GTX's rolling
twenty four (24) month forecasts.

          14.3.2 EXCESS QUANTITIES. If GTX orders a quantity of Orion Product in
excess of one hundred twenty-five percent (125%) of GTX's purchase forecast
provided two (2) Calendar Quarters prior to such order, Orion shall deliver the
quantity in excess of one hundred twenty-five percent (125%) up to one hundred
fifty percent (150%) of such forecast within one hundred twenty (120) days from
receipt and confirmation of GTX's purchase order. If GTX orders a quantity of
Orion Product in excess of one hundred fifty percent (150%) of GTX's purchase
forecast provided two (2) Calendar Quarters prior to such order, Orion shall use
commercially reasonable efforts to supply the quantity in excess of one hundred
fifty percent (150%) up to two hundred percent (200%) of such forecast as soon
as practical, but in no event later than one hundred eighty (180) days from
receipt and confirmation of GTX's purchase order. If GTX orders a quantity of
Orion Product in excess of two hundred percent (200%) of GTX's purchase forecast
provided two (2) Calendar Quarters prior to such Order, Orion shall use
commercially reasonable efforts to supply the quantities in excess of such
forecast as soon as practical.

          14.3.3 MINIMUM QUANTITIES. Of the amounts of Orion Product indicated
by GTX in its rolling monthly forecasts, GTX shall purchase at least one hundred
percent (100%) of its estimated requirement for Orion Product for the first
three (3) months of such forecast, eighty percent (80%) of its estimated
requirement of Orion Product for the fourth, fifth and sixth months of such
forecast, and fifty percent (50%) of its estimated requirement of Orion Product
for the seventh, eighth and ninth months of such forecast. All orders and
deliveries of Orion Product shall be in full batch sizes of Orion Product, as
determined by Orion from time to time. Orion shall notify GTX in writing prior
to the date upon which GTX must provide its first commercial order of Orion
Product under this Article 14 of what the size of a full batch of Orion Product
is at such time.

     14.4 PRICES AND PAYMENT.

          14.4.1 COMMERCIAL PRICING FORMULA. Orion's annual price of bulk Orion
Product to GTX, its Affiliates or its Unaffiliated Sublicensees for commercial
purposes, delivered [ * ] (with the foregoing being interpreted to effect
[ * ]), shall be:

          [ * ]

          14.4.2 INVOICING AND PAYMENT. Orion shall invoice GTX for commercial
orders of Orion Product shipped, and GTX shall pay such invoice within thirty
(30) days of receipt.

          14.4.3 PRICE CHANGES. GTX may, no more than once per year, request
that Orion determine whether the average cost of the raw materials set forth in
Schedule C used to manufacture Product during the immediately preceding year
has, in the aggregate, changed by more than five percent (5%) of the average
cost thereof that applied during the year immediately preceding the date that is
one year earlier than the date of GTX's request (any such change, a "Significant
Cost Change"). Reasonably promptly following any such request by GTX, Orion
shall make such determination and notify GTX of the result of such
determination. Additionally,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-36
<PAGE>
if Orion determines that a Significant Cost Change has occurred (other than in
response to such a request by GTX), it shall so notify GTX. If Orion determines
that a Significant Cost Change has occurred upon GTX's request or upon Orion's
own investigation, then the Parties shall (no more than once annually) adjust
the price to reflect such Significant Cost Change. Such price shall apply to
Orion Products purchased by GTX following the date of Orion's notice to GTX that
a Significant Cost Change has occurred.

          14.4.4 EXCEPTION. Notwithstanding the foregoing, GTX shall not owe
Orion any payment pursuant to this Section 14.4 for any Product that is sold to
a Third Party for development or commercialization of a [ * ] as to which GTX
owes Orion payments described in Section 3.1.6.

     14.5 RESALE PRICES. GTX, its Affiliates and GTX Unaffiliated Sublicensees
shall be free to set their own resale prices for the Product sold in the GTX
Territory.

     14.6 PRODUCT SUPPLY FOR TESTING AND REGISTRATION; SUPPLY OF TOREMIFENE.

          14.6.1 PRODUCT SUPPLY FOR TESTING AND REGISTRATION. The supply price
for the [ * ] tablet of bulk Orion Product for clinical trials shall be [ * ]
per tablet. Orion shall supply GTX or its Affiliates with such quantities of
[ * ] tablets of bulk Product as GTX or its Affiliates may require of Orion
Product and/or placebos for use in clinical trials of Products. The price for
the [ * ] tablet of bulk Orion Product for clinical trials shall be [ * ] per
tablet. Orion shall supply GTX with such quantities of [ * ] tablets of bulk
Product as GTX or its Affiliates may require of Orion Product and/or placebos
for use in clinical trials of Products. The price for the [ * ] tablet of bulk
Product for clinical trials shall be [ * ] per tablet. Orion shall supply GTX
with such quantities as GTX or its Affiliates may require of [ * ] tablets of
Orion Product and/or placebos for use in clinical trials of Products. The price
for a [ * ] placebo for such clinical trials shall be [ * ], per tablet. All
Orion Product supplied for testing and registration pursuant to this Section
14.6 shall be provided in bulk packaging. Notwithstanding the foregoing, GTX
shall not owe Orion any payment pursuant to this Section 14.6 for any Product
that is sold to a Third Party for development or commercialization of a [ * ] as
to which GTX owes Orion payments described in Section 3.1.6.

          14.6.2 SUPPLY OF TOREMIFENE. For the sole purpose of aiding GTX or its
Affiliates in its efforts to obtain Regulatory Approval for the Product for use
in the Field in the GTX Territory, Orion shall, during the Term, upon written
order thereof by GTX, provide GTX, free of charge, with up to [ * ] of
Toremifene in bulk powder form (the "Powder"). GTX undertakes to use such Powder
only for studies necessary to support Regulatory Approval for Product for use in
the Field, excluding the Orion Field in the Orion Territory. Upon ordering
Powder from Orion, GTx shall provide Orion with a detailed description of such
study(ies) and the expected amount of Powder needed for said study(ies).

     As consideration for Orion's agreement to provide the Powder to GTX, all
results, data, information, inventions, memoranda, reports, discoveries, work
products and other results (including without limitation any patents(s) granted
thereon), which are conceived, derived, reduced to practice, made and/or
developed by or on behalf of GTX and arising out of or relating to the use of
the Powder (hereinafter referred to as "Results") shall be jointly owned by GTX
and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-37
<PAGE>
Orion such that each Party shall have a one-half undivided interest in and to
such results, without a duty of accounting to the other Party. Orion's interest
in the Results, and any patent rights related thereto, shall be subject to the
licenses granted to GTX pursuant to Section 2.1 to the extent such Results are
included in the Orion Patent Rights or Orion Know-How. GTX hereby grants to
Orion an exclusive, royalty-free, worldwide license with the right to grant
sublicenses, under GTX's joint interest in the Results and any intellectual
property rights relating thereto for use in developing, using, having used,
selling, having sold, importing, marketing and distributing products outside of
the Field and in the Orion Field in the Orion Territory. Orion hereby grants to
GTX an exclusive, royalty-free, worldwide license, with the right to grant
sublicenses, under Orion's joint interest in the Results and any intellectual
property rights relating thereto, for use in developing, using, having used,
selling, having sold, importing, marketing and distributing products in the
Field (excluding in the Orion Field in the Orion Territory), to the extent such
rights are not otherwise included in the Orion Patent Rights or Orion Know-How
licensed to GTX pursuant to Section 2.1.1.

     Any use of the Results by GTX other than for the purposes of this Agreement
shall not be permitted without the express written consent of Orion, which Orion
may withhold at its sole discretion.

     Without prejudice to the foregoing, the Results shall be deemed both
Orion's and GTX's Confidential Information and shall be used and treated for
purposes of Section 8 of this Agreement as Confidential Information of the other
Party. GTX shall promptly disclose to Orion all Results immediately when such
Results are available.

     GTX and Orion shall mutually determine whether or not any of the Results
provide the basis for any patentable inventions. If both Orion and GTX consider
that patents for any such inventions involving Results should be sought, then
such applications shall, in accordance with what has been stated herein above,
be filed in the Parties' joint name, and the Parties shall share equally all
costs of filing, prosecuting and maintaining relevant patent applications and
patents. The Parties shall negotiate in good faith on the division of
responsibilities with regard to drafting, filing, prosecuting and maintaining
the relevant patent applications and patents. If the Parties do not decide that
patent application(s) should be filed for any patentable inventions included in
the Results, then the Results shall continue to be treated as Confidential
Information of both Parties.

     14.7 AGREEMENT TERMS GOVERN. Except as otherwise agreed in writing by the
Parties, the terms and conditions of this Agreement shall govern Orion and its
Affiliates' sale of Orion Product to GTX, its Affiliates and GTX Unaffiliated
Sublicensees during the Term, notwithstanding any conflicting terms and
conditions set forth in GTX's forecast, order or purchase documents or in
Orion's sale or acceptance documents and any such conflicting terms are hereby
expressly rejected.

     14.8 PRICE ADJUSTMENT FOR COMMERCIAL SUPPLY. It is agreed upon by the
Parties that the price of the [ * ] tablet of Orion Product to GTX, its
Affiliates or Unaffiliated Sublicensees shall be reduced below [ * ] based upon
attaining certain milestone purchases of Product as follows: if GTX purchases
annually an aggregate amount of [ * ] of tablet [ * ], the price of the tablet
shall be [ * ] per [ * ] tablet. Similarly, (i) the price to GTX of the [ * ]
tablet of Orion

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-38
<PAGE>
Product shall be reduced if GTX purchases annually [ * ] of the [ * ] tablets
such that the price per [ * ] tablet of Orion Product shall be [ * ], and (ii)
the price to GTX of the [ * ] tablet of Orion Product shall be reduced if GTX
purchases annually [ * ] of the [ * ] tablets such that the price per [ * ]
tablet of Orion Product shall be [ * ]. If a price adjustment is triggered under
this Section 14.8, then the adjusted price shall apply to the entire amount of
the relevant tablets purchased during the relevant year. Orion shall within
thirty (30) days after the end of such year, pay to GTX an amount equal to the
number of relevant tablets actually purchased during such year, multiplied by
the difference between the price paid by GTX for supply of the relevant tablets
and the lower price that is actually applicable due to the adjustment to be made
pursuant to this Section 14.8.

     14.9 TERMINATION OF PRODUCT SUPPLY. Orion shall, at its sole discretion,
have the right upon providing [ * ] prior written notice thereof, to terminate
its obligations under this Article 14 relating to the manufacture and supply of
Orion Product and/or Toremifene (pursuant to Section 14.6.2) in the event that
Orion permanently ceases the manufacture of Toremifene and/or Orion Product. For
the avoidance of doubt, the right of termination relating to the manufacture and
supply of Orion Product and/or Toremifene set forth in this Section 14.9 shall
not restrict or alter Orion's rights under Section 7.7. In the event that Orion
so terminates such obligations, Orion shall grant GTX a contingent license under
the Orion Patent Rights, Orion Know-How and the Manufacturing Patents to make
and have made Product for use in the Field in the GTX Territory (except for use
of the Product in the Orion Field in the Orion Territory) during the Term, with
such license to be exclusive in the Field (but excluding the Orion Field in the
Orion Territory) and sublicensable (but only for the purpose of having Products
manufactured for GTX, its Affiliates or Unaffiliated Sublicensees). Such license
shall become effective upon GTX's receipt of notice from Orion under this
Section 14.9. Orion shall during such [ * ] notice period, and as soon as
practically possible after GTX's written request, provide GTX with Product
Manufacturing Know-How to the extent reasonably necessary to enable GTX to
exercise its back-up manufacturing right pursuant to this Section 14.9,
including without limitation providing up to ten (10) person-days of technology
transfer assistance at GTX's site of manufacture of Product using Orion
personnel skilled in such manufacturing operations, at no charge to GTX.

15.  PRODUCT WARRANTIES AND INDEMNIFICATION

     15.1 PRODUCT WARRANTIES AND LIMITATIONS.

          15.1.1 ORION WARRANTIES. Orion warrants and represents that the Orion
Product manufactured by Orion, its Affiliate(s) or subcontractor(s), as the case
may be, and delivered to GTX, its Affiliate(s) or GTX Unaffiliated
Sublicensee(s) hereunder for resale shall (i) from the date of shipment until
the end of the specified shelf-life conform to the Specifications (provided,
however, that Orion Product has after shipment been handled and stored properly
and been afforded sufficient protection against deterioration and damage) and
shall have been manufactured in accordance with U.S. FDA Good Manufacturing
Practices and equivalent Good Manufacturing Practices in Europe to the extent
applicable to Orion, its Affiliates or subcontractors as the manufacturer(s) of
Orion Product, and (ii) be transferred free and clear of any security interests,
liens and encumbrances. It is expressly agreed that, except as expressly
provided for in Section 11.2, no representation, warranty, commitment or
obligations given,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-39
<PAGE>
made or undertaken by Orion in this Agreement shall apply with regard to any
Product manufactured by a party other than Orion, its Affiliates or
subcontractors, including without limitation any Product manufactured by or on
behalf of GTX under its stand-by and other manufacturing rights pursuant to
Section 7.7, 14.9, 16.1, 17.3.2, 17.4 or 21.2.2.

          15.1.2 LIMITATIONS. Except as otherwise expressly stated herein, no
warranties or representations, express or implied are made or shall be deemed to
have been made by Orion, its Affiliate or subcontractor including without
limitation the warranties of fitness for a particular purpose and
merchantability, regarding any Product, including without limitation the Orion
Product and Other Product. Subject to Orion's warranty and indemnification
obligations under this Agreement for Orion Product, Orion shall have no
responsibility or liability for any Product, including without limitation Orion
Product and Other Product manufactured by Orion and/or used, supplied, marketed,
or sold by GTX, its Affiliates or GTX Unaffiliated Sublicensees.

     15.2 CERTIFICATE OF ANALYSIS. Orion shall furnish GTX with one or more
certificates of analysis for each batch of Orion Product supplied hereunder, in
the form required by law in each country of GTX Territory where the Orion
Product is marketed, with shipment of each such batch.

     15.3 PRODUCT INSPECTIONS.

          15.3.1 GTX INSPECTION AND ANALYSIS. GTX shall inspect and analyze a
representative sample of Orion Product from batches supplied by Orion promptly
after receipt. If, after inspection, GTX reasonably believes the shipment does
not meet the Specifications, GTX shall notify Orion in writing within thirty
(30) days after GTX's receipt of any such goods. If GTX does not so notify
Orion, GTX shall be deemed to have waived all claims against Orion for said
quantity delivered, except for any latent defects that could not have been
reasonably discovered upon such inspection, which defects shall be notified by
GTX to Orion within fourteen (14) days from discovery of same. Any claims by GTX
regarding goods delivered shall specify in reasonable detail the nature and
basis for the claim and cite relevant Orion lot numbers or other information to
enable specific identification of the goods involved. GTX shall not be required
to accept Orion Product having a shelf life of less than eighty percent (80%) of
the stated expiration dating on the date of shipment by Orion.

          15.3.2 ORION RESPONSE. Orion shall respond to all claims made by GTX
on a case-by-case basis and Orion shall have the right to first inspect any
goods involved before being required to take any action with respect thereto.
Orion shall review any such claim of nonconformity made by GTX within thirty
(30) business days of receipt of GTX's notice under Section 15.3.1 and conduct
any required testing of the goods involved as soon as possible, but in no event
later than forty-five (45) days after receipt thereof, or earlier if the U.S.
FDA or any corresponding regulatory authority in the GTX Territory requires an
earlier response from Orion. If such review and testing by Orion (or testing by
an independent laboratory as set forth below) confirms that a claimed quantity
does not meet the Specifications, then, at Orion's expense, GTX shall dispose of
or return such quantity involved as Orion shall direct in writing and Orion
shall replace such quantity with conforming goods as soon as possible, but in no
event later than sixty (60) days after testing is completed, which shall be
GTX's sole and exclusive remedy for such non-conformity. If the Parties fail to
agree as to whether a delivered quantity meets the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-40
<PAGE>
Specifications, then the Parties shall have the batch in dispute analyzed by a
mutually agreed upon independent testing laboratory located in the country in
which Orion Product to which goods relate is intended for resale, or, if the
Parties agree, in Finland. Such laboratory's determination shall be deemed final
as to any dispute over the Specifications and the nonprevailing Party shall bear
the costs of such independent laboratory's testing.

     15.4 PRODUCT STORAGE. Each Party shall properly store Orion Product under
conditions that will not adversely affect the quality or normal shelf life
thereof.

     15.5 GTX RESPONSIBILITIES IN GTX TERRITORY.

          15.5.1 LABELING. GTX shall be responsible for packaging of the
Product, and for all labeling, inserts, packaging and promotional materials and
any other materials which accompany, are distributed, used or referred to in any
way by GTX, its Affiliate(s) or GTX Unaffiliated Sublicensee(s) in connection
with the Product and GTX shall ensure that same shall conform to all legal
requirements in each country of the GTX Territory in which the Product is sold.
Subject to applicable legal and regulatory requirements and space limitations,
all Product labeling, packaging, inserts and promotional materials shall
indicate that the Product is marketed by GTX. GTX shall, upon written request
therefore by Orion, provide Orion with copies of representative samples of
materials which GTX, its Affiliates and GTX Unaffiliated Sublicensees intend to
use in connection with the marketing, promotion and sale of the Product thirty
(30) days prior to their first use thereof, provided that nothing herein or
otherwise, including without limitation any request by Orion to be furnished
with such materials or review of same, shall be construed as Orion assuming any
liability or responsibility for such materials or their conformity to all legal
requirements in any country of the GTX Territory in which the Product is sold
and such request and/or review by Orion of such materials shall be without
prejudice to the first sentence of this Section 15.5. GTX, its Affiliates, or
GTX Unaffiliated Sublicensee shall register, promote, market and sell the
Product in the GTX Territory only for the indications for which relevant
Regulatory Approvals have been obtained and only in accordance with applicable
legal and governmental authority requirements.

          15.5.2 NOTIFICATION. GTX shall also be responsible for notifying,
reporting or registering this Agreement or the business relationship created
hereby with any government authorities in the GTX Territory to the extent
legally required. Orion shall provide GTX with such assistance as GTX may
reasonably request in connection therewith.

     15.6 RECIPROCAL INDEMNIFICATION PROVISIONS.

          15.6.1 ORION INDEMNIFICATION. Orion shall defend, indemnify and hold
GTX, its Affiliates, GTX Unaffiliated Sublicensees, and its and their officers,
directors and employees, harmless from and against any and all liabilities,
damages, claims, demands, costs, or expenses (including reasonable attorneys'
fees) Losses claimed by any Third Party for any property or other economic loss
or damage or injury or death suffered by it to the extent the same is determined
to have been caused by (A) the negligence, fault, willful wrongdoing or any
other act or omission in relation to the manufacture by Orion, its Affiliates or
subcontractor(s) of the Orion Product, or a material breach of this Agreement by
Orion, its Affiliate(s) or Unaffiliated Sublicensee(s), or (B) or a breach by
Orion of the warranties set forth in Section 15.1 and/or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-41
<PAGE>
20.1(i), or (C) the manufacture, use, sale, importation, distribution and/or
marketing of the Product for use in the Orion Field and in the Orion Territory
by Orion, its Affiliates or Unaffiliated Sublicensees, except with respect to
each of (A) and (B) to the extent that such Losses are caused by activities for
which GTX must defend, indemnify and hold harmless pursuant to Section 15.6.2.

          15.6.2 GTX INDEMNIFICATION. GTX shall defend, indemnify and hold
Orion, its Affiliates, and its and their the officers, directors and employees
harmless from and against any and all Losses claimed by any Third Party for any
property or other economic loss or damage, injury or death suffered by it to the
extent the same is determined to have been caused by (A) a breach by GTX of
[ * ](i); (B) the negligence, fault, willful wrongdoing or any other act or
omission, or material breach of this Agreement by GTX, its Affiliates or
Unaffiliated Sublicensees; (C) the manufacture, use, sale, importation,
distribution, and/or marketing of the Product by GTX, its Affiliates or
Unaffiliated Sublicensees in the Field in the GTX Territory, including without
limitation any product liability claim for property or other economic loss or
damage, injury or death suffered by a Third Party arising out of or relating to
the Product or Other Product or use thereof, except with respect to each of (B)
and (C) to the extent that such Losses are caused by activities for which Orion
must defend, indemnify and hold harmless GTX pursuant to Section 15.6.1.

     15.7 CONDITIONS FOR INDEMNIFICATION. With respect to any indemnification
obligations of either Party to the other Party under this Agreement, the
following conditions must be met for such indemnification obligations to become
applicable: (A) the indemnified Party shall notify the indemnifying Party
promptly in writing of any claim which may give rise to an obligation on the
part of the indemnifying Party hereunder; (B) the indemnifying Party shall be
allowed to timely undertake the sole control of the defense of any such action
and claim, including all negotiations for the settlement, or compromise of such
claim or action at its sole expense; and (C) the indemnified Party shall render
reasonable assistance, information, cooperation and authority to permit the
indemnifying Party to defend such action, it being agreed that any out-of-pocket
expenses or other expenses incurred by the indemnified Party in rendering the
same shall be borne or reimbursed promptly by the indemnifying Party. Neither
Party shall consent to the entry of any judgment or settle or otherwise
compromise any such action or suit in a way that adversely affects the other
Party's intellectual property rights or other rights, obligations or interests
with respect to Products, or imposes obligations on such other Party, without
such other Party's prior written consent.

     15.8 LIABILITY INSURANCE. GTX shall procure and maintain insurance,
including product liability insurance, adequate to cover its obligations
hereunder and which are consistent with normal business practices of prudent
companies commercializing products of similar nature that present similar
liability risks. It is understood that such insurance shall not be construed to
create a limit of GTX's liability with respect to its any of its obligations
hereunder, including without limitation its indemnification and compensation
obligations under this Agreement. GTX shall provide Orion with written evidence
of such insurance (including without limitation financial information that
describes the amounts available under such insurance) upon request. This Section
15.8 shall survive the termination expiration of this Agreement for ten (10)
years for whatsoever reason.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-42
<PAGE>
16.  STANDBY MANUFACTURING RIGHTS; INVENTORY MAINTENANCE

     16.1 INABILITY TO MANUFACTURE OR SUPPLY. If Orion is unable to supply or
manufacture Orion Product, as ordered pursuant to Sections 14.1.2 and 14.3.2,
for ninety (90) or more consecutive days after the agreed delivery time for any
reason (including but not limited to a Force Majeure event), save as for reasons
arising from acts or omissions of GTX, its Affiliates and/or its Unaffiliated
Sublicensees, including without limitation failure by GTX, its Affiliates and/or
its Unaffiliated Sublicensees to notify Orion of Orion's failure to deliver
Orion Product ordered pursuant to Sections 14.1.2 and 14.3.2, then GTX may, at
its option, responsibility and expense, elect to manufacture or have a Third
Party manufacture Toremifene and/or Orion Product for use in manufacturing and
selling the Product for use in the Field anywhere in the GTX Territory (except
for use in the Orion Field in the Orion Territory) until such time as Orion can
demonstrate to GTX's reasonable satisfaction that Orion is capable of resuming
the manufacture of Toremifene and/or Orion Product, as applicable. To the extent
necessary to implement such standby manufacturing rights, Orion hereby grants
GTX a contingent license under the Orion Patent Rights, Orion Know-How and
Manufacturing Patents to make and have made Toremifene and/or Orion Product for
use in the Field in the GTX Territory (except for use in the Orion Field in the
Orion Territory). Such license shall be exclusive and sublicensable (but only
for the purpose of having Products manufactured for GTX, its Affiliates or
Unaffiliated Sublicensees), with such license to become effective only under the
circumstances specified in the preceding sentence. In such case, Orion shall as
soon as practically possible provide GTX with Product Manufacturing Know-How to
the extent reasonably necessary to enable GTX to exercise its back-up
manufacturing right pursuant to this Section 16.1, including without limitation
providing up to ten (10) person-days of technology transfer assistance at GTX's
site of manufacture of Product using Orion personnel skilled in such
manufacturing operations, at no charge to GTX. Orion shall promptly notify GTX
in writing of any circumstances rendering it unable to manufacture Product and
the estimated duration of such circumstances. GTX's standby-manufacturing rights
under this Section 16.1 shall be GTX's sole and exclusive remedy for Orion's
failure to manufacture or have manufactured Orion Product for supply to GTX
under Article 14.

     16.2 BACK-UP MANUFACTURING RIGHT. GTX shall have the right to require Orion
to qualify and maintain the qualification for, at GTX's expense (as described
below), a back-up facility(ies) for use in manufacturing Product for supply to
GTX pursuant to Article 14 at any time after GTX's good faith forecasted Net
Sales of Products provided pursuant to Section 14.3 [ * ] in a given Year, or
actual Net Sales for Product in any given Year [ * ]. GTX shall exercise such
right by written notice to Orion. Promptly after receiving such notice, Orion
and GTX shall meet to discuss the manner in which Orion proposes to qualify and
maintain the qualification for such back-up manufacturing facility(ies) (for
example, by qualifying a site owned by Orion or by engaging a Third Party
manufacturer to qualify another facility), the timing for qualifying such
facility(ies), and Orion's estimated costs incurred directly in connection with
qualifying such facility(ies) (which costs may include, by way of example,
Orion's costs of obtaining Regulatory Approvals necessary to enable the sale in
the Territory of Product manufactured at such site). Orion shall promptly
thereafter, subject to agreement on reimbursement by GTX of Orion's related
costs and expenses, qualify such back-up facility and maintain the qualification
for such facility (including obtaining relevant Regulatory Approvals

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-43
<PAGE>
and making appropriate regulatory filings) to assure continued supply of Product
in the event Orion is unable to supply Products in the amounts ordered pursuant
to Article 14. GTX shall reimburse Orion for [ * ], or [ * ] the Parties.
Nothing in this Section 16.2 shall be deemed to limit Orion's obligations under
Article 14, or to prevent GTX from seeking any remedies available to it under
law or in equity for any breach by Orion under such Sections.

     16.3 MAINTENANCE OF INVENTORY. Orion shall, at all times during the Term,
maintain or have maintained, either itself or through a subcontractor, an amount
of Toremifene and other raw materials critical for the manufacture of Products
containing such Toremifene sufficient to manufacture the amount of Product
forecasted to be ordered by GTX pursuant to Section 14.3 during the subsequent
[ * ] period of time. The Parties will agree upon an appropriate amount of
reserve supplies to be maintained by Orion during the [ * ] following the First
Commercial Sale of Product in the Prostate Cancer Field at the time GTX provides
an update to its forecasted requirements to support launch of Product in such
field pursuant to Section 14.1. Such supplies shall serve as a reserve supply to
be used by Orion solely to manufacture Product for GTX if any shortfall in the
amount of Product supplied by Orion pursuant to Article 14 occurs or is
reasonably anticipated to occur. Nothing in this Section 16.3 shall be deemed to
limit Orion's obligations under Article 14.

17.  MANUFACTURING INSPECTIONS AND CHANGES

     17.1 REGULATORY INSPECTIONS. Each Party shall allow representatives of the
U.S. FDA and any other regulatory agency or authority with jurisdiction over the
manufacture, marketing and distribution of the Product to tour and inspect all
facilities utilized by such Party in the manufacture, testing, packaging,
storage, and shipment of Product sold under this Agreement, and shall co-operate
with such representatives in every reasonable manner. Upon notification by the
U.S. FDA or any other regulatory agency of such agency's intent to conduct an
inspection, the Party receiving such notification will immediately inform the
other Party of such inspection with such advance notice as to allow the other
Party to have representatives present during such inspection (to the extent such
presence is allowed by such regulatory agency). Each Party shall also provide
the other Party with a copy of any U.S. FDA Form 483 notices of adverse
findings, regulatory letters or similar notifications it receives from any other
governmental authority setting forth adverse findings or non compliance with any
applicable laws, regulations or standards relating to the Product within five
(5) days of its own receipt thereof. Each Party shall also provide the other
Party with a copy of its proposed written response to such governmental
authority before submission and shall incorporate any changes thereto which the
other Party may reasonably request.

     17.2 ORION-INITIATED MANUFACTURING CHANGES. Save as for changes required
under applicable laws and regulations or by any competent regulatory or other
authority, during the Term, Orion shall not make any material changes to its
manufacturing operations for Toremifene or Orion Product to be supplied to GTX
pursuant to this Agreement, without informing GTX prior to such changes;
provided that if such changes would require GTX to make additional filings with
regulatory authorities or to seek additional Regulatory Approvals for Orion
Product, then Orion shall not make such change without GTX's prior written
consent, such consent not to be unreasonably withheld, conditioned or delayed

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-44
<PAGE>
     17.3 GTX-INITIATED MANUFACTURING CHANGES.

          17.3.1 GTX REQUEST FOR MANUFACTURING CHANGES. Prior to Orion providing
GTX with notice pursuant to Section 14.9, GTX may, from time to time during the
Term and as agreed in this Section 17.3, make a written and detailed request for
changes in Orion's manufacturing operations, or the Specifications, for
Toremifene or Orion Product. Such changes that are required and mandatory under
applicable laws and regulations in a Major Country shall be deemed "Required
Manufacturing Changes", and such changes that are intended to promote quality
control/quality assurance, and/or to achieve greater efficiency or cost savings
in the manufacturing process but are not so required and mandatory shall be
deemed "Other Manufacturing Changes".

          17.3.2 REQUIRED MANUFACTURING CHANGES. Provided that GTX furnishes
Orion with evidence of Required Manufacturing Changes, Orion shall commence the
implementation of Required Manufacturing Changes as soon as practicable, but in
no event later than (i) ninety (90) days after receipt of GTX's request (or
within such other longer time period as may be mutually agreed upon by the
Parties if implementation within ninety (90) days is impossible or reasonably
impractical, such agreement not to be unreasonably withheld, conditioned or
delayed by GTX) or (ii) earlier if required by the U.S. FDA or any corresponding
regulatory authority in a Major Country. If Orion does not commence the
implementation of Required Manufacturing Changes within the time period
referenced in the preceding sentence or does not notify GTX in writing that
Orion disputes whether GTX's requested changes are Required Manufacturing
Changes, then GTX shall have the option to exercise standby manufacturing rights
for Toremifene and Product pursuant to Section 16.1 until such time as Orion
implements such Required Manufacturing Changes. If Orion notifies GTX in writing
that Orion disputes whether GTX's requested changes are Required Manufacturing
Changes, the Parties shall resolve such dispute by reference to a mutually
agreed upon independent Third Party regulatory expert as soon as possible for a
binding determination of whether the requested changes are Required
Manufacturing Changes. If such independent Third Party regulatory expert
determines that GTX's requested changes are Required Manufacturing Changes,
Orion shall implement such changes as soon as possible. Any modification to the
Specifications that is necessary to implement or reflect a Required
Manufacturing Change shall be deemed to be included in the Specifications, and
any Products manufactured thereunder by Orion shall be deemed Orion Products.

          17.3.3 OTHER MANUFACTURING CHANGES. Orion shall give due consideration
to making Other Manufacturing Changes proposed by GTX. Orion shall within sixty
(60) days from receipt of GTX's written request for Other Manufacturing Changes
provide GTX a written response to such request indicating whether it would be
willing to discuss, and as appropriate, negotiate the terms and conditions under
which Orion would be willing to implement such Other Manufacturing Changes.

     17.4 NEW DOSAGE STRENGTHS AND FORMULATIONS. Upon written request by GTX,
the Parties shall meet in person or by teleconference to discuss, and as
appropriate, negotiate the terms under which Orion would be willing to
manufacture and supply to GTX any dosage strengths or formulations of the
Product other than those that are available as an Orion Product as of the
Restatement Date (including without limitation any combination Product
containing

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-45
<PAGE>
Toremifene and another active ingredient) or any Product otherwise having
specifications different from Orion Product Specifications (such Products,
collectively "Other Product(s)"), as provided in this Section 17.4.

     The Parties shall conduct such discussions during a sixty (60) day period
following GTX's written request setting forth in sufficient detail the changes
proposed by GTX, or any mutually agreed extension of such time period
("Evaluation Period"). If Orion would be willing to manufacture such Other
Product, Orion shall within the Evaluation Period notify GTX of the terms and
conditions under which it would be willing to do so, and the Parties shall
negotiate a written amendment to this Agreement to include the applicable terms
and conditions under which Orion would manufacture and supply such Other
Product, including without limitation the supply price of such Other Product.
Upon execution of such amendment, such Other Product shall be deemed to be an
Orion Product. Such negotiation shall be conducted for up to one hundred twenty
(120) days following GTX's receipt of Orion's notice of such terms and
conditions ("Negotiation Period"). It is expressly agreed that Orion shall have
no obligation to manufacture and supply any Other Product unless a mutually
acceptable definitive written amendment to this Agreement, if any, in relation
to such Other Product is executed by duly authorized representatives of both
Parties.

     In the event Orion notifies GTX within the Evaluation Period that it will
not be interested in supplying such Other Product, or the Parties do not amend
this Agreement during the Negotiation Period to specify applicable terms for, or
execute another agreement governing, Orion's supply of such Other Product for
use in the Field (other than use in the Orion Field in the Orion Territory),
then if GTX has a good faith basis for requiring supply of such Other Product,
including but not limited to its desire to develop a dosage strength of Product
other than one which is in clinical development by or on behalf of GTX as of the
Restatement Date and in which an Orion Product is available, or a formulation of
Product that incorporates a new technology or another active ingredient in order
to optimize the pharmacokinetic properties of Product, improve the competitive
position of Product in the market, or to increase the efficiency or safety of
Products, GTX shall have the right to manufacture, or engage a Third Party
subcontractor to manufacture, such Other Product for sale and use in the Field
only. GTX shall exercise such right to manufacture or have manufactured an Other
Product for sale and use in the Field (except for use in the Orion Field in the
Orion Territory) pursuant to this Section 17.4 in good faith only, and not for
the purpose of obtaining the right to manufacture Product by, for example,
proposing minor changes to the Product formulation that do not present a
commercially reasonable basis for development. To the extent reasonably
necessary to implement such manufacturing right, Orion hereby grants GTX a
contingent license under Orion's Patent Rights, Orion Know-How, Manufacturing
Patents, and Product Manufacturing Know-How to make and have made the relevant
Other Product for use in the Field in the GTX Territory (except for use in the
Orion Field in the Orion Territory). Such license shall be exclusive and
sublicensable but only for the purpose of having Products manufactured for GTX,
its Affiliates and Unaffiliated Sublicensees), and shall become effective only
under the circumstances specified in this Section 17.4.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-46
<PAGE>
18.  PRODUCT RECALLS

     18.1 RECALL NOTIFICATION. Each Party shall promptly notify the other Party
in writing of any facts relating to the advisability of the recall, destruction
or withholding from the market of the Product anywhere in the GTX Territory (any
of the foregoing, a "Recall").

     18.2 RECALL IMPLEMENTATION IN GTX TERRITORY. If at any time (A) any
governmental or regulatory authority in the GTX Territory issues a request,
directive or order for a Recall; (B) a court of competent jurisdiction orders a
Recall in the GTX Territory; or (C) GTX determines, following consultation with
Orion (except in emergency situations in which there is insufficient time for
such consultation), that a Recall in the GTX Territory is necessary or
advisable, GTX shall take all appropriate corrective actions to effect the
Recall and Orion shall provide GTX with such cooperation in connection with the
Recall as GTX may reasonably request.

     18.3 RECALL COSTS AND EXPENSES IN GTX TERRITORY. GTX shall bear the costs
and expenses of any Recall in the GTX Territory, provided that Orion shall bear
all costs and expenses of any Recall in the GTX Territory to the extent such
Recall is the result of a breach in the warranties set forth in Section 15.1.

19.  ADVERSE DRUG EXPERIENCES

     19.1 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS.

               (A) To ensure that all relevant safety information for Toremifene
is shared between the Parties, the following information will be exchanged: (i)
GTX will provide to Orion all regulatory safety updates (e.g. 120-day safety
updates, annual reports, and post-authorization safety updates) concerning
Product and information regarding all serious adverse events from clinical
studies and all spontaneous adverse reactions, including reports from literature
concerning the Product coming to the knowledge of GTX; and (ii) Orion will
provide to GTX Periodic Safety Update Reports prepared in accordance with ICH
E2C or equivalent guidelines as adopted by the European Medicines Evaluation
Agency (EMEA) relevant to Product for use in the Orion Field in the Orion
Territory, and information regarding all serious adverse events from clinical
studies and all spontaneous adverse reactions, including reports from literature
concerning Product, coming to the knowledge of Orion. All of the above mentioned
safety information shall be exchanged reasonably in advance of any applicable
regulatory deadlines or upon release of such information. In addition, any
safety information which may negatively affect the benefit-risk ratio of
Products or that may have consequences regarding the product information (e.g.
labeling, data sheets, instruction leaflets) or may require immediate safety
measures to be taken by either Party shall be forwarded to the other Party
without any delay. Each Party is responsible for any regulatory safety reporting
requirements with respect to maintaining its own Regulatory Approval
applications and complying with regulatory requirements for Products that it has
the right to sell pursuant to this Agreement according to applicable laws, rules
and regulations.

               (B) The intent of Section 19.1(a) is to enable each Party to
comply with regulatory requirements for Toremifene products, which requirements
may change from

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-47
<PAGE>
time to time. Concurrently with the execution of this Agreement, the Parties
shall execute an agreement setting forth a mutually acceptable detailed
procedure generally consistent with the intent of Section 19.1(a) that enables
each Party to comply with such regulatory requirements with respect to such
Products. Under such agreement, from time to time after the Restatement Date,
the Parties shall meet upon request by either Party to discuss and agree upon
any modifications to such detailed procedure necessary to ensure that each Party
is in compliance with regulatory reporting requirements for Products that it has
the right to develop and sell pursuant to this Agreement.

     This Article 19 shall survive the expiration or termination of this
Agreement.

20.  REPRESENTATIONS AND WARRANTIES

     20.1 REPRESENTATIONS AND WARRANTIES OF THE PARTIES. Each Party hereby
represents and warrants to the other Party as follows:

               (A) CORPORATE STATUS. It is a corporation duly organized and
validly existing under the laws of its state or other jurisdiction of
incorporation or formation;

               (B) AUTHORITY. It has the power and authority to execute and
deliver this Agreement, and to perform its obligations hereunder;

               (C) NO CONFLICTS. The execution, delivery and performance by it
of this Agreement and its compliance with the terms and provisions hereof does
not and will not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) any loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or
instrument binding or affecting it or its property; (ii) the provisions of its
charter documents or by-laws; or (iii) any order, whit, injunction or decree of
any court or governmental authority entered against it or by which any of its
property is bound;

               (D) NO APPROVALS. Except for the regulatory filings and approvals
for the Product referenced herein, no authorization, consent or approval of any
governmental authority or Third Party is required for the execution, delivery or
performance by it of this Agreement, and the execution, delivery or performance
of this Agreement will not violate any law, rule or regulation applicable to
such party;

               (E) ENFORCEABILITY. This Agreement has been duly authorized,
executed and delivered and constitutes its legal, valid and binding obligation
enforceable against it in accordance with its terms subject, as to enforcement,
to bankruptcy, insolvency, reorganization and other laws of general
applicability relating to or affecting creditors' rights and to the availability
of particular remedies under general equity principles;

               (F) COMPLIANCE WITH LAWS. It shall comply with all applicable
local, state, national, regional and governmental laws and regulations relating
to its activities under this Agreement; and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-48
<PAGE>
               (G) NEGATIVE DATA OR INFORMATION. It has, to the best of its
management's knowledge, no knowledge of negative data or information regarding
the Product, which, to the best of its reasonable belief, would have a material
effect on the regulatory approval process and/or on the commercialization of the
Product in the Field.

               (H) NO DEBARMENT. It has not been and will not be debarred under
Section 306 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 335a(a) or
(b). In the event that such Party becomes aware of, or receives notice of, the
debarment of any individual, corporation, partnership, or association performing
activities which relate to the Products, it shall notify the other Party
immediately and address the issue as directed by the other Party.

               (I) NO IMPROPER CONTENT ON FARESTON U.S. WEB PAGES. It has not
and will not place any links or information on the Fareston U.S. Web Pages
pursuant to Article 9 that would: (A) infringe on the intellectual property
rights of any Third Party; (B) violate any law, statute, ordinance or
regulation; (C) be defamatory, trade libelous, unlawfully threatening or
unlawfully harassing; or (D) contain any viruses or other computer programming
routines that damage, detrimentally interfere with, surreptitiously intercept or
expropriate any system, data or personal information.

     20.2 REPRESENTATION BY ORION. Orion hereby represents and warrants to GTX
that:

               (A) As of the Restatement Date, Orion has entered into the
Fareston Repurchase Agreement pursuant to which Orion has terminated its
agreement with Shire dated 6 September, 1999, as amended, under which Shire had
been granted licenses or other rights to develop and/or commercialize Products
in the USA in the Breast Cancer Field.

     20.3 REPRESENTATION BY GTX. GTX hereby represents and warrants to Orion
that:

               (A) As of the Restatement Date, GTX has acquired sufficient
rights and licenses from The University of Tennessee Research Foundation to the
patent applications included in the GTX Patent Rights that are listed in Part II
of Schedule A that are necessary for the purpose of performing its obligations
under this Agreement.

21.  TERM AND EARLY TERMINATION RIGHTS

     21.1 TERM. The Term shall extend for the period provided in Section 1.51.

     21.2 TERMINATION FOR CAUSE. Either Party shall have the right, without
prejudice to any other rights or remedies available to it, either to terminate
this Agreement or the license rights granted to a Party under this Agreement on
a country-by-country basis for cause as described in this Section 21.2 as
follows:

          21.2.1 BANKRUPTCY. Either Party shall have the right to terminate this
Agreement and same shall terminate upon expiry of a sixty (60) days notice
period, if the other Party becomes insolvent, is adjudged bankrupt, applies for
judicial or extra-judicial settlement with its creditors, makes an assignment
for the benefit of its creditors, voluntarily files for bankruptcy or has a
receiver or trustee (or the like) in bankruptcy appointed by reason of its
insolvency, or in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-49
<PAGE>
the event an involuntary bankruptcy action is filed against the other Party and
not dismissed within ninety (90) days, or if the other Party becomes the subject
of liquidation or dissolution proceedings or otherwise discontinues business.

          21.2.2 MATERIAL BREACH. If either Party commits a material breach of
this Agreement and if the Party alleged to be in breach of this Agreement fails
to (i) cure such breach or (ii) commence bona fide dispute resolution
proceedings under Section 25.2 contesting whether a breach has occurred and/or
whether such breach is a material breach, in either case within sixty (60) days
after receipt of written notice from the Party asserting the breach, then the
Party asserting the breach may terminate this Agreement in its entirety (if such
breach is a material breach, other than as specified in Sections 6.4.2 and
12.11.1 or 12.11.2), or, if such breach is by GTX and is described in Section
6.4.2 or in Section 12.11.1, then Orion may terminate its supply obligations as
set forth under Article 14 and terminate the license granted to GTX pursuant to
Section 2.1, in each case with respect to the Major Country in relation to which
such material breach occurred under Section 6.4.2 or 12.11.1. If the Agreement
is terminated either in its entirety or with regard to a particular Major
Country, as the case may be, then if GTX is the breaching Party, GTX shall grant
to Orion a nonexclusive, royalty-bearing license, with the right to grant
sublicenses, under the GTX Patent Rights, the Trademarks, the Regulatory
Approvals (by means of assignment or transfer of, or authorization to
cross-reference, relevant Regulatory Approval(s)) and the GTX Know-How to make,
have made, develop, use, sell, offer for sale, market and promote, and import
Products in the country(ies) in which GTX's license terminates, or, if Orion is
the breaching Party, then the license granted to GTX shall be expanded to
include an exclusive, sublicensable license under the Orion Patent Rights, Orion
Know-How, and Manufacturing Patents to make and have made Products for use in
the Field in the GTX Territory, (except for use in the Orion Field in the Orion
Territory). In the event of termination of the Agreement due to Orion's breach,
Orion shall as soon as practically possible provide GTX with Product
Manufacturing Know-How to the extent reasonably necessary to enable GTX to
exercise its manufacturing right pursuant to this Section, including without
limitation providing up to ten (10) person-days of technology transfer
assistance at GTX's site of Manufacture or Product using Orion personnel skilled
in such manufacturing operations, at no charge to GTX.

               (A) If the non-breaching Party obtains a license under this
Agreement as provided in Section 21.2.2, it shall pay to the other Party a
running royalty equal to [ * ] of Net Sales of Product by the non-breaching
Party, its Affiliates or Unaffiliated Sublicensees. Furthermore, if GTX is the
breaching Party, GTX shall promptly transfer to Orion, at GTX's expense, all
Regulatory Approvals and registration filings for the Product in the territory
in which Orion obtains such license, together with such documentation,
information and data in its possession as Orion may need for regulatory
compliance in the course of exercising its rights in such territory with respect
to Product.

     21.3 TERMINATION BY MUTUAL AGREEMENT. The Parties may terminate this
Agreement at any time by drafting and executing a mutually acceptable written
agreement. The written agreement shall specify the consequences of such
termination.

     21.4 TERMINATION BY GTX FOR SAFETY OR EFFICACY REASONS. If at any time
during the Term: (i) GTX decides not to file an application for Regulatory
Approval in any country or decides to withdraw such application due to
documented adverse reactions or other safety issues

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-50
<PAGE>
with the Product or the Product's lack of efficacy or limited efficacy
(collectively, "Safety or Efficacy Issues"); (ii) GTX's application(s) for
Regulatory Approval in any country is rejected due to Safety or Efficacy Issues;
(iii) GTX's application(s) for Regulatory Approval in any country is
subsequently withdrawn because of Safety or Efficacy Issues; or (iv) the Product
is withdrawn or recalled from the market in any country because of Safety or
Efficacy Issues, then GTX may, at its option, terminate this Agreement with
respect to such country upon thirty (30) days prior written notice to Orion. GTX
must exercise this right of termination within the later of (a) sixty (60) days
of the occurrence of the event giving rise to such right or (b) thirty (30) days
of GTX's last meeting, if any, with the relevant regulatory authorities,
provided that GTX uses reasonable diligence to schedule such meeting and that
Orion is providing reasonable co-operation to GTX in connection with such
meeting. GTX may, at its option, exercise its right of termination under this
Section 21.4 on a country-by-country basis, and, if GTX does so, GTX's
termination notice shall specify the country or countries of the GTX Territory
affected. GTX shall transfer to Orion, at Orion's expense, all Regulatory
Approvals and registration filings for the Product in the country for which it
terminates its license, together with such documentation, information and data
in its possession as Orion may need for regulatory compliance in the course of
any further development of Product in such country Orion may elect to conduct
thereafter.

     21.5 EFFECT OF TERMINATION. Termination or expiration of this Agreement
through any means and for any reason shall not relieve the Parties of any
obligations accruing prior thereto and shall be without prejudice to the rights
and remedies of either Party with respect to any prior breach of any of the
provisions of this Agreement.

22.  NOTICES

     22.1 MANNER OF GIVING NOTICES. All notices required or permitted in
connection with this Agreement shall be writing and may be given by personal
delivery, prepaid registered or certified airmail letter, courier, facsimile,
addressed to the Party to receive the same at its address set forth below, or to
such other address as it shall later designate by like notice to the other
Party. Notice of termination of this Agreement if given by facsimile shall be
confirmed by prepaid registered or certified airmail letter dated and posted
within twenty-four (24) hours. The effective date of receipt of any notice if
served by facsimile shall be deemed the first business day in the city of
destination following the transmission or dispatch thereof and, if served by
courier shall deemed the second business day in the city of destination
following the dispatch thereof unless earlier received. Notice by personal
delivery shall be effective as of the date of such delivery.

     22.2 ADDRESSES FOR NOTICES.

     Notices to Orion shall be sent to:

     Orion Corporation
     Orion Pharma
     Attn: President of Orion Pharma
     Orionintie 1, P.O. Box 65
     FIN-02101 Espoo

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-51
<PAGE>
     Finland
     Facsimile: 358-9-429-3044

     With a copy to:

     Orion Corporation
     Orion Pharma
     Attn: Legal Counsel
     Orionintie 1, P.O. Box 65
     FIN-02101 Espoo
     Finland
     Facsimile: 358-9-429-4088

     Notices to GTX shall be sent to:

     GTx, Inc.
     Attn: President, with a copy to the General Counsel
     3 North Dunlap Avenue
     Van Vleet Building, Third Floor
     Memphis, Tennessee 38163
     U.S.A.
     Telephone: 1-901-523-9700 x107
     Facsimile: 1-901-523-9772

     With a copy to:
     Cooley Godward LLP
     Five Palo Alto Square
     3000 El Camino Real
     Palo Alto, CA 94306-2155

     Attention: Robert Jones, Esq.
     Telephone: (650) 843-5034
     Facsimile: (650) 849-7400

23.  INTEGRATION

     This Agreement represents the entire Agreement between the Parties relating
to the subject matter hereof and supersedes all prior arrangements,
understandings, correspondence, notes, minutes and agreements between the
Parties (or their predecessors in interest) whether written or oral. No
supplement, modification or amendment of this Agreement shall be binding unless
executed by the Parties in writing and signed by the duly authorized
representatives of both Parties.

24.  ASSIGNMENT

     Neither Party may assign this Agreement or any of its rights hereunder, nor
delegate any of its duties or obligations hereunder, to any Third Party without
the prior written consent of the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-52
<PAGE>
other Party, except (i) to an Affiliate in accordance with the terms of this
Agreement, in which case notification thereof shall be provided to the other
Party prior to such assignment to an Affiliate, or (ii) in connection with a
merger, consolidation or similar reorganization. For clarity, this Agreement
shall survive any such merger, consolidation or reorganization of either Party
with or into, another party and no consent for such merger, consolidation or
reorganization shall be needed. Neither Party shall unreasonably withhold its
consent (which shall be provided promptly after a request is made) to any
contemplated assignment if such contemplated assignment is in connection with
the sale by either Party of all or substantially all of its assets to a Third
Party. Any assignment of this Agreement to an Affiliate of the assigning Party
shall not relieve the assigning Party of its responsibilities and obligations
hereunder.

25.  GOVERNING LAW AND DISPUTE RESOLUTION

     25.1 GOVERNING LAW. This Agreement, including the validity, construction,
interpretation and performance thereof, shall be governed entirely by the laws
of Sweden. It is the specific intent and agreement of the Parties that the
United Nations Convention on the International Sale of Goods shall not apply to
this Agreement.

     25.2 DISPUTE RESOLUTION. All disputes arising out of or in connection with
this Agreement (except those involving actions commenced by or involving Third
Parties and affecting or involving only one of the Parties) shall be resolved
with the following mechanism:

          25.2.1 ATTEMPTED AMICABLE RESOLUTION. The Parties shall promptly give
each other written notice of any disputes requiring resolution hereunder, which
written notice shall specify the Section(s) of this Agreement the other Party is
alleged to have breached and shall briefly state the initiating Party's claims,
and the Parties shall use reasonable efforts to resolve any such disputes in an
amicable manner.

     Any disputes arising in connection with this Agreement which cannot be
resolved in an amicable manner by representatives of the Parties shall be
referred, not later than thirty (30) days after initiation of dispute resolution
proceedings under this Section 25.2.1, to the following corporate officers of
the Parties for resolution:

     For GTX: Chief Executive Officer (or his or her designee)

     For Orion: President of Orion-Pharma (or his or her designee)

     Such officers (or their designees) shall attempt to resolve the dispute and
shall communicate with each other by facsimile or telephone or in personal
meetings in an effort to resolve the dispute.

          25.2.2 ARBITRATION. Any disputes (excluding any dispute, controversy
or claim arising out of or relating to the validity, enforceability, scope or
infringement of patent or trademark rights) arising in connection with this
Agreement which cannot be resolved by the Parties within forty-five (45) days
after initiation of dispute resolution proceedings under Section 25.2.1 shall be
finally settled by binding arbitration under the Rules of the Arbitration
Institute of the Stockholm Chamber of Commerce, Stockholm, Sweden in accordance
with said

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-53
<PAGE>
Rules then in effect with proceedings to be held in Stockholm, Sweden in the
English language. Reasonable submission of evidence shall be permitted in any
such proceeding to the extent permitted under and consistent with such Rules.
Judgment upon any award rendered by the arbitrator(s) in such proceedings may be
issued and enforced by any court having competent jurisdiction. Any disputes
arising out of or relating to the validity, enforceability, scope or
infringement of patent or trademark rights shall be submitted for resolution by
a court of competent jurisdiction.

     25.3 EFFECT OF COMMENCING DISPUTE RESOLUTION. If either Party in good faith
commences dispute resolution proceedings under Section 25.2, (A) any applicable
notice periods or cure periods hereunder (including but not limited to the
periods referenced in Sections 21.2 and 21.4) shall be temporarily suspended
pending the outcome of such dispute resolution proceedings and (B) the
non-breaching Party may, at its option, pay any amounts payable to the other
Party that are in dispute into an interest-bearing escrow account pending the
outcome of such dispute resolution proceedings.

26.  LIMITATION OF DAMAGES

     Except for indirect damages resulting from breach of Article 8, in no event
shall either Party be liable to the other Party for any indirect, consequential
or punitive damages in connection with the performance of this Agreement or any
breach of this Agreement (excluding such damages payable to a Third Party which
are subject to the indemnification obligations of the Parties set forth in this
Agreement.

27.  FORCE MAJEURE

     Neither Party shall be held in breach of this Agreement for failure to
perform any of its obligations hereunder to the extent and for the time period
such performance is prevented in whole or in part by reason of any Force Majeure
event, including but not limited to industrial disputes, strikes, lockouts,
riots, mobs, fires, floods, and other natural disasters and Acts of God, wars
declared or undeclared, civil strife, embargo, delays in delivery or defects or
shortages of raw materials from suppliers, loss or breakdown of any production
equipment, losses or shortage of power, damage to or loss of goods in transit,
currency restrictions, or events caused by reason of laws, regulations or orders
by any government, governmental agency or instrumentality or by any other
supervening unforeseeable circumstances whatsoever beyond the control of the
Party so affected. The Party so affected shall (A) give prompt written notice to
the other Party of the nature and date of commencement of the Force Majeure
event and its expected duration and (B) use its reasonable efforts to avoid or
remove the Force Majeure event as soon as possible to the extent it is so able
to do.

28.  RELATIONSHIP OF PARTIES

     The relationship of the Parties under this Agreement is that of independent
contractors. Nothing contained in this Agreement shall be construed so as to
constitute the Parties as partners, joint venturers or agents of the other.
Neither Party has any express or implied right or authority under this Agreement
to assume or create any obligations or make any warranties and representations
on behalf of or in the name of the other Party, or to bind the other Party to
any

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-54
<PAGE>
contract, agreement or undertaking with any Third Party, and no conduct of the
Parties pursuant to the terms of this Agreement shall be deemed to establish
such right or authority. Neither Party shall make any representation to Third
Parties that the relationship created hereby constitutes a partnership, joint
venture or agency relationship.

29.  SEVERABILITY

     In case one or more of the provisions contained in this Agreement shall,
for any reason, be held invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provisions
of this Agreement, but this Agreement shall be construed by limiting such
invalid, illegal or unenforceable provision, if such is not possible, by
deleting such provision from this Agreement.

30.  NON-WAIVER

     The failure by either Party at any time to enforce any of the terms or
provisions or conditions of this Agreement or exercise any right hereunder shall
not constitute a waiver of the same or affect that Party's rights thereafter to
enforce or exercise the same. No waiver of any of the provisions of this
Agreement shall be deemed binding unless executed in writing by the Party to be
bound by it.

31.  HEADINGS

     The headings in this Agreement are for convenience of reference only and
shall not be used in the interpretation of any provisions hereof.

32.  GOVERNING LANGUAGE

     The English language version of this Agreement shall be controlling in all
respects regardless of whether any translations into any other languages are
made.

33.  EXECUTION

     This Agreement shall be executed by the Parties in two (2) original
counterparts, one (1) original counterpart being retained by each Party and
either of which shall be deemed sufficient to prove the existence and terms and
conditions hereof. This Agreement may be executed by the Parties by the exchange
of facsimile signature pages, with signed original counterparts of the Agreement
to be exchanged by the Parties promptly thereafter.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-55
<PAGE>
     IN WITNESS WHEREOF, the Parties' duly authorized representatives hereto
have executed this Agreement as of the Restatement Date.

ORION CORPORATION                       GTX, INC.


By:                                     By:
       ------------------------------          ---------------------------------
                                               Mitchell Steiner, M.D.

Title:                                  Title: Vice-Chairman and CEO
       ------------------------------          GTx, Inc.
       Orion Corporation Orion Pharma


By:                                     By:
       ------------------------------          ---------------------------------
       Timo Lappalainen                        Marc Hanover

Title:                                  Title: President and COO
       ------------------------------          GTx, Inc.
       Orion Corporation Orion Pharma

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-56
<PAGE>
SCHEDULE A:PART I

<TABLE>
<CAPTION>
COUNTRY/JURISDICTION          TITLE                   INVENTORS            PATENT NO.     ISSUE DATE    STATUS
--------------------   ------------------   ----------------------------   ----------   -------------   ------
<S>                    <C>                  <C>                            <C>          <C>             <C>
UNITED STATES          METHOD FOR           1. MITCHELLS S. STENIER        6,265,448    July 24, 2001   Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHAW

UNITED STATES          METHOD FOR           1. MITCHELLS S. STENIER        6,413,534    July 2, 2002    Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHAW

UNITED STATES          METHOD FOR           1. MITCHELLS S. STENIER        6,410,043    June 2, 2002    Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHAW

UNITED STATES          METHOD FOR           1. MITCHELLS S. STENIER        6,413,535    June 2, 2002    Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHAW

UNITED STATES          METHOD FOR           1. MITCHELL S. STEINER         6,413,533    July 2, 2002    Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHOW
                                            (THE UNIVERSITY OF TENNESSEE
                                            RESEARCH CORPORATION)

UNITED STATES          METHOD FOR           1. MITCHELL S. STEINER         6,632,447    Oct 14, 2003    Issued
                       CHEMOPREVENTION OF
                       PROSTATE CANCER      2. SHARAN RAGHOW
                                            (THE UNIVERSITY OF TENNESSEE
                                            RESEARCH CORPORATION)
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-57
<PAGE>
SCHEDULE A: PART II

APPLICATIONS FILED IN THE UNITED STATES

[ * ]

APPLICATIONS FILED IN FOREIGN JURISDICTIONS

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-58
<PAGE>
                        SCHEDULE B: PART I. ORION PATENTS

TITLE: NOVEL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE
     (TOREMIFENE)

<TABLE>
<CAPTION>
Country               Patent No           Expiry
-----------------   ------------   --------------------
<S>                 <C>            <C>
AU   Australia      556608         May 25, 2008 *
BG   Bulgaria       98379          May 20, 2003
CA   Canada         1185977        May, 20, 2003
CN   China          A-FI96091019   December 20, 2003
DK   Denmark        170927         December 21, 2003 *
EP   Europe         95875          December 21, 2003 *
CH   Switzerland    95875          May 19, 2008 *
IT   Italy          95875          February 14, 2008 *
SE   Sweden         95875          May 20, 2008 *
FI   Finland        77839          December 21, 2003 *
HK   Hong Kong      83/89          May 20, 2003
HU   Hungary        193536         May 26, 2003
HU   Hungary        200742         May 26, 2003
IE   Ireland        55023          December 21, 2003 *
IL   Israel         68784          May 25, 2003
JP   Japan          2105540        May 25, 2003
JP   Japan          1739006        June 29, 2005 *
JP   Japan          1959197        May 25, 2003
JP   Japan          1867986        May 25, 2003
LV   Latvia         5066           May 26, 2003
NO   Norway         156164         December 21, 2003 *
NZ   New Zealand    204349         May 25, 2003
RO   Romania        C-20106 **     December 29, 2004
SG   Singapore      654/88         May 20, 2003
SU   Russia         1508955        May 26, 2003
US   USA            4696949        September 29, 2009 *
US   USA            5491173        September 29, 2004
US   USA            4996225        February 17, 2008
ZA   South Africa   833803         May 25, 2003
</TABLE>

EP = Germany, Belgium, Austria, Italy, Sweden, Netherlands, Switzerland,
Lichtenstein, Luxemburg, Great Britain, France

*    Patent term extension

**   Pipe-line protection based on US 4696949

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-59
<PAGE>
SCHEDULE B: PART II. ORION PATENT APPLICATIONS

TITLE: NOVEL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE
     (TOREMIFENE)

<TABLE>
<CAPTION>
Country   Patent Appln. No
-------   ----------------
<S>       <C>
[ * ]
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-60
<PAGE>
                           SCHEDULE C: SPECIFICATIONS

SPECIFICATIONS FOR [ * ] TABLETS

<TABLE>
<CAPTION>
                                           SPECIFICATION
                     -----------------------------------------------------------
TEST                       [ * ]               [ * ]                [ * ]
------------------   -----------------   -----------------   -------------------
<S>                  <C>                 <C>                 <C>
CHARACTERS
Colour                     [ * ]               [ * ]                [ * ]
Shape                      [ * ]               [ * ]                [ * ]
Score                      [ * ]               [ * ]                [ * ]
Code                       [ * ]               [ * ]                [ * ]
Coating                    [ * ]               [ * ]                [ * ]

[ * ]
[ * ]                      [ * ]               [ * ]                [ * ]

[ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-61
<PAGE>
                        SCHEDULE D: GTX'S MSR OBLIGATION

                   (TO BE COMPLETED PURSUANT TO SECTION 6.1.1)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-62
<PAGE>
                       SCHEDULE E: ORION PRODUCT APPROVALS

REGISTRATION STATUS 27.9.2001
ORION PHARMA

Status: Approved, Pending
Submission types: Marketing authorizations
(2 PAGES)

<TABLE>
<CAPTION>
                                                                  Decision
Sent Date   Appl. Date   Product                 Country          Date            Decision   M.A. holder
---------   ----------   ---------------------   --------------   -------------   --------   ----------------------
<S>         <C>          <C>                     <C>              <C>             <C>        <C>
N=39

[ * ]       [ * ]        [ * ]                   [ * ]                            [ * ]      [ * ]
[ * ]                    [ * ]                   [ * ]                            [ * ]      [ * ]
[ * ]                    [ * ]                   [ * ]                            [ * ]      [ * ]
[ * ]                    [ * ]                   [ * ]                            [ * ]      [ * ]
[ * ]                    [ * ]                   [ * ]                            [ * ]      [ * ]
[ * ]                    [ * ]                   [ * ]                            [ * ]      [ * ]
30.12.87    30.12.87     Fareston 20 mg tablet   Finland          21.12.88        Approved   Orion-yhtyma Oy Farmos
27.12.88                 Fareston 60 mg tablet   Russia           12.12.89        Approved   Orion Corporation
27.12.88                 Fareston 20 mg tablet   Russia           12.12.89        Approved   Orion Corporation
26.02.93                 Fareston 60 mg tablet   Latvia           20.05.93        Approved   Orion-yhtyma Oy Farmos
26.02.93                 Fareston 20 mg tablet   Latvia           20.05.93        Approved   Orion-yhtyma Oy Farmos
26.05.92                 Fareston 60 mg tablet   Norway           31.07.95        Approved   Orion Corporation
10.11.93                 Fareston 60 mg tablet   Ukraine          02.02.96        Approved   Orion Corporation
10.11.93                 Fareston 20 mg tablet   Ukraine          02.02.96        Approved   Orion Corporation
14.11.94    30.11.94     Fareston 60 mg tablet   Sweden           14.02.96        Approved   Orion Corporation
14.11.94    30.11.94     Fareston 60 mg tablet   Finland          14.02.96        Approved   Orion Corporation
27.11.94    30.11.94     Fareston 60 mg tablet   United Kingdom   14.02.96        Approved   Orion Corporation
27.11.94    30.11.94     Fareston 60 mg tablet   Spain            14.02.96        Approved   Orion Corporation
27.11.94    30.11.94     Fareston 60 mg tablet   Portugal         14.02.96        Approved   Orion Corporation
27.11.94    29.11.94     Fareston 60 mg tablet   Netherlands      14.02.96        Approved   Orion Corporation
27.11.94    29.11.94     Fareston 60 mg tablet   Luxembourg       14.02.96        Approved   Orion Corporation
27.11.94    28.11.94     Fareston 60 mg tablet   Italy            14.02.96        Approved   Orion Corporation
27.11.94    29.11.94     Fareston 60 mg tablet   Ireland          14.02.96        Approved   Orion Corporation
27.11.94    01.12.94     Fareston 60 mg tablet   Greece           14.02.96        Approved   Orion Corporation
27.11.94    28.11.94     Fareston 60 mg tablet   Germany          14.02.96        Approved   Orion Corporation
27.11.94    30.11.94     Fareston 60 mg tablet   France           14.02.96        Approved   Orion Corporation
27.11.94    30.11.94     Fareston 60 mg tablet   Belgium          14.02.96        Approved   Orion Corporation
17.11.92                 Fareston 60 mg tablet   Austria          14.02.96        Approved   Orion Corporation
27.11.94                 Fareston 60 mg tablet   Denmark          14.02.96        Approved   Orion Corporation
31.03.96                 Fareston 60 mg tablet   Uzbekistan       16.09.96        Approved   Orion Corporation
31.03.96                 Fareston 20 mg tablet   Uzbekistan       16.09.96        Approved   Orion Corporation
19.12.94    03.01.95     Fareston 60 mg tablet   United  States   29.05.97        Approved   Orion Corporation
                                                 of America
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-63
<PAGE>
<TABLE>
<CAPTION>
                                                                  Decision
Sent Date   Appl. Date   Product                 Country          Date            Decision   M.A. holder
---------   ----------   ---------------------   --------------   -------------   --------   ----------------------
<S>         <C>          <C>                     <C>              <C>             <C>        <C>
10.04.95    15.07.96     Fareston 60 mg tablet   Hungary          14.01.98        Approved   Orion Corporation
01.08.97    01.08..97    Fareston 60 mg tablet   Cyprus           23.04.98        Approved   Orion Corporation
10.07.96                 Fareston 60 mg tablet   Taiwan, R.O.C.   29.09.98        Approved   Orion Corporation
31.03.95                 Fareston 60 mg tablet   Dominican        29.12.98        Approved   Orion Corporation
                                                 Republic
10.11.95    26.04.96     Fareston 60 mg tablet   China            13.02.99        Approved   Orion Corporation
30.07.01                 Fareston 60 mg tablet   Georgia          30.07.01        Approved   Orion Corporation
30.07.01                 Fareston 20 mg tablet   Georgia          30.07.01        Approved   Orion Corporation
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      B-64
<PAGE>
                                    EXHIBIT C

                           PHARMACOVIGILANCE AGREEMENT

--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

1. PURPOSE

The purpose of this Agreement is to describe the procedures and define the
responsibilities which the Parties, Orion and GTX, shall adopt to ensure
compliance with the regulatory requirements for pharmacovigilance and to satisfy
the business interests of Orion and GTX with regard to safety issues of the
Product.

This Agreement is made pursuant to the Amended and Restated License and Supply
Agreement dated January 1, 2005 between Orion and GTX, and the Purchase
Agreement between Orion and GTX dated December 13, 2005 (together, the "Other
Agreements"). All capitalized terms not defined herein shall have the meaning
given in the Other Agreements. This Agreement is entered into pursuant to
Section 19.1 of the Amended and Restated License and Supply Agreement, and is
not intended to supercede or alter the Parties obligations under either of the
Other Agreements. In the event of any conflict between this Agreement and the
Other Agreements, the Other Agreements shall govern. Additionally, any
information exchanged between the Parties shall be deemed Confidential
Information of the disclosing Party under the Amended and Restated License and
Supply Agreement. Any disputes arising hereunder shall be resolved as provided
in Section 25 of the Amended and Restated License and Supply Agreement.

2. LANGUAGE OF ALL EXCHANGE, CONTACT PERSONS AND TERMINOLOGY

The language of all exchange shall be English.

The contact person(s) for each of the Parties are identified in Appendix 1. Each
Party may change its contact persons and shall notify the other Party thereof in
writing.

Throughout this document terms and definitions of terms as adopted by the
International Conference on Harmonisation of the Technical Requirements of
Pharmaceuticals for Human Use ("ICH") are used.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       C-1
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

3. GLOBAL SAFETY DATABASE

3.1 ORION FIELD [ * ]

Orion shall be responsible for the maintenance and consistency of a complete
safety database for spontaneous (including literature) adverse event ("AE")
reports as well as clinical study serious adverse event ("SAE") reports
concerning the Product in the Orion FIELD. GTX shall keep a secondary safety
database for all reports from such events occurring in the USA, and any other
reports it receives with respect to Product in the [ * ], as considered
necessary by GTX to maintain its NDA in the USA in the Orion Field. Duplicate
reports within the Orion and GTX databases shall be identified and deleted from
the databases by the Parties.

GTX shall be responsible for forwarding all reports received with respect to the
USA to Orion within the timeframes defined in Section 4 in order to enable the
entry of such reports into the Orion database.

Orion will within [ * ] of the date of this Agreement transfer or assure the
transfer to GTX of the current database containing the spontaneously reported
AEs that have been received to date since the marketing of the Product in the
USA.

Orion, at the reasonable request of GTX, shall perform queries of the complete
safety database for spontaneous reports for use in regulatory filings in the USA
in a timely manner to allow GTX to fulfill regulatory requirements related to
maintenance of the NDA in the USA and related documents.

3.2 FIELD (EXCLUDING THE ORION FIELD)

GTX shall be responsible for the maintenance and consistency of a complete
safety database for spontaneous (including literature) AE reports as well as
clinical study SAE reports concerning the Product in the Field (outside of the
Orion Field). Orion shall keep a secondary safety database if considered
necessary by Orion for reports concerning the Product in the Field (outside of
the Orion Field).

4. EXCHANGE OF INDIVIDUAL AE REPORTS

4.1 GENERAL

Exchange of individual AE and SAE reports shall be between the central
pharmacovigilance units of Orion and GTX, Orion Pharma Drug Safety ("DS") and
GTX Drug Safety Department, which shall collect and distribute the data in their
own safety networks according to their own Standard Operating Procedures
("SOPs").

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-2
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

4.2 SPONTANEOUS REPORTS

-    FROM GTX TO ORION

GTX shall provide information of spontaneous reports originating from the GTX
Territory in writing, using the FDA form 3500A within the timeframes defined
below.

-    Serious spontaneous reports are to be sent to Orion no later than [ * ]
     after receipt by GTX.

-    Non-serious spontaneous reports are to be sent to Orion no later than [ * ]
     after receipt by GTX.

-    FROM ORION TO GTX

Orion DS shall provide information of spontaneous reports with respect to the
Orion Territory in writing, using the CIOMS I form within the timeframes defined
below.

-    Serious spontaneous reports are to be sent to GTX no later than [ * ] after
     receipt by Orion.

-    Non-serious spontaneous reports: to be discussed, usually in Periodic
     Safety Update reports only.

4.3 REPORTS FROM CLINICAL STUDIES

From clinical studies sponsored by Orion or GTX, the investigator shall report
all SAEs to the respective company according to each company's SOPs.

-    FROM GTX TO ORION

GTX shall provide to Orion all clinical study SAEs originating from the GTX
Territory in writing, using FDA form 3500A within the timeframes defined below.

-    Death and life-threatening SAEs within [ * ] after receipt by GTX.

-    All other SAEs within [ * ] after receipt by GTX

-    Non-serious AEs are not in the scope of this Agreement.

-    FROM ORION TO GTX

Orion shall provide to GTX all clinical study SAEs originating from any
territory outside of the Orion Territory coming to the knowledge of Orion in
writing, using the CIOMS I form within the timeframes defined below:

-    Death and life-threatening SAEs within [ * ] after receipt by Orion.

-    All other SAEs within [ * ] after receipt by Orion.

-    Non-serious AEs are not in the scope of this Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-3
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

4.4 FOLLOW-UP INFORMATION

The Party first notified of an AE is responsible for obtaining follow-up
information required for a proper assessment of the AE. This information shall
be exchanged as described in Section 4.

5. ASSESSMENT OF INDIVIDUAL REPORTS

Each Party shall be responsible for its own medical assessment of the reported
AEs when entering the report into its database according to their internal SOPs.
The global safety database concerning the Orion Field shall reflect Orion's
assessment, while the global safety database concerning the Field (but excluding
the Orion Field) shall reflect GTX's assessment. In the event that there is a
difference in seriousness or causality assessments of a case received from
either Party and entered into a database, discussion between the Parties shall
take place and agreement reached to allow timely reporting. Any resultant action
must be communicated between the Parties.

5.1 SPONTANEOUS REPORTS

In general, the principle of the implied positive causality shall be applied to
all spontaneously reported AEs received by Orion. Orion shall assess
expectedness, labeling and listedness issues for each report according to Orion
internal SOPs.

GTX will make a reasonable assessment of causality for each spontaneously
reported AE received. In accordance with 21 CFR 310.305, GTX will submit all
spontaneously reported AEs to FDA that are serious and unexpected (unlabeled)
regardless of causality according to FDA regulations. In general, GTX will
provide the GTX assessment of causality in the submission as further information
for FDA.

5.2 REPORTS FROM CLINICAL STUDIES

The assessment of causality of the Product with respect to the SAE occurring in
a clinical study shall be made by the responsible investigator and the sponsor
of the clinical study according to the procedure in the study protocol and the
sponsor's applicable guideline/SOP, respectively. For clinical study reports the
causality scales of the Parties are attached in Appendix 2.

Assessment of labelling (expectedness) shall be made by the Parties according to
their applicable guideline/SOP using a common Investigator's Brochure and/or
Core Data Sheet and approved national labelling.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-4
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

6. LITERATURE REVIEW

Orion shall be responsible for reviewing, processing and exchanging individual
reports from the world-wide literature concerning the Product in Orion Field.
GTX shall assist by notifying Orion of reports observed in the GTX Territory.

GTX shall be responsible for reviewing, processing and exchanging individual
reports from the world-wide literature concerning the Product in Field excluding
Orion Field. Orion stall assist by notifying GTX of reports observed in the
Orion Territory.

Individual reports identified in literature shall be exchanged as individual AE
reports (Section 4).

7. PERIODIC SAFETY REPORTS

7.1 ORION FIELD [ * ]

Orion shall be responsible for preparing global PSURs according to the ICH E2C
Guideline as adopted by the European Union Committee for Proprietary Medicinal
Products Pharmacovigilance Working Party relevant to Product for use in the
Orion Field in the Orion Territory. The periodicity of PSURs is based on the
European Birth Date of the Product. Orion may change the periodicity, if
considered necessary.

GTX is responsible for providing Orion with the necessary information for the
PSUR as defined in the above CPMP Guidelines and as needed by Orion for the
preparation of PSURs. GTX shall provide this information as soon as possible and
at least within [ * ] of the data lock point (the last day of that PSUR period,
or "DLP"). This information shall include at least the following:

-    Update of regulatory authority or Marketing Authorisation Holder actions
     taken for safety reasons;

-    Patient exposure in clinical studies conducted by GTX during the PSUR
     period;

-    Short discussion of all GTX ongoing and completed studies (non-clinical,
     clinical and epidemiological), studies specifically planned or in progress
     and published studies;

-    addressing safety issues or yielding safety information with potential
     impact on Product information.

Final PSUR shall be provided by Orion to GTX upon issuance.

GTX shall be responsible for preparation of any periodic reports relevant to
Product for use in the Orion Field to maintain its NDA in the USA. The NDA
annual report for NDA [ * ] is due on [ * ] of each year and the database lock
for the annual report will be [ * ] of each year. GTX will send a request for
information on or shortly after [ * ] that will include at least the following
information:

-    A summary of the spontaneous reports of serious adverse events during the
     reporting period;

-    Update of regulatory authority or Marketing Authorisation Holder actions
     taken for safety reasons during the reporting period;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-5
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

-    Patient exposure in clinical studies conducted by Orion during the
     reporting period;

-    A summary of the on-going, completed and published studies (nonclinical,
     clinical and epidemiological) during the reporting period;

-    A summary of the planned studies (nonclinical, clinical and
     epidemiological) specifically planned to be conducted with estimated
     timelines, including start dates and expected completion dates (if known).

7.2 FIELD (EXCLUDING ORION FIELD)

GTX shall be responsible for all regulatory safety updates concerning the
Product for use outside the Orion Field. Final annual reports shall be provided
by GTX to Orion upon issuance.

8. STANDARD REFERENCE DOCUMENTS

8.1 PRODUCT LABELING

-    Orion Field [ * ]

Orion shall be responsible for maintaining the Company Core Safety Information
(CCSI) for the Product in Orion Field [ * ]. Orion will provide to GTX of any
planned changes related to product safety to the CCSI prior to implementation
with sufficient time for GTX to review and comment on the proposed changes.

GTX shall be responsible for maintaining the labeling in the USA for the Product
in Orion Field. GTX will provide to Orion any planned changes related to Product
safety to the labeling in the USA prior to implementation with sufficient time
for Orion to review and comment on the proposed changes.

-    Field (excluding Orion Field)

GTX shall be responsible for maintaining the labeling in the USA and CCSI for
the Product in Field, excluding Orion Field.

9. SUBMISSION TO REGULATORY AUTHORITIES

9.1 FDA

GTX shall be responsible for maintaining the NDA and for submitting all
applicable reports to FDA.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-6
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

9.2 RA REQUESTS FOR ADDITIONAL SAFETY INFORMATION

Responses to all pharmacovigilance-related requests from the RAs shall be the
responsibility of the Party to which the questions are addressed.

Coordination of the response to an additional safety information request is the
responsibility of the Party receiving the request. Depending on the nature of
the request there may be a need to discuss and mutually agree between the
Parties, if global safety database need to be queried.

10. SIGNAL IDENTIFICATION

Each Party shall notify the other in writing of any potential safety signals
identified and discuss and agree any proposed actions, including safety changes
in the relevant labeling reference documents.

Both Parties shall identify the representatives needed to evaluate and agree on
the necessary actions.

11. AMENDMENTS TO THIS AGREEMENT

Any amendments to this Agreement, except those made to Appendix 1 and 2, require
signatures of both Orion and GTX.

12. MEETINGS

The Parties shall meet to discuss pharmacovigilance issues and/or changes to
this Agreement at the reasonable request of either of the Parties.

13. MISCELLANEOUS

Neither Party may assign this Agreement or any of its rights hereunder, nor
delegate any of its duties or obligations hereunder, to any third party without
the prior written consent of the other Party, except (i) to an affiliate in
accordance with the terms of this Agreement, in which case notification thereof
shall be provided to the other Party prior to such assignment to an affiliate,
or (ii) in connection with a merger, consolidation or similar reorganization.
Neither Party may assign its rights hereunder where permitted except in
connection with a permitted assignment of such Party's rights under the Amended
and Restated License and Supply Agreement. For clarity, this Agreement shall
survive any such merger, consolidation or reorganization of either Party with or
into, another Party and no consent for such merger, consolidation or
reorganization shall be needed. Neither Party shall unreasonably withhold its
consent (which

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-7
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

shall be provided promptly after a request is made) to any contemplated
assignment if such contemplated assignment is in connection with the sale by
either Party of all or substantially all of its assets to a third party. Any
assignment of this Agreement to an affiliate of the assigning Party shall not
relieve the assigning Party of its responsibilities and obligations hereunder.

This Agreement, including the validity, construction, interpretation and
performance thereof, shall be governed entirely by the laws of Sweden.

The relationship of the Parties under this Agreement is that of independent
contractors. Nothing contained in this Agreement shall be construed so as to
constitute the Parties as partners, joint venturers or agents of the other.
Neither Party has any express or implied right or authority under this Agreement
to assume or create any obligations or make any warranties and representations
on behalf of or in the name of the other Party, or to bind the other Party to
any contract, agreement or undertaking with any third party, and no conduct of
the Parties pursuant to the terms of this Agreement shall be deemed to establish
such right or authority. Neither Party shall make any representation to third
parties that the relationship created hereby constitutes a partnership, joint
venture or agency relationship.

In case one or more of the provisions contained in this Agreement shall, for any
reason, be held invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provisions
of this Agreement, but this Agreement shall be construed by limiting such
invalid, illegal or unenforceable provision, if such is not possible, by
deleting such provision from this Agreement.

This Agreement, together with the Amended and Restated License and Supply
Agreement dated January 1, 2005, represents the entire agreement between the
Parties relating to the subject matter hereof and except as provided below
supersedes all prior arrangements, understandings, correspondence, notes,
minutes and as between the Parties (or their predecessors in interest) whether
written or oral. Notwithstanding the foregoing, nothing herein is intended to
supersede or affect the Parties' rights under the Purchase Agreement dated
December 13, 2004, and the Amended and Restated License and Supply Agreement
dated January 1, 2005.

The failure by either Party at any time to enforce any of the terms or
provisions or conditions of this Agreement or exercise any right hereunder shall
not constitute a waiver of the same or affect that Party's rights thereafter to
enforce or exercise the same. No waiver of any of the provisions of this
Agreement shall be deemed binding unless executed in writing by the Party to be
bound by it.

This Agreement shall be executed by the Parties in two (2) original
counterparts, one (1) original counterpart being retained by each Party and
either of which shall be deemed

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-8
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

sufficient to prove the existence and terms and conditions hereof. This
Agreement may be executed by the Parties by the exchange of facsimile signature
pages, with signed original counterparts of the Agreement to be exchanged by the
Parties promptly thereafter.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-9
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

THIS AGREEMENT HAS BEEN AGREED UPON AND ADOPTED BY ORION AND GTX AND WILL BECOME
EFFECTIVE JANUARY 1, 2005.

ORION CORPORATION                       GTX Inc.

Date:                                   Date:
      -------------------------------         ----------------------------------

-------------------------------------   ----------------------------------------

[ * ]

Date:                                   Date:
      -------------------------------         ----------------------------------

-------------------------------------   ----------------------------------------

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-10
<PAGE>
--------------------------------------------------------------------------------
SCHEDULE                 SUPERSEDES          VALID FROM
PHARMACOVIGILANCE DATA   - N/A               Signature date
EXCHANGE AGREEMENT
--------------------------------------------------------------------------------
PARTIES:

-    ORION CORPORATION (HEREINAFTER ORION)

-    GTX, INC. (HEREINAFTER GTX)
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
Draft Dec 10, 2004
--------------------------------------------------------------------------------

APPENDIX 1: LIST OF CONTACT PERSONS
ORION:

INDIVIDUAL REPORTS/TRANSMISSION RELATED ISSUES:
[ * ]

GENERAL MEDICAL ISSUES:
[ * ]

OVERALL RESPONSIBILITY FOR INTERNATIONAL PHARMACOVIGILANCE:
[ * ]

GTX:
[ * ]
[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-11
<PAGE>
APPENDIX 2: COMPANY CAUSALITY FOR CLINICAL STUDY REPORTS (IF NEEDED)

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      C-12
<PAGE>
                                    EXHIBIT D

                           QUALITY ASSURANCE AGREEMENT

     QUALITY ASSURANCE AGREEMENT

     This agreement is entered into between ORION CORPORATION, a corporation
     organized and existing under the laws of Finland, established at Orionintie
     1, P.O. Box 65, FIN-02101 Espoo, Finland (hereinafter referred to as
     "ORION") and GTX, INC., a corporation organized and existing under the laws
     of the State of Delaware, U.S.A. and having its principal office at 3 North
     Dunlap Avenue, Van Vleet Building, Memphis, Tennessee 38163, USA
     (hereinafter referred to as "GTx").

     This agreement applies to the Product named in the Appendix 1 (hereinafter
     referred to as "the Product").

     In order to establish the division of responsibilities relating to the
     quality assurance procedures determined in the "Good Manufacturing Practice
     for Medicinal Products in the European Community (Commission Directive
     91/356/EEC, Medicinal Products for Human Use)", equivalent to US, GMP as
     defined in Part 11 of Chapter 21 of the Code of Federal Regulations, the
     parties agree as follows:

1.   When performing its obligations under this agreement, ORION shall at all
     times comply with the requirements of the applicable regional GMPs for
     which the Product is intended.

2.   The detailed responsibilities of the parties for the Product are listed in
     Appendix 1.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       D-1
<PAGE>
3.   Release activities shall follow the general format outlined in Appendix 2:
     "Release Procedures and Responsibilities for Fareston 60mg tablets".

4.   In the event ORION shall desire to make any change in the manufacturing
     location, it shall do so in accordance with the applicable provisions of
     the applicable agreement executed between the parties.

5.   ORION shall perform its manufacturing and quality control obligations in
     accordance with the requirements set forth in the registration approval(s)
     granted by the relevant regulatory authorities for the Product.

6.   ORION shall send to GTx the certificate of analysis with each batch of the
     Products delivered. Furthermore, GTx may also request the full batch
     documentation concerning a particular batch. ORION agrees to deliver to GTx
     such documentation within [ * ] from GTx's request.

7.   Upon prior notification to ORION, GTx is entitled to inspect the
     manufacturing and quality control facilities related to the Product.

8.   The person appointed responsible for the quality assurance of the Product
     within GTx is [ * ] and within ORION [ * ]. A listing of responsible
     personnel is in Appendix 3.

9.   Neither party may assign this agreement or any of its rights hereunder, nor
     delegate any of its duties or obligations hereunder, to any third party
     without the prior written consent of the other party, except (i) to an
     affiliate in accordance with the terms of this agreement, in which case
     notification thereof shall be provided to the other party prior to such
     assignment to an affiliate, or (ii) in connection with a merger,
     consolidation or similar reorganization. For clarity, this agreement shall
     survive any such merger, consolidation or reorganization of either party
     with or into, another party and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-2
<PAGE>
     no consent for such merger, consolidation or reorganization shall be
     needed. Neither party shall unreasonably withhold its consent (which shall
     be provided promptly after a request is made) to any contemplated
     assignment if such contemplated assignment is in connection with the sale
     by either party of all or substantially all of its assets to a third party.
     Any assignment of this agreement to an affiliate of the assigning party
     shall not relieve the assigning party of its responsibilities and
     obligations hereunder.

10.  This agreement, including the validity, construction, interpretation and
     performance thereof, shall be governed entirely by the laws of Sweden. It
     is the specific intent and agreement of the parties that the United Nations
     Convention on the International Sale of Goods shall not apply to this
     agreement.

11.  The relationship of the parties under this agreement is that of independent
     contractors. Nothing contained in this agreement shall be construed so as
     to constitute the parties as partners, joint venturers or agents of the
     other. Neither party has any express or implied right or authority under
     this agreement to assume or create any obligations or make any warranties
     and representations on behalf of or in the name of the other party, or to
     bind the other party to any contract, agreement or undertaking with any
     third party, and no conduct of the parties pursuant to the terms of this
     agreement shall be deemed to establish such right or authority. Neither
     party shall make any representation to third parties that the relationship
     created hereby constitutes a partnership, joint venture or agency
     relationship.

12.  In case one or more of the provisions contained in this agreement shall,
     for any reason, be held invalid, illegal or unenforceable in any respect,
     such invalidity, illegality or unenforceability shall not affect any other
     provisions of this agreement, but this agreement shall be construed by
     limiting such

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-3
<PAGE>
     invalid, illegal or unenforceable provision, if such is not possible, by
     deleting such provision from this agreement.

13.  This agreement represents the entire agreement between the parties relating
     to the subject matter hereof and supersedes all prior arrangements,
     understandings, correspondence, notes, minutes and agreements between the
     parties (or their predecessors in interest) whether written or oral. No
     supplement, modification or amendment of this agreement shall be binding
     unless executed by the parties in writing and signed by the duly authorized
     representatives of both parties. Nothing herein is intended to supersede or
     affect the parties' rights under the Purchase Agreement dated December 13,
     2004, and the Amended and Restated License and Supply Agreement dated
     January 1, 2005.

14.  The failure by either party at any time to enforce any of the terms or
     provisions or conditions of this agreement or exercise any right hereunder
     shall not constitute a waiver of the same or affect that party's rights
     thereafter to enforce or exercise the same. No waiver of any of the
     provisions of this agreement shall be deemed binding unless executed in
     writing by the party to be bound by it.

15.  The English language version of this agreement shall be controlling in all
     respects regardless of whether any translations into any other languages
     are made.

16.  This agreement shall be executed by the parties in two (2) original
     counterparts, one (1) original counterpart being retained by each party and
     either of which shall be deemed sufficient to prove the existence and terms
     and conditions hereof. This agreement may be executed by the parties by the
     exchange of facsimile signature pages, with signed original counterparts of
     the agreement to be exchanged by the parties promptly thereafter.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-4
<PAGE>
Date:                                   Date:

ORION CORPORATION                       GTx

-------------------------------------   -------------------------------------

-------------------------------------   -------------------------------------

<TABLE>
<S>     <C>          <C>
ENCLS   Appendix 1   Product/Division of Responsibilities

        Appendix 2   Product Release

        Appendix 3   Responsible Personnel
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-5
<PAGE>
APPENDIX 1 PRODUCT/DIVISION OF RESPONSIBILITIES

PRODUCT:

<TABLE>
<S>                  <C>
Name:                Fareston(TM) Tablets, 60 MG
Active Ingredient:   Toremifene Citrate
Strength:            60 mg
Dosage form:         Tablets
Packaging size:      Bulk containers
</TABLE>

     The following responsibilities will be assumed by the agreeing parties.

DIVISION OF RESPONSIBILITIES:

<TABLE>
<CAPTION>
                                                                     THIRD PARTY
ITEM                           ORION                   GTX              VENDOR
--------------------   --------------------   --------------------   -----------
<S>                    <C>                    <C>                    <C>
MANUFACTURING RESPONSIBILITY
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]

FINAL PRODUCT PACKAGER (MANUFACTURER OF FINISHED PRODUCT)
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
GMP COMPLIANCE
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-6
<PAGE>
<TABLE>
<CAPTION>
                                                                     THIRD PARTY
ITEM                           ORION                   GTX              VENDOR
--------------------   --------------------   --------------------   -----------
<S>                    <C>                    <C>                    <C>
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
[  *  ]                [  *  ]                [  *  ]                [  *  ]
</TABLE>

Date:                                   Date:

ORION CORPORATION

-------------------------------------   ----------------------------------------

-------------------------------------   ----------------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-7
<PAGE>
                                   APPENDIX 2
        RELEASE PROCEDURES AND RESPONSIBILITIES FOR FARESTON 60MG TABLETS

This procedure applies to Fareston 60 mg tablet.

     1.   Orion will supply product to GTx that has been manufactured, packaged
          and tested under cGMP.

     2.   The product will be manufactured, packaged and tested in accordance
          with NDA [ * ] and all approved supplements, and any compendial
          monographs which may exist in the future.

          GTx will not distribute any Fareston without first receiving a "Final
          Release Certificate" from Orion stating the following:

               -    The batch number of the bulk drug tablets being released.

               -    The expiration date of the batch being released.

               -    A statement confirming the batch meets all Regulatory
                    requirements as defined in NDA [ * ], subsequent amendments,
                    and any compendial monographs, which may exist in the
                    future, and is released by Orion for distribution in the
                    United States.

     3.   GTx or its agent (hereinafter referred to as "GTx") will receive this
          product into a cGMP warehouse either owned by GTx or an appropriately
          qualified contract facility (hereinafter referred as the "GTx
          Distribution Center") operating in compliance with GMP, as defined by
          the US Food and Drug Administration. Such GTx Distribution Center will
          include, without limitation, temperature controls including recording
          devices and appropriate record keeping.

     4.   GTx will select a transportation agent and provide the information to
          Orion for use.

     5.   The GTx Distribution Center will be in compliance with cGMP. This will
          include but not be limited to a [ * ].

     6.   GTx will perform an incoming inspection of the released batch to
          verify quantity of bulk drug product received and a visual inspection
          confirming the presence of the appropriate batch number and expiration
          date. Should a batch fail the above inspection, GTx will place the
          batch on hold pending the conclusion of an appropriate investigation.
          GTx will notify both the Head of Quality Assurance of Orion and the
          Head of Quality Assurance or designee of the authorized packaging site
          of this deficiency.

     7.   GTx will maintain an appropriate Customer Complaints program in
          compliance with 21 Code of Federal Regulations. Customer complaints
          regarding Fareston will be forwarded to the appropriate Quality
          Assurance Manager at Orion for

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       D-8
<PAGE>
          investigations. Orion will also provide an investigation report to the
          Director of GTx's Corporate Quality Unit within [ * ].

     8.   Should a US Recall of Fareston become necessary, GTx Quality Assurance
          will notify the Director of Orion's Corporate Quality Unit
          immediately. GTx will coordinate the Recall in accordance to its
          procedures and applicable Regulations. GTx will update Orion, as
          appropriate.

Date:                                    Date:

Orion Corporation                        GTx, Inc.

--------------------------------------   ---------------------------------------
[ * ]                                    [ * ]

--------------------------------------   ---------------------------------------
[ * ]                                    [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       D-9
<PAGE>
                                   APPENDIX 3
                              RESPONSIBLE PERSONNEL

COMPANY NAME: ORION PHARMA

Responsible Contacts:
[ * ]

[ * ]

COMPANY NAME: GTX, INC.

Responsible Contacts:
[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      D-10
<PAGE>
                                    EXHIBIT E

                            SALES AND MARKETING PLAN

                                      [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      E-1
<PAGE>
                                    EXHIBIT F

                              [ * ] SPECIFICATIONS

                        SPECIFICATIONS FOR [ * ] TABLETS

<TABLE>
<CAPTION>
                                           SPECIFICATION
                     -----------------------------------------------------------
TEST                       [ * ]               [ * ]                [ * ]
------------------   -----------------   -----------------   -------------------
<S>                  <C>                 <C>                 <C>
CHARACTERS
Colour                     [ * ]               [ * ]                [ * ]
Shape                      [ * ]               [ * ]                [ * ]
Score                      [ * ]               [ * ]                [ * ]
Code                       [ * ]               [ * ]                [ * ]
Coating                    [ * ]               [ * ]                [ * ]

[ * ]
[ * ]                      [ * ]               [ * ]                [ * ]

[ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
[ * ]                      [ * ]               [ * ]                [ * ]
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                       F-1
<PAGE>
                                    EXHIBIT G

                     LETTER OF TRANSFER OF OWNERSHIP OF NDA

January 1, 2005

Richard Pazdur, M.D., Director
Division of Oncology Drug Products, HFD-150
Center for Drug Evaluation and Research
Food and Drug Administration
Woodmont Office Complex 2, Room 2055
1451 Rockville Pike
Rockville, MD 20852

Dear Dr. Pazdur:

RE:  FARESTON(R) (TOREMIFENE CITRATE) TABLETS
     NDA [ * ]
     TRANSFER OF NDA

Reference is made to New Drug Application [ * ], approved on 29 May 1997. This
letter is to acknowledge that effective January 1, 2005, GTx, Inc., rather than
Orion Corporation, will act as the sponsor of NDA [ * ] for FARESTON(R)
(toremifene citrate) Tablets and fulfill the obligations set forth in 21 CFR
314.

The primary point of contact is now:

     [ * ]

Please amend your records accordingly.

Sincerely,


ORION PHARMA SIGNATURE

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      G-1
<PAGE>
                                    EXHIBIT H

                                 GTX FDA LETTER

January 1, 2005

Richard Pazdur, M.D., Director
Division of Oncology Drug Products, HFD-150
Center for Drug Evaluation and Research
Food and Drug Administration
Woodmont Office Complex 2, Room 2055
1451 Rockville Pike
Rockville, MD 20852

Dear Dr. Pazdur:

RE:  FARESTON(R) (TOREMIFENE CITRATE) TABLETS
     NDA [ * ]
     TRANSFER OF OWNERSHIP OF NDA

Reference is made to New Drug Application [ * ], approved on 29 May 1997. This
correspondence and attached signed Form FDA 356h serve as notification of the
change in ownership of this NDA. The new sponsor of the application is GTx, Inc.
The sponsor contact information is:

          [ * ]

This change in ownership becomes effective upon the Agency's receipt of the
letter of transfer from Orion Corporation dated January 1, 2005. Pursuant to the
provisions in 21 CFR 314.72, all rights and responsibilities associated with the
subject New Drug Application have been transferred to GTx, Inc. In addition, all
documentation relevant to NDA [ * ] for FARESTON(R) (toremifene citrate) Tablets
has been transferred to GTx, Inc.

Should you have any questions regarding this submission, please contact me at
[ * ].

Sincerely,

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      H-1
<PAGE>
                               DISCLOSURE SCHEDULE

PART 1.1(D):

     As of the Date of Agreement, no Assumed Contracts or Restricted Contracts
are known to either Party; however, if the Parties identify any contracts to be
transferred to GTx pursuant to this Agreement, they will update this Disclosure
Schedule to include such contract(s).

PART 2.6:

NONE

PART 2.7:

[ * ]

PART 3.3:

NONE

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>   <C>                                                                   <C>
 1.   PURCHASE AND SALE OF ASSETS; RELATED AGREEMENTS....................     1

      1.1     Assets to be Transferred...................................     1

      1.2     Intellectual Property License to Purchased Assets..........     2

      1.3     Liabilities to be Assumed..................................     2

      1.4     Liabilities Not to be Assumed..............................     3

      1.5     Deposit; Purchase Price....................................     3

      1.6     Other Agreements...........................................     3

      1.7     Allocation of Purchase Price...............................     3

      1.8     Further Action.............................................     3

      1.9     Closing....................................................     4

 2.   REPRESENTATIONS AND WARRANTIES OF ORION............................     4

      2.1     Due Organization...........................................     4

      2.2     Right to Assign Purchased Assets; Title to Purchased
              Assets.....................................................     4

      2.3     Contracts..................................................     4

      2.4     Proceedings; Orders........................................     5

      2.5     Authority; Binding Nature of Agreements....................     5

      2.6     Consents...................................................     5

      2.7     No Debarment; Compliance with Laws.........................     5

      2.8     Filings....................................................     6

 3.   REPRESENTATIONS AND WARRANTIES OF GTX..............................     6

      3.1     Due Organization...........................................     6

      3.2     Authority; Binding Nature of Agreement.....................     6

      3.3     Consents...................................................     7

      3.4     Proceedings; Orders........................................     7

      3.5     No Debarment...............................................     7

 4.   PRE-CLOSING COVENANTS OF ORION.....................................     7

      4.1     Fareston Repurchase Agreement..............................     7

      4.2     Operation Of Business......................................     7

      4.3     Filings and Consents.......................................     7

      4.4     Best Efforts...............................................     8
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      -i-
<PAGE>
                                 TABLE OF CONTENTS
                                    (CONTINUED)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>   <C>                                                                   <C>
      4.5     Confidentiality............................................     8

 5.   PRE-CLOSING COVENANTS OF GTX.......................................     8

      5.1     Filings and Consents.......................................     8

      5.2     Best Efforts...............................................     8

      5.3     Confidentiality............................................     8

 6.   CONDITIONS PRECEDENT TO GTX'S OBLIGATION TO CLOSE..................     8

      6.1     Accuracy Of Representations................................     8

      6.2     Performance Of Obligations.................................     9

      6.3     Additional Documents.......................................     9

      6.4     No Proceedings.............................................     9

 7.   CONDITIONS PRECEDENT TO ORION'S OBLIGATION TO CLOSE................     9

      7.1     Accuracy Of Representations................................     9

      7.2     GTx's Performance..........................................    10

      7.3     No Proceedings.............................................    10

      7.4     [*]........................................................    10

 8.   INDEMNIFICATION, ETC...............................................    10

      8.1     Survival of Representations................................    10

      8.2     Indemnification by Orion...................................    11

      8.3     Limitations................................................    11

      8.4     Indemnification by GTx.....................................    12

      8.5     Limitations................................................    12

      8.6     Indemnification Procedures; Defense of Third Party Claims..    13

      8.7     Other Claims...............................................    13

 9.   POST-CLOSING COVENANTS.............................................    14

      9.1     Transfer of NDA; Access....................................    14

      9.2     Marketing Plan.............................................    14

      9.3     Letters Regarding NDA......................................    15

10.   CONFIDENTIALITY....................................................    15

      10.1    Confidential Information...................................    15

11.   MISCELLANEOUS PROVISIONS...........................................    15
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                      -ii-
<PAGE>
                                 TABLE OF CONTENTS
                                    (CONTINUED)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>   <C>                                                                   <C>
      11.1    Further Assurances.........................................    15

      11.2    Fees and Expenses..........................................    15

      11.3    Notices....................................................    15

      11.4    Publicity..................................................    16

      11.5    Headings...................................................    17

      11.6    Counterparts...............................................    17

      11.7    Governing Law; Dispute Resolution..........................    17

      11.8    Effect of Commencing Dispute Resolution....................    18

      11.9    Successors and Assigns; Assignment.........................    18

      11.10   Waiver.....................................................    18

      11.11   Amendments.................................................    19

      11.12   Severability...............................................    19

      11.13   Parties in Interest........................................    19

      11.14   Independent Contractors....................................    19

      11.15   Entire Agreement...........................................    19

      11.16   Disclosure Schedule........................................    19

FIELD. "FIELD............................................................     2
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.


                                     -iii-